<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2102</journal-id><journal-id journal-id-type="pmc-domain">pharmaceuticals</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11946379</article-id><article-id pub-id-type="pmcid-ver">PMC11946379.1</article-id><article-id pub-id-type="pmcaid">11946379</article-id><article-id pub-id-type="pmcaiid">11946379</article-id><article-id pub-id-type="pmid">40143076</article-id><article-id pub-id-type="doi">10.3390/ph18030297</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00297</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Prodrug Approach as a Strategy to Enhance Drug Permeability</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0840-0183</contrib-id><name name-style="western"><surname>de Souza</surname><given-names initials="MM">Mateus Mello</given-names></name><xref rid="af1-pharmaceuticals-18-00297" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2643-810X</contrib-id><name name-style="western"><surname>Gini</surname><given-names initials="ALR">Ana Lu&#237;sa Rodriguez</given-names></name><xref rid="af1-pharmaceuticals-18-00297" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-3696-1085</contrib-id><name name-style="western"><surname>Moura</surname><given-names initials="JA">Jhonnathan Alves</given-names></name><xref rid="af2-pharmaceuticals-18-00297" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2540-6395</contrib-id><name name-style="western"><surname>Scarim</surname><given-names initials="CB">Cau&#234; Benito</given-names></name><xref rid="af1-pharmaceuticals-18-00297" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4141-0455</contrib-id><name name-style="western"><surname>Chin</surname><given-names initials="CM">Chung Man</given-names></name><xref rid="af1-pharmaceuticals-18-00297" ref-type="aff">1</xref><xref rid="af3-pharmaceuticals-18-00297" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2460-2829</contrib-id><name name-style="western"><surname>dos Santos</surname><given-names initials="JL">Jean Leandro</given-names></name><xref rid="af1-pharmaceuticals-18-00297" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00297" ref-type="aff">2</xref><xref rid="c1-pharmaceuticals-18-00297" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Moreau</surname><given-names initials="E">Emmanuel</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00297"><label>1</label>School of Pharmaceutical Sciences, S&#227;o Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil; <email>mello.souza@unesp.br</email> (M.M.d.S.); <email>ana.gini@unesp.br</email> (A.L.R.G.); <email>caue.scarim@unesp.br</email> (C.B.S.); <email>chung.man-chin@unesp.br</email> (C.M.C.)</aff><aff id="af2-pharmaceuticals-18-00297"><label>2</label>Institute of Chemistry, S&#227;o Paulo State University (UNESP), Araraquara 14800-900, SP, Brazil; <email>jhonnathan.alves@unesp.br</email></aff><aff id="af3-pharmaceuticals-18-00297"><label>3</label>Union of the Colleges of the Great Lakes (UNILAGO), School of Medicine, Advanced Research Center in Medicine (CEPAM), Sao Jose do Rio Preto 15030-070, SP, Brazil</aff><author-notes><corresp id="c1-pharmaceuticals-18-00297"><label>*</label>Correspondence: <email>jean.santos@unesp.br</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2025</year></pub-date><volume>18</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">485336</issue-id><elocation-id>297</elocation-id><history><date date-type="received"><day>06</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>12</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-28 09:25:15.020"><day>28</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceuticals-18-00297.pdf"/><abstract><p>Absorption and permeability are critical physicochemical parameters that must be balanced to achieve optimal drug uptake. These key factors are closely linked to the maximum absorbable dose required to provide appropriate plasma levels of drugs. Among the various strategies employed to enhance drug solubility and permeability, prodrug design stands out as a highly effective and versatile approach for improving physicochemical properties and enabling the optimization of biopharmaceutical and pharmacokinetic parameters while mitigating adverse effects. Prodrugs are compounds with reduced or no activity that, through bio-reversible chemical or enzymatic processes, release an active parental drug. The application of this technology has led to significant advancements in drug optimization during the design phase, and it offers broad potential for further development. Notably, approximately 13% of the drugs approved by the U.S. Food and Drug Administration (FDA) between 2012 and 2022 were prodrugs. In this review article, we will explore the application of prodrug strategies to enhance permeability, describing examples of market drugs. We also describe the use of the prodrug approach to optimize PROteolysis TArgeting Chimeras (PROTACs) permeability by using conjugation technologies. We will highlight some new technologies in prodrugs to enrich permeability properties, contributing to developing new effective and safe prodrugs.</p></abstract><kwd-group><kwd>prodrug</kwd><kwd>drug permeability</kwd><kwd>PROTAC</kwd><kwd>permeability</kwd><kwd>molecular optimization</kwd><kwd>drug discovery</kwd></kwd-group><funding-group><award-group><funding-source>Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de S&#227;o Paulo (FAPESP)</funding-source><award-id>2023/05739-6</award-id><award-id>2023/14078-3</award-id></award-group><award-group><funding-source>National Council for Scientific and Technological Development (CNPq)</funding-source><award-id>302433/2023-6</award-id></award-group><award-group><funding-source>Pro-reitoria de P&#243;s-Gradua&#231;&#227;o UNESP</funding-source><award-id>PROPG edital 01/2025</award-id></award-group><funding-statement>This research was funded by Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de S&#227;o Paulo (FAPESP), grant numbers 2023/05739-6 and 2023/14078-3, and the National Council for Scientific and Technological Development (CNPq) (process number 302433/2023-6). The APC was funded by Pro-reitoria de P&#243;s-Gradua&#231;&#227;o UNESP&#8212;PROPG edital 01/2025.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00297"><title>1. Introduction</title><p>The discovery of new drugs is a lengthy, costly, and high-risk process, involving substantial financial investment and a high probability of failure. From 2000 to 2018, the average cost of developing a new drug was estimated at USD 172.7 million, including post-marketing studies. When accounting for failed attempts, the cost rises significantly to USD 515.8 million [<xref rid="B1-pharmaceuticals-18-00297" ref-type="bibr">1</xref>]. Studies indicate that 9 out of 10 approved drugs fail in demonstrating efficacy and safety during various stages of development [<xref rid="B2-pharmaceuticals-18-00297" ref-type="bibr">2</xref>]. The primary reasons for these failures include a lack of clinical efficacy (40&#8211;50%), safety concerns due to drug-induced toxicity (30%), inadequate drug-like properties (10&#8211;15%), and insufficient strategic planning regarding commercialization and addressing medical needs with an improved efficacy and safety profile compared to existing treatments, when available [<xref rid="B3-pharmaceuticals-18-00297" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00297" ref-type="bibr">4</xref>].</p><p>Following the identification of hits during large-scale systematic screening campaigns, it becomes essential to optimize these compounds to ensure their potency with respect to their molecular target. Additionally, a thorough evaluation of the compounds&#8217; properties, aimed at ensuring adequate tissue exposure, can facilitate a more favorable balance between efficacy, toxicity, and the appropriate dosage. Among the various properties assessed, solubility and permeability are particularly important to maintain an equilibrium, which ensures optimal absorption and exposure to the therapeutic target [<xref rid="B3-pharmaceuticals-18-00297" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00297" ref-type="bibr">4</xref>].</p><p>It has been noted that approximately 40% of marketed drugs, and up to 75% of those in development, exhibit challenges related to low solubility [<xref rid="B5-pharmaceuticals-18-00297" ref-type="bibr">5</xref>]. To address this issue, a variety of strategies have been employed to enhance this important physicochemical property, including particle size reduction [<xref rid="B6-pharmaceuticals-18-00297" ref-type="bibr">6</xref>], the use of advanced pharmaceutical systems (e.g., cyclodextrins [<xref rid="B7-pharmaceuticals-18-00297" ref-type="bibr">7</xref>], lipid-based systems [<xref rid="B8-pharmaceuticals-18-00297" ref-type="bibr">8</xref>], amorphous solid dispersions [<xref rid="B9-pharmaceuticals-18-00297" ref-type="bibr">9</xref>], surfactants [<xref rid="B10-pharmaceuticals-18-00297" ref-type="bibr">10</xref>], and co-solvents [<xref rid="B11-pharmaceuticals-18-00297" ref-type="bibr">11</xref>], among others), as well as the preparation of salts [<xref rid="B12-pharmaceuticals-18-00297" ref-type="bibr">12</xref>], polymorphs [<xref rid="B13-pharmaceuticals-18-00297" ref-type="bibr">13</xref>], co-crystals [<xref rid="B14-pharmaceuticals-18-00297" ref-type="bibr">14</xref>], and the application of prodrug strategies [<xref rid="B15-pharmaceuticals-18-00297" ref-type="bibr">15</xref>]. Among these strategies, the prodrug approach was revealed to be a promising tool to enhance drug solubility [<xref rid="B16-pharmaceuticals-18-00297" ref-type="bibr">16</xref>].</p><p>A prodrug is a minimally active or inactive compound that contains a parental drug and undergoes biotransformation in vivo, either through chemical or enzymatic cleavage, facilitating the release of the active molecule at effective levels [<xref rid="B17-pharmaceuticals-18-00297" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00297" ref-type="bibr">18</xref>]. Bioprecursors and carrier-linked prodrugs represent the primary types of prodrugs. In the case of carrier-linked prodrugs, the carrier can either possess therapeutic activity (as seen in mutual prodrugs) or may not (as in the classical prodrugs) [<xref rid="B16-pharmaceuticals-18-00297" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00297" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00297" ref-type="bibr">18</xref>]. Notably, approximately 13% of the drugs approved by the U.S. Food and Drug Administration (FDA) between 2012 and 2022 were prodrugs [<xref rid="B18-pharmaceuticals-18-00297" ref-type="bibr">18</xref>].</p><p>Prodrugs play a critical role in addressing solubility and permeability challenges, with advanced design strategies improving bioavailability, stability, and targeted delivery. In addition to improving solubility, prodrugs can also be utilized to modulate drugs&#8217; permeability. A noteworthy analysis conducted by Fralish and colleagues (2024) identified approximately 95 design goals using prodrug strategies, with around 59% of these aimed at enhancing bioavailability, primarily through improvements in permeability (35%) and solubility (15%) [<xref rid="B19-pharmaceuticals-18-00297" ref-type="bibr">19</xref>]. While technologies like cheminformatics and computational modeling have expanded possibilities, challenges such as navigating vast chemical spaces and addressing pharmacogenomic variability remain. Integrating machine learning and pharmacogenomics is essential for advancing safer, more effective therapies.</p><p>Membrane permeability is a crucial factor for small molecules to achieve intracellular targets since it is well established that low permeability correlates with low efficacy. In eukaryotic cells, drug permeability across membranes can occur mainly through both active and passive transport mechanisms [<xref rid="B20-pharmaceuticals-18-00297" ref-type="bibr">20</xref>]. Active transport is facilitated by transport proteins that utilize energy (e.g., adenosine triphosphate (ATP) hydrolysis) to assist compounds in crossing the membrane, with the drug&#8217;s affinity for the transport protein playing a critical role in this process [<xref rid="B21-pharmaceuticals-18-00297" ref-type="bibr">21</xref>]. However, reliance on transport proteins can result in saturation kinetics due to the limited availability of these proteins within the membrane [<xref rid="B21-pharmaceuticals-18-00297" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00297" ref-type="bibr">22</xref>]. On the other hand, passive transport does not require energy, as drugs cross the membrane through diffusion. In this case, factors such as the partition coefficient between the membrane and the external aqueous environment, as well as the drug concentration to establish a concentration gradient, contribute to the transport process without energy expenditure. The key factors influencing membrane permeability via passive diffusion include polarity, molecular weight, and lipophilicity [<xref rid="B23-pharmaceuticals-18-00297" ref-type="bibr">23</xref>]. Typically, compounds with lower polarity, smaller molecular weight, and higher lipophilicity (within certain limits) exhibit greater permeability [<xref rid="B24-pharmaceuticals-18-00297" ref-type="bibr">24</xref>].</p><p>The estimation of membrane permeability can be assessed using Fick&#8217;s first law, expressed as Jr = Pm &#215; Ci, where Jr represents the drug flux rate (mass/area/time), Pm corresponds to membrane permeability, and Ci is the concentration of the drug at the intestinal membrane surface [<xref rid="B25-pharmaceuticals-18-00297" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00297" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-18-00297" ref-type="bibr">27</xref>].</p><p>The Biopharmaceutical Classification System (BCS) serves as a valuable tool for classifying drugs based on their permeability and water solubility. According to the BCS, drugs are categorized based on solubility and permeability into four main classes [<xref rid="B26-pharmaceuticals-18-00297" ref-type="bibr">26</xref>]: Class I (high solubility and permeability), Class II (low solubility and high permeability), Class III (high solubility and low permeability), and Class IV (low solubility and low permeability) (<xref rid="pharmaceuticals-18-00297-t001" ref-type="table">Table 1</xref>) [<xref rid="B26-pharmaceuticals-18-00297" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-18-00297" ref-type="bibr">27</xref>].</p><p>The apparent permeability coefficient (P<sub>app</sub>) is commonly used in in vitro experiments to evaluate the degree of drug permeability between donor and receptor compartments. While the methods used will be detailed later in the text, they are generally correlated with flux between donor and receptor compartments [<xref rid="B25-pharmaceuticals-18-00297" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00297" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-18-00297" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-18-00297" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-18-00297" ref-type="bibr">29</xref>]. On the other hand, effective permeation (P<sub>eff</sub>) is used to determine in vivo permeability. Although databases for jejunum permeability are well described, information is still missing regarding distal sites (e.g., colon and ileum) in the gastrointestinal tract [<xref rid="B30-pharmaceuticals-18-00297" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00297" ref-type="bibr">31</xref>]. Both methods present pros and cons and the combination of P<sub>app</sub> and P<sub>eff</sub> seems to be a good way to reduce drawbacks [<xref rid="B32-pharmaceuticals-18-00297" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceuticals-18-00297" ref-type="bibr">33</xref>].</p><p>Notably, the prodrug approach represents a valuable strategy for modulating membrane permeability [<xref rid="B34-pharmaceuticals-18-00297" ref-type="bibr">34</xref>]. In this review article, we will examine the potential of this approach in addressing challenges related to drug permeability, focusing on drug market and under-developed compounds. New technologies, such as PROteolysis TArgeting Chimeras (PROTACs) and conjugation approaches, will be discussed to provide a comprehensive overview of how prodrugs can be effectively utilized to overcome obstacles in drug optimization and development.</p></sec><sec id="sec2-pharmaceuticals-18-00297"><title>2. Permeability Determination Methods</title><p>The determination of permeability for prodrugs can be assessed through several methods, which includes in silico, in vitro, cell based, in situ perfusion, ex vivo gut sacs, and ex vivo diffusion chambers (<xref rid="pharmaceuticals-18-00297-f001" ref-type="fig">Figure 1</xref>). In this context, the general principles of these methods and their application to evaluate prodrug permeability is described below.</p><sec id="sec2dot1-pharmaceuticals-18-00297"><title>2.1. In Silico Determination Methods</title><p>The assessment of organic compound permeability using computational approaches is an interesting parameter to be characterized during the early phases of drug development, especially for prodrugs. In silico methods facilitate the identification of promising compounds from extensive chemo-libraries in large-scale screening studies and contribute to the molecular optimization process. Some filters such as the "rule of five" are widely used and described as poor permeation and absorption is more commonly found in compounds exhibiting more than five hydrogen bond donors, 10 hydrogen bonding acceptors, molecular weight superior to 500 Da, and calculated logarithm of the octanol/water partition coefficient (logP) values superior to 5 [<xref rid="B43-pharmaceuticals-18-00297" ref-type="bibr">43</xref>]. Based on the number of compounds and the research stage, the knowledge of permeability profile allows for the evaluation of pharmacokinetic and biopharmaceutical properties, playing a crucial role in selecting the most suitable pharmaceutical form and formulation [<xref rid="B44-pharmaceuticals-18-00297" ref-type="bibr">44</xref>].</p><p>Computational approaches for assessing permeability via passive diffusion utilize techniques that incorporate lipophilicity, molecular dynamics, and machine learning (ML) [<xref rid="B45-pharmaceuticals-18-00297" ref-type="bibr">45</xref>]. The in silico characterization of a chemical structure&#8217;s lipophilicity involves the use of molecular descriptors, such as logP, which represents the logarithmic ratio of the <italic toggle="yes">n</italic>-octanol/water partition coefficient. This parameter is typically regressed against experimental data to enhance the predictive accuracy of the model [<xref rid="B46-pharmaceuticals-18-00297" ref-type="bibr">46</xref>]. LogP can be calculated by using various methods, including the hydrophobic fragmental constant approach (&#931;f system) for octanol/water partitioning, atom contribution method ALOGP, and element contribution KLOGP [<xref rid="B47-pharmaceuticals-18-00297" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceuticals-18-00297" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-18-00297" ref-type="bibr">49</xref>]. Another method is the physics-based molecular dynamics (MD) simulations, which are applicable for simulating nanoscale systems and estimating permeability values. For passive permeability, some of the following techniques can be used, depending on the research aim. The potential of mean force and the diffusivity through the membranes allow the calculation of the permeability coefficient (Pe). The most commonly used are the permeant counting method, the homogeneous solubility&#8211;diffusion model, and the inhomogeneous solubility&#8211;diffusion model [<xref rid="B45-pharmaceuticals-18-00297" ref-type="bibr">45</xref>,<xref rid="B50-pharmaceuticals-18-00297" ref-type="bibr">50</xref>]. Disadvantages of MD simulation that use all-atom MD (AAMD) simulations related to time consumption can be addressed by reducing the degree of freedom and using coarse-grained MD (CGMD) [<xref rid="B51-pharmaceuticals-18-00297" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-18-00297" ref-type="bibr">52</xref>]. The third approach to estimate the permeability by in silico methods involves the use of artificial intelligence ML methods [<xref rid="B53-pharmaceuticals-18-00297" ref-type="bibr">53</xref>]. The prediction of permeability commonly explores deep neural networks (DNNs) and deep learning (DL) methods. These methods provide values of permeability with high accuracy, and the values can be refined by using experimental data [<xref rid="B54-pharmaceuticals-18-00297" ref-type="bibr">54</xref>]. Chen and colleagues (2020), using the ML model named Least Absolute Shrinkage and Selection Operator (LASSO), reported that the critical descriptors to estimate permeability are hydrophobic/hydrophilic, electro-topological, polarizability, and electrostatic properties [<xref rid="B53-pharmaceuticals-18-00297" ref-type="bibr">53</xref>]. Several examples of web-service for in silico prediction of permeability have been described, including PerMM [<xref rid="B35-pharmaceuticals-18-00297" ref-type="bibr">35</xref>], admetSAR 2.0 [<xref rid="B36-pharmaceuticals-18-00297" ref-type="bibr">36</xref>], admetSAR 3.0 [<xref rid="B37-pharmaceuticals-18-00297" ref-type="bibr">37</xref>], ADMETopt [<xref rid="B38-pharmaceuticals-18-00297" ref-type="bibr">38</xref>], OptADMET [<xref rid="B39-pharmaceuticals-18-00297" ref-type="bibr">39</xref>], Interpretable-ADMET [<xref rid="B40-pharmaceuticals-18-00297" ref-type="bibr">40</xref>], SwissADME [<xref rid="B41-pharmaceuticals-18-00297" ref-type="bibr">41</xref>], and pkCSM [<xref rid="B42-pharmaceuticals-18-00297" ref-type="bibr">42</xref>], among others (<xref rid="pharmaceuticals-18-00297-f001" ref-type="fig">Figure 1</xref>). These methods are very useful during the drug design stage, and they must be coupled with experimental assays to confirm the results.</p><p>In silico methods are widely utilized to evaluate the permeability of prodrugs, demonstrating a satisfactory correlation with experimental data [<xref rid="B55-pharmaceuticals-18-00297" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-18-00297" ref-type="bibr">56</xref>]. A notable example is used for peptide prodrug design to optimize drug permeability, in which a peptide is linked to a drug through a bio-reversible linker [<xref rid="B57-pharmaceuticals-18-00297" ref-type="bibr">57</xref>]. Although peptide membrane permeability is a common issue faced during drug development, some strategies to improve peptide permeability such as cyclization, amide-to-ester replacement, and <italic toggle="yes">N</italic>-methylation have been shown to be a promising approach. In addition, cell-penetrating peptides (CPPs), a short strand composed of 5&#8211;30 amino acids, can overcome barriers such as low drug permeability [<xref rid="B58-pharmaceuticals-18-00297" ref-type="bibr">58</xref>]. In order to determine the permeability of peptides, Tan and colleagues (2024) used a ML model to develop a platform named KNIME (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/ifyoungnet/PharmPapp">https://github.com/ifyoungnet/PharmPapp</uri>) (accessed on 4 January 2025) to assist researchers during a prodrug drug design [<xref rid="B59-pharmaceuticals-18-00297" ref-type="bibr">59</xref>]. Another platform used to predict peptide permeability was developed by Chen and colleagues, named BBP predict (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://i.uestc.edu.cn/BBPpredict/cgi-bin/BBPpredict.pl">http://i.uestc.edu.cn/BBPpredict/cgi-bin/BBPpredict.pl</uri>) (accessed on 4 January 2025), which used ML methods with high accuracy, and is superior to others such as BBPpred and B3Pred [<xref rid="B60-pharmaceuticals-18-00297" ref-type="bibr">60</xref>].</p><p>The prediction of the ability of drugs to act on the central nervous system poses a significant challenge due to the semi-permeability and selectivity of the blood&#8211;brain barrier (BBB). Conducting clinical experiments to assess BBB permeability is a time-consuming process, and in this context, predictive systems have immense potential to aid in the optimization of compounds and even anticipate the need for the development of specific formulations. Methods for predicting the permeability of compounds in the central nervous system commonly utilize physicochemical descriptors (i.e., molar mass, logP, polar surface area, numbers of hydrogen bond donors and acceptors, ionization potential, and water-accessible and Van der Waals volumes, among others) to evaluate membrane crossing via passive diffusion. However, the complexity of transport systems in substrate recognition, particularly for more hydrophilic compounds, requires more advanced analysis and presents significant challenges [<xref rid="B61-pharmaceuticals-18-00297" ref-type="bibr">61</xref>].</p><p>To solve this issue, Gao and colleagues (2022) developed a prediction model that considered both passive diffusion and active transport aiming to predict reposition drugs for central nervous system (CNS) diseases [<xref rid="B62-pharmaceuticals-18-00297" ref-type="bibr">62</xref>]. In the same year, Kumar and colleagues (2022) explored deep learning and ML algorithms for a dataset of 3605 compounds to develop the &#8220;DeePred-BBB&#8221; model (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/12rajnish/DeePred-BBB">https://github.com/12rajnish/DeePred-BBB</uri>) (accessed on 4 January 2025) with deep learning prediction accuracy of up to 97.6% [<xref rid="B63-pharmaceuticals-18-00297" ref-type="bibr">63</xref>]. BBBper is another example of an ML-based tool available online (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bbbper.mdu.ac.in">http://bbbper.mdu.ac.in</uri>) (accessed on 4 January 2025) to predict BBB permeability [<xref rid="B63-pharmaceuticals-18-00297" ref-type="bibr">63</xref>]. The prediction of the ability to cross the BBB was also described by several other platforms elsewhere, especially by using deep learning and ML methods [<xref rid="B64-pharmaceuticals-18-00297" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-18-00297" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceuticals-18-00297" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceuticals-18-00297" ref-type="bibr">67</xref>].</p></sec><sec id="sec2dot2-pharmaceuticals-18-00297"><title>2.2. In Vitro Determination of Permeability</title><p>In vitro methods to determine drug permeability involve partitioning among aqueous and lipophilic phases, and such methods can be classified into two main types: artificial membrane systems and cell-based models. One of the most described artificial methods is the Parallel Artificial Membrane Permeability Assay (PAMPA) [<xref rid="B68-pharmaceuticals-18-00297" ref-type="bibr">68</xref>]. The principle of the method is simple and consists of a system divided into two compartments, where the organic compound diffuses via passive diffusion through an artificial membrane. Despite the ease that enables large-scale screening, this method has the drawback of exclusively evaluating passive diffusion processes. For organic compounds that rely on transport systems, inaccurate determinations may occur, and in such cases, cell-based models are required [<xref rid="B69-pharmaceuticals-18-00297" ref-type="bibr">69</xref>].</p></sec><sec id="sec2dot3-pharmaceuticals-18-00297"><title>2.3. PAMPA Assay</title><p>The passive diffusion method is predominantly assessed using PAMPA assays, with adaptations involving phosphatidylcholine and egg lecithin to establish an additional barrier in the system [<xref rid="B70-pharmaceuticals-18-00297" ref-type="bibr">70</xref>]. It has been reported that the method shows good correlation with permeability in the human jejunum [<xref rid="B71-pharmaceuticals-18-00297" ref-type="bibr">71</xref>]. In general, this method involves preparing a dilution of the test compound in an aqueous solution, which is subsequently added to the donor compartment of a plate. A porous-bottomed 96-well filter plate is positioned atop the donor plate, establishing direct contact with the donor solution. This setup is maintained for varying durations (1&#8211;18 h) after the compound is quantified in the acceptor well through analytical techniques, such as Liquid Chromatography&#8211;Mass Spectrometry (LC-MS) (<xref rid="pharmaceuticals-18-00297-f001" ref-type="fig">Figure 1</xref>). This method allows characterizing the effective P<italic toggle="yes"><sub>e</sub></italic> range of tested compounds [<xref rid="B72-pharmaceuticals-18-00297" ref-type="bibr">72</xref>].</p><p>He and colleagues (2020) developed a noteworthy real-time PAMPA assay by introducing a modification to the standard method. This approach enabled the detection of direct fluorescence using a fluorescent artificial receptor, comprising an encapsulated fluorescent dye and a macrocycle, which was incorporated into the acceptor chamber. This innovative method not only facilitates the quantification of permeability but also distinguishes between slow and fast diffusion across the membrane, making it a valuable tool for drug discovery, particularly for prodrugs susceptible to hydrolysis reactions [<xref rid="B73-pharmaceuticals-18-00297" ref-type="bibr">73</xref>].</p><p>Several examples using PAMPA assays have been reported for prodrugs, for example, the angiotensin II receptor antagonist candesartan [<xref rid="B74-pharmaceuticals-18-00297" ref-type="bibr">74</xref>] and oseltamivir [<xref rid="B75-pharmaceuticals-18-00297" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-18-00297" ref-type="bibr">76</xref>].</p></sec><sec id="sec2dot4-pharmaceuticals-18-00297"><title>2.4. Cell-Based Models</title><p>The cell-based permeability assessment model is widely utilized due to its ability to evaluate not only passive diffusion but also active transport, paracellular permeability, and efflux mechanisms. Among these models, the Caco-2 and Madin&#8211;Darby Canine Kidney (MDCK) cell lines are the most employed (<xref rid="pharmaceuticals-18-00297-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B77-pharmaceuticals-18-00297" ref-type="bibr">77</xref>]. Caco-2 cells exhibit the morphology of intestinal epithelium, while MDCK cells resemble distal tubule epithelium. Another significant difference lies in the types of transport systems. For Caco-2 cells, the most well-known systems include OATP1B1, OATP1B3, OATP2B1, PepT1, OCT1, OCT2, and OCT3. In contrast, for MDCK cells, the most recognized transporters are OCT2, peptides, and monocarboxylic acids. Efflux transporters can also vary, with Caco-2 cells predominantly expressing P-gp, MRP2, MRP4, and BCRP, while MDCK cells commonly express Mdr1, Mrp1, Mrp2, and Mrp5 [<xref rid="B78-pharmaceuticals-18-00297" ref-type="bibr">78</xref>].</p><p>The cell-based model experiment is relatively straightforward and involves plating the cells onto a porous support until they reach confluence, covering the surface of the device. For Caco-2 cells, confluence is achieved after 21 days, whereas for MDCK cells, it takes only 3&#8211;4 days. The tested compounds are added in a buffered saline solution to the apical surface of the cell layer, and after permeation, they are quantified in the basolateral collecting chamber using analytical methods [<xref rid="B29-pharmaceuticals-18-00297" ref-type="bibr">29</xref>,<xref rid="B78-pharmaceuticals-18-00297" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceuticals-18-00297" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceuticals-18-00297" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceuticals-18-00297" ref-type="bibr">81</xref>].</p><p>Another possibility, by altering the order of addition into the basolateral layer, allows for the assessment of permeability through transporters (Basolateral to Apical Experiment: Ba-Ap). If the values obtained are the same, passive diffusion is the predominant process; however, if they differ, transport systems are likely involved in the permeability of the test compound [<xref rid="B72-pharmaceuticals-18-00297" ref-type="bibr">72</xref>]. Some limitations of the cell model are related to the low solubility of compounds and potential cytotoxicity, which may lead to inaccurate apparent permeability (P<sub>app</sub>) results.</p><p>For example, Shen and colleagues synthesized dipeptide prodrugs of prednisone for ocular use, aiming to increase water solubility, enhance permeability, and reduce efflux by P-gp. The authors targeted the PepT1 and PepT2 transport systems, utilizing the valine&#8211;valine (Val-Val) sequence conjugated to prednisone and valine (Val) conjugated to prednisone to avoid P-gp-mediated efflux. It was demonstrated that the solubility of the Val&#8211;prednisone (4.24 mg/mL) and Val-Val&#8211;prednisone (3.11 mg/mL) prodrugs was significantly higher than that of the parental drug prednisone (0.31 mg/mL), while also exhibiting good chemical stability. The dipeptide prodrug (Val-Val&#8211;prednisone) (<xref rid="pharmaceuticals-18-00297-f002" ref-type="fig">Figure 2</xref>) showed a half-life of 27 h at pH 7.4 and did not exhibit cytotoxic effects in MDCK cells at concentrations ranging from 5 to 250 &#956;M. Unlike the parent corticosteroid, the Val-Val dipeptide prodrug was not a substrate for P-gp and was recognized by the peptide transport system in MDCK cells [<xref rid="B82-pharmaceuticals-18-00297" ref-type="bibr">82</xref>]. A similar strategy involving dipeptides to enhance drug permeability was described for several drugs, including acyclovir [<xref rid="B83-pharmaceuticals-18-00297" ref-type="bibr">83</xref>], lopinavir [<xref rid="B84-pharmaceuticals-18-00297" ref-type="bibr">84</xref>], and decitabine [<xref rid="B85-pharmaceuticals-18-00297" ref-type="bibr">85</xref>].</p></sec><sec id="sec2dot5-pharmaceuticals-18-00297"><title>2.5. Other Methods to Determine the Permeability of Prodrugs</title><p>Several other methods have been used to evaluate the permeability of prodrugs, such as in situ perfusion, ex vivo gut sacs, and ex vivo diffusion chambers [<xref rid="B86-pharmaceuticals-18-00297" ref-type="bibr">86</xref>]. The in situ perfusion method allows the determination of prodrug permeability using the intact intestine, commonly through a single-pass approach, although recirculating methods have also been described [<xref rid="B87-pharmaceuticals-18-00297" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceuticals-18-00297" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceuticals-18-00297" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceuticals-18-00297" ref-type="bibr">90</xref>]. In the single-pass method, a cannula is inserted into a section of the intestine of an anesthetized animal, and an aqueous solution containing the test compound is infused, allowing the determination of the effective permeability (P<sub>eff</sub>) calculated from the difference between the injected concentration and the collected concentration. Despite its use in animal models, the method has disadvantages, such as the need to standardize the flow rate, equilibrium time, intestinal region used, animal species, feeding status, solution osmolarity, and pH, among other factors (<xref rid="pharmaceuticals-18-00297-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B88-pharmaceuticals-18-00297" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceuticals-18-00297" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceuticals-18-00297" ref-type="bibr">90</xref>]. The in situ perfusion method can also be utilized to evaluate compound permeability across the BBB [<xref rid="B91-pharmaceuticals-18-00297" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceuticals-18-00297" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceuticals-18-00297" ref-type="bibr">93</xref>].</p><p>The everted gut sac model is another experimental approach for evaluating permeability, in which a section of the intestine, removed from an experimental animal, is everted over a tube. In this model, intestinal sacs of up to 4 cm are tied and immersed in a buffer solution containing the test substance. The concentration of the test compound is then measured using analytical methods [<xref rid="B94-pharmaceuticals-18-00297" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceuticals-18-00297" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceuticals-18-00297" ref-type="bibr">96</xref>,<xref rid="B97-pharmaceuticals-18-00297" ref-type="bibr">97</xref>]. The ex vivo diffusion chamber method involves extracting a segment of the intestine from an animal and placing it into a chamber containing donor and acceptor solutions. This method can also be used to evaluate the permeability of prodrugs [<xref rid="B98-pharmaceuticals-18-00297" ref-type="bibr">98</xref>]. Such a method was used to evaluate the permeability of phenytoin prodrugs by using excised porcine nasal mucosa assembled in an Ussing chamber [<xref rid="B99-pharmaceuticals-18-00297" ref-type="bibr">99</xref>]. Several experiments using ex vivo diffusion chamber methods have been reported elsewhere, highlighting their application [<xref rid="B15-pharmaceuticals-18-00297" ref-type="bibr">15</xref>,<xref rid="B100-pharmaceuticals-18-00297" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-18-00297" ref-type="bibr">101</xref>]. Annaert and colleagues (2000) reported that the adefovir dipivoxil prodrug (<xref rid="pharmaceuticals-18-00297-f003" ref-type="fig">Figure 3</xref>) exhibited an 100-fold increase in permeability by using in vitro models. This significant increase in permeability is the result of the functionalization of hydroxyls to form the methyl pivalate ester, which acts as a plasma carrier (<xref rid="pharmaceuticals-18-00297-f003" ref-type="fig">Figure 3</xref>). However, the authors did not find the same correlation when using Ussing chambers, which highlights the importance of combining different permeability methods to characterize the effects of prodrugs [<xref rid="B102-pharmaceuticals-18-00297" ref-type="bibr">102</xref>].</p></sec></sec><sec id="sec3-pharmaceuticals-18-00297"><title>3. Examples of Market Prodrugs Designed to Enhance Drug Permeability</title><p>To comprehend the impact of the prodrug approach to modify physical&#8211;chemical properties, all logP values reported in the figures within this subchapter were calculated using in silico methods with MarvinSketch 24.3.0, 2024, ChemAxon software (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.chemaxon.com">www.chemaxon.com</uri>).</p><p>In the context of passive transport, the diffusion of drugs through the membrane is facilitated by the absence of charges in the molecular structure. As a result, charged compounds typically exhibit lower permeability compared to neutral ones [<xref rid="B103-pharmaceuticals-18-00297" ref-type="bibr">103</xref>]. This challenge can be addressed by masking the molecular charge by carrier groups in prodrugs. Several prodrugs available on the market have been developed using this strategy [<xref rid="B17-pharmaceuticals-18-00297" ref-type="bibr">17</xref>].</p><p>Dimethyl fumarate (DMF) (1) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>), for instance, is a hygroscopic powder with antifungal properties, which is often used as a dehumidifying agent to prevent contamination and deterioration. In 1959, Schweckendiek explored the use of DMF for psoriasis, drawing attention to the therapeutic potential of this simple molecule [<xref rid="B104-pharmaceuticals-18-00297" ref-type="bibr">104</xref>]. Today, DMF is approved not only for the treatment of psoriasis but also for multiple sclerosis. The drug exerts a pleiotropic effect on various targets, including erythroid-derived factor 2 (Nrf2), hydroxycarboxylic acid receptor 2 (HCAR2), and factor nuclear kappa B (NF-&#954;B), among others [<xref rid="B105-pharmaceuticals-18-00297" ref-type="bibr">105</xref>]. Monomethyl fumarate (2) is the active form; however, the presence of the charged carboxylic acid at physiological pH limits its absorption through biological membranes via passive diffusion. To address this issue, the dimethyl derivative improves lipophilic parameters, thereby enhancing absorption [<xref rid="B106-pharmaceuticals-18-00297" ref-type="bibr">106</xref>]. After oral administration, DMF is rapidly bioconverted by esterases into monomethyl fumarate (2), the active metabolite, with a half-life of 36 h, while DMF itself has a half-life of 12 min [<xref rid="B107-pharmaceuticals-18-00297" ref-type="bibr">107</xref>].</p><p>The discovery of oseltamivir (3) (solubility: 82 mg/mL; logP: 1.2) serves as an excellent example of the successful application of the prodrug approach to enhance membrane permeability. In 2009, the H1N1 swine flu affected approximately 60 million individuals in the United States, resulting in an estimated 12,000 fatalities [<xref rid="B108-pharmaceuticals-18-00297" ref-type="bibr">108</xref>]. Oseltamivir (3) is an antiviral medication that functions by inhibiting the viral neuraminidase, an enzyme that cleaves sialic acid to prevent the release of viral particles. Due to the conserved nature of the neuraminidase active site, the drug demonstrates efficacy against various viral subtypes, with inhibitory concentration (IC<sub>50</sub>) values ranging from 0.01 to 69.2 nM [<xref rid="B109-pharmaceuticals-18-00297" ref-type="bibr">109</xref>]. Structure-based drug design focused on the neuraminidase active site was instrumental in the development of the compound GS 4071, which has an IC<sub>50</sub> value of 2 nM against H1N1 and water solubility of 100 mg/mL. However, despite its effectiveness in inhibiting the viral enzyme, GS 4071 exhibited low bioavailability (~5%) in rats<sup>43</sup>, which prompted further molecular optimization to address the charged carboxylic acid that contributed to its low permeability. The ethyl ester prodrug successfully led to the development of oseltamivir (3), which demonstrated improved bioavailability in mice (30%), dogs (70%), and humans (80%) [<xref rid="B109-pharmaceuticals-18-00297" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceuticals-18-00297" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceuticals-18-00297" ref-type="bibr">111</xref>]. In vivo, human carboxylesterase 1 (CES1) hydrolyzes the ethyl ester, converting it into the active form [<xref rid="B112-pharmaceuticals-18-00297" ref-type="bibr">112</xref>,<xref rid="B113-pharmaceuticals-18-00297" ref-type="bibr">113</xref>].</p><p>Mofetil mycophenolate (4) (solubility: 43 mcg/mL; log P: 2.68) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) is an immunosuppressive prodrug used to prevent allograft rejection, which acts by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH). It is about five times more potent to inhibit IMPDH type II isoforms expressed in lymphocytes than type I isoforms expressed in various cells, and thus interferes in the de novo synthesis of guanosine [<xref rid="B114-pharmaceuticals-18-00297" ref-type="bibr">114</xref>]. Although active, the inferior oral bioavailability of the parental mycophenolic acid (5) motivated the carboxylic acid masking to enhance membrane permeability. After oral administration of mofetil mycophenolate (4), the levels of mycophenolic acid (5) in plasma ranged from 80.7 to 94% [<xref rid="B115-pharmaceuticals-18-00297" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceuticals-18-00297" ref-type="bibr">116</xref>]. Differently from the acid character of mycophenolic acid (5) that is ionized in plasma, mofetil mycophenolate (4) exhibits a slightly basic (pKa 5.7) and more neutral profile that favors its membrane diffusion by passive transport [<xref rid="B117-pharmaceuticals-18-00297" ref-type="bibr">117</xref>]. After oral administration of mofetil mycophenolate (4), it undergoes fast presystemic bioconversion through the CES-1 and CES-2 [<xref rid="B118-pharmaceuticals-18-00297" ref-type="bibr">118</xref>].</p><p>Dabigatran etexilate (6) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) serves as a notable example of a double-prodrug strategy [<xref rid="B119-pharmaceuticals-18-00297" ref-type="bibr">119</xref>]. This compound marks a significant advancement in the treatment of venous thromboembolism, achieving FDA approval more than 60 years after the introduction of traditional anticoagulants such as warfarin [<xref rid="B120-pharmaceuticals-18-00297" ref-type="bibr">120</xref>]. Classic anticoagulants, including warfarin and heparin, function as indirect thrombin inhibitors. Warfarin acts by inhibiting vitamin K epoxide reductase, while heparin exerts its effects by targeting specific clotting factors, both of which disrupt the blood coagulation cascade [<xref rid="B120-pharmaceuticals-18-00297" ref-type="bibr">120</xref>]. In contrast, dabigatran etexilate (6) demonstrated superior thromboprophylaxis and safety in randomized clinical trials, offering improved outcomes over conventional treatments for vascular events [<xref rid="B121-pharmaceuticals-18-00297" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceuticals-18-00297" ref-type="bibr">122</xref>].</p><p>The active compound, dabigatran (7) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>), is a reversible competitive inhibitor of thrombin, which was developed through studies on the crystal structure of the bovine thrombin&#8211;benzamidine complex [<xref rid="B123-pharmaceuticals-18-00297" ref-type="bibr">123</xref>]. However, dabigatran&#8217;s two ionizable groups result in poor cellular permeability. By incorporating hydrophobic ethyl ester and hexyloxycarbonyl carbamide chains, dabigatran etexilate (6), a double-prodrug, was created to enable oral absorption. Upon first-pass metabolism via hepatic and pancreatic carboxylesterases, the prodrug is converted into the active form, dabigatran (7) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>), which exhibits a Ki of 4.5 nM. This active compound forms a stable complex with thrombin, effectively inhibiting its role in the coagulation cascade [<xref rid="B120-pharmaceuticals-18-00297" ref-type="bibr">120</xref>,<xref rid="B124-pharmaceuticals-18-00297" ref-type="bibr">124</xref>].</p><p>Capecitabine (8) (logP 1.43) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) is a carbamate derivative of the metabolically active 5-fluorouracil (9), representing another excellent example of prodrug development aimed at enhancing bioavailability. The oral formulation of capecitabine has rendered the intravenous administration of 5-fluorouracil largely obsolete [<xref rid="B125-pharmaceuticals-18-00297" ref-type="bibr">125</xref>]. Capecitabine is a antimetabolite agent indicated for various malignancies, including early-stage triple-negative breast cancer [<xref rid="B126-pharmaceuticals-18-00297" ref-type="bibr">126</xref>], pancreatic cancer [<xref rid="B127-pharmaceuticals-18-00297" ref-type="bibr">127</xref>], colorectal cancer [<xref rid="B128-pharmaceuticals-18-00297" ref-type="bibr">128</xref>], and biliary tract cancer [<xref rid="B129-pharmaceuticals-18-00297" ref-type="bibr">129</xref>]. Capecitabine (8) undergoes biotransformation in the liver, where carboxylesterases convert it to 5&#8242;-deoxy-5-fluorouridine (5&#8242;-DFUR). This intermediate is subsequently metabolized to 5-fluorouracil (5-FU) (9) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) by cytidine deaminase and thymidine phosphorylase (dThdPase), enzymes that are overexpressed in many tumor types. Due to this series of three metabolic steps, capecitabine is classified as a pre-prodrug of 5-FU [<xref rid="B130-pharmaceuticals-18-00297" ref-type="bibr">130</xref>].</p><p>While &#946;-lactam antibiotics have profoundly transformed human history since the discovery of penicillin (10), the growing emergence of resistance poses significant global concerns [<xref rid="B131-pharmaceuticals-18-00297" ref-type="bibr">131</xref>,<xref rid="B132-pharmaceuticals-18-00297" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceuticals-18-00297" ref-type="bibr">133</xref>]. Among the various mechanisms of resistance, the expression of the enzyme &#946;-lactamase is the most prevalent and significant determinant of bacterial resistance to &#946;-lactams, particularly in Gram-negative bacteria [<xref rid="B134-pharmaceuticals-18-00297" ref-type="bibr">134</xref>]. This is especially concerning as the rapid spread of resistance mechanisms threatens to render &#946;-lactams, currently the most widely used drugs for treating bacterial infections, completely obsolete [<xref rid="B135-pharmaceuticals-18-00297" ref-type="bibr">135</xref>,<xref rid="B136-pharmaceuticals-18-00297" ref-type="bibr">136</xref>,<xref rid="B137-pharmaceuticals-18-00297" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceuticals-18-00297" ref-type="bibr">138</xref>,<xref rid="B139-pharmaceuticals-18-00297" ref-type="bibr">139</xref>]. The enzyme &#946;-lactamase catalyzes the hydrolytic cleavage of the &#946;-lactam ring, thereby neutralizing the antibacterial activity of several drug classes, including penicillins, cephalosporins, and carbapenems [<xref rid="B140-pharmaceuticals-18-00297" ref-type="bibr">140</xref>]. Serine &#946;-lactamases, a common subclass of &#946;-lactamase enzymes, can be effectively inhibited by compounds such as clavulanic acid, tazobactam, and sulbactam. However, metallo-&#946;-lactamases (MBLs), which utilize zinc ions in their active site for catalysis, are not susceptible to inhibition by these drugs. This resistance to conventional inhibitors makes MBL-producing bacteria a particular concern in clinical settings [<xref rid="B141-pharmaceuticals-18-00297" ref-type="bibr">141</xref>].</p><p>The prodrug strategy in &#946;-lactams has been used in many ways to improve PK/PD properties and resist the action of &#946;-lactamases. The problem of instability at acidic pH inherent to the penicillin penem core was the first challenge faced. The high susceptibility to hydrolysis of the &#946;-lactam ring limits its oral absorption, which motivated the development of aminopenicillins, such as ampicillin (11) and amoxicillin (12) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). The presence of the primary amine group at the &#946;-carbon of the carbonyl, in addition to increasing the stability of &#946;-lactams at stomach pH, generates an analogous structure of tripeptides that increases absorption mediated by peptide transporters present in the enterocyte membrane [<xref rid="B142-pharmaceuticals-18-00297" ref-type="bibr">142</xref>]. However, the presence of an acid carboxyl group present in different &#946;-lactam cores also penalizes the oral bioavailability of aminopenicillins. With this information in mind, the classical application of ester prodrugs was used to develop drugs with better permeability, such as pivampicillin (13), talampicillin (14), bacampicillin (15), hetacillin (16), and lenampicillin (17) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). All these prodrugs are extensively cleaved by bacterial esterases and release the active metabolite [<xref rid="B143-pharmaceuticals-18-00297" ref-type="bibr">143</xref>].</p><p>Sofosbuvir (SOF) (18) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) is a low-molecular-weight prodrug used in the treatment of chronic hepatitis C virus (HCV) infections. After oral administration, SOF (18) is rapidly metabolized into its active form, uridine triphosphate (GS-461203), through a series of enzymatic reactions, with phosphorylation being the key process for inhibiting viral replication (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). The conversion of SOF (18) into its active metabolite (26) is essential for its efficacy, as the triphosphate directly inhibits HCV RNA polymerase. The permeability of SOF (25) across biological membranes is influenced by its solubility, which is pH-dependent and can affect its bioavailability. In vitro studies have shown that co-administration with ledipasvir (LDV), an NS5A protein inhibitor of HCV, significantly increases SOF (25) permeability, resulting in a 2.3-fold increase in plasma exposure. This interaction helps optimize therapeutic efficacy, as increased exposure may improve clinical outcomes. Additionally, the half-life of SOF (25), approximately 12 h, allows for convenient dosing and facilitates treatment adherence, particularly in prolonged regimens, as it reduces the need for frequent administration. The pharmacokinetic profile of SOF (25), with its efficient conversion to the active triphosphate, is a well-established option for the treatment of HCV [<xref rid="B144-pharmaceuticals-18-00297" ref-type="bibr">144</xref>].</p><p>Tenofovir (TFV) (19) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) is a nucleoside analogue widely used in the treatment of HIV infection, primarily acting as a competitive inhibitor of reverse transcriptase, thereby preventing the reverse transcription of viral RNA into DNA and inhibiting HIV replication. As a prodrug, TFV (19) undergoes intracellular conversion to its active form, tenofovir diphosphate (TFV-DP) (20), through a phosphorylation process catalyzed by cellular kinases, predominantly in T lymphocytes and macrophages (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). This conversion to TFV-DP (20) is critical for its antiviral activity, as TFV-DP (20) is incorporated into the growing viral DNA strand, resulting in chain termination and inhibition of viral replication. Tenofovir disoproxil fumarate (TDF) (21) and tenofovir alafenamide (TAF) (22) are prodrugs of TFV (19), differing in their chemical structures and the efficiency with which they are converted to TFV (19) in target cells (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). TDF (21) is converted into TFV (19) through hydrolysis of the disoproxil ester group, followed by the formation of TFV-DP (20). In contrast, TAF (22) is more efficiently metabolized within cells, releasing TFV (19) directly into target cells, thus allowing for lower oral doses of equivalent TFV (19) to be administered. This results in reduced plasma concentrations of TFV (27), minimizing systemic exposure to off-target organs such as the kidneys and reducing the renal toxicity associated with TDF (20). Furthermore, TAF (22) does not rely on renal transporters for cellular uptake, which further enhances its safety profile, particularly regarding renal toxicity. In terms of in vitro activity, TFV (19) exhibits an effective concentration (EC<sub>50</sub>) against HIV-1 of approximately 5.0 &#181;M. In comparison, TDF (29) and TAF (20) demonstrate significantly greater potency, with EC<sub>50</sub> values of 0.05 &#181;M and 0.005 &#181;M, respectively [<xref rid="B145-pharmaceuticals-18-00297" ref-type="bibr">145</xref>].</p><p>Adefovir dipivoxil (23) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) is a prodrug used in the treatment of viral infections, particularly hepatitis B and HIV (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). Upon administration, the prodrug undergoes hydrolysis of the pivaloyloxymethyl (POM) ester group, converting it into adefovir, which is subsequently phosphorylated by cellular kinases to form adefovir diphosphate (PMEA-DP) (24) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). This active metabolite (24) is then incorporated into the growing viral DNA strand during replication, leading to chain termination and inhibition of viral replication. This phosphorylation process, critical for the drug&#8217;s antiviral activity, predominantly occurs in lymphocytes and hepatocytes, which are the primary target cells for the virus. The presence of the POM moiety in adefovir dipivoxil (23) plays a crucial role in enhancing the drug&#8217;s lipid solubility, which in turn improves its permeability across biological membranes. This structural modification allows the prodrug (23) to efficiently enter target cells, ensuring higher intracellular concentrations of the active form, adefovir diphosphate (24). Additionally, the co-crystallization of adefovir dipivoxil with carboxylic acids has been shown to improve its stability, which is beneficial in preventing degradation under challenging environmental conditions and enhancing overall bioavailability. Although adefovir dipivoxil (31) demonstrates improved permeability and stability compared to its active form, adefovir diphosphate (32), its renal excretion remains a concern. The drug and its metabolites are primarily eliminated through the kidneys, which may contribute to renal toxicity, especially with prolonged use. Therefore, careful monitoring of renal function is essential to optimize therapeutic outcomes while minimizing adverse effects. The reduced plasma concentrations of adefovir, achieved by using the prodrug, help mitigate systemic exposure to off-target organs, reducing the potential for toxicity [<xref rid="B146-pharmaceuticals-18-00297" ref-type="bibr">146</xref>,<xref rid="B147-pharmaceuticals-18-00297" ref-type="bibr">147</xref>].</p><p>Fosphenytoin (25) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) is a prodrug of phenytoin (26), developed to address the poor solubility and erratic absorption of phenytoin when administered through conventional routes. Its phosphate ester formulation enhances water solubility, enabling safer and more efficient intravenous and intranasal administration, particularly in emergency situations such as the management of epileptic seizures and status epilepticus. The conversion of fosphenytoin (25) to phenytoin (26) (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) occurs rapidly in a concentration-dependent manner, facilitated by the activity of alkaline phosphatases present in the nasal mucosa and other tissues. This biotransformation process ensures the efficient release of the active drug, bypassing first-pass metabolism and thereby enhancing therapeutic efficacy [<xref rid="B99-pharmaceuticals-18-00297" ref-type="bibr">99</xref>].</p><sec id="sec3dot1-pharmaceuticals-18-00297"><title>3.1. Prodrugs to Enhance Ocular, Skin, and CNS Permeability</title><p>Tafluprost (27) (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>) is a fluorinated ester analogue of prostaglandin F<sub>2&#945;</sub> (28) used to treat ocular hypertension and open-angle glaucoma. Due to its lipophilicity as an ester, tafluprost (27) quickly penetrates the cornea, followed by hydrolysis to its active form, tafluprost acid (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>), by carboxyl esterase. The peak of plasmatic concentration peaks is achieved after 10 min of administration and falls below 10 pg/mL after 30 min. It may be used in monotherapy but achieves greater intraocular pressure reduction in conjunction with timolol [<xref rid="B148-pharmaceuticals-18-00297" ref-type="bibr">148</xref>,<xref rid="B149-pharmaceuticals-18-00297" ref-type="bibr">149</xref>]. It binds almost exclusively to the FP receptor, activating uveoscleral outflow and reducing intraocular pressure. In comparison to other prostaglandin analogs, latanoprost and travoprost, the binding affinity of tafluprost (27) towards FP is 12- and 2.8-fold higher, respectively [<xref rid="B150-pharmaceuticals-18-00297" ref-type="bibr">150</xref>].</p><p>Ophthalmic epinephrine (29) (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>) is used to reduce intraocular pressure in the treatment of open angle glaucoma [<xref rid="B151-pharmaceuticals-18-00297" ref-type="bibr">151</xref>]. Uveoscleral outflow is activated once epinephrine binds to &#945;2 adrenergic receptors [<xref rid="B152-pharmaceuticals-18-00297" ref-type="bibr">152</xref>]. However, epinephrine&#8217;s (29) reduced lipophilicity makes its corneal penetration difficult, resulting in undesirable side effects like irritation, eyebrow pain and adrenochrome deposits in the cornea and conjunctiva [<xref rid="B153-pharmaceuticals-18-00297" ref-type="bibr">153</xref>]. Esterification of its phenolic hydroxyl group makes it 100 to 600 times more lipophilic than its parent drug, increasing corneal permeability and nearly eliminating the side effects. After penetration, dipivefrin (30) is hydrolyzed by esterase enzymes, releasing epinephrine (29) [<xref rid="B151-pharmaceuticals-18-00297" ref-type="bibr">151</xref>]. Both epinephrine (29) and dipivefrin (30) are absorbed locally, followed by systemic absorption [<xref rid="B154-pharmaceuticals-18-00297" ref-type="bibr">154</xref>]. Between 55% and 65% of the initially administered ophthalmic doses of these drugs are absorbed into systemic circulation (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) [<xref rid="B154-pharmaceuticals-18-00297" ref-type="bibr">154</xref>].</p><p>While generally safe, cataract surgery can induce inflammation and adverse effects, such as elevated intraocular pressure and cystoid macular edema (CME), potentially reducing long-term visual acuity [<xref rid="B155-pharmaceuticals-18-00297" ref-type="bibr">155</xref>]. Consequently, topical NSAIDs are used in post-operative care, reducing ocular pain, inflammation, and CME. In comparison to NSAIDs like ketorolac, bromfenac, and flurbiprofen, nepafenac (31) is most likely to improve post-operative care [<xref rid="B156-pharmaceuticals-18-00297" ref-type="bibr">156</xref>]. Nepafenac (31) is a prodrug derived from amfenac (32), where the polar charge-bearing carboxyl group is converted to an amide, increasing its lipophilicity and corneal penetration [<xref rid="B157-pharmaceuticals-18-00297" ref-type="bibr">157</xref>]. Once nepafenac is bioactivated by hydrolases, the resulting amfenac inhibits Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes, halting arachidonic acid cascade and its inflammatory effects (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) [<xref rid="B158-pharmaceuticals-18-00297" ref-type="bibr">158</xref>].</p><p>Tazarotene (42) is a synthetic retinoid approved to treat acne vulgaris, plaque psoriasis, and photoaging (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) [<xref rid="B159-pharmaceuticals-18-00297" ref-type="bibr">159</xref>]. Additionally, it has been displayed to be efficient in the treatment of basal cell carcinoma [<xref rid="B160-pharmaceuticals-18-00297" ref-type="bibr">160</xref>], in situ squamous cell carcinoma [<xref rid="B161-pharmaceuticals-18-00297" ref-type="bibr">161</xref>], and ichthyosis [<xref rid="B162-pharmaceuticals-18-00297" ref-type="bibr">162</xref>], among others. Tazarotene (33) is administered topically, its lipophilic, uncharged nature makes its absorption quick in the lipid rich stratum corneum. Once it reaches the keratinocytes in the epidermis, it is quickly metabolized by esterases into its active form, tazarotenic acid (34), which selectively binds to the retinoic acid receptors (RARs) RAR-&#946; and RAR-&#947;. Binding results in modulation of three pathogenic factors, reducing inflammation, normalizing keratinocyte differentiation, and reducing skin cell hyperproliferation (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) [<xref rid="B163-pharmaceuticals-18-00297" ref-type="bibr">163</xref>]. Less than 6% of tazarotenic acid (34) is absorbed into the bloodstream, leading to minimal plasma concentrations and reduced systemic absorption [<xref rid="B164-pharmaceuticals-18-00297" ref-type="bibr">164</xref>].</p><p>Betamethasone dipropionate (35), a glucocorticoid prodrug, is administered topically by itself or in conjunction with calcipotriol in the treatment of psoriasis (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>). The parental drug, betamethasone (36) (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>), binds on the glucocorticoid receptors, then the ligand&#8211;receptor pair acts as a transcription factor or enhances other transcription factors, modulating gene expression (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). Anti-inflammatory genes, such as DUSP1, GILZ, and ANXA1, are transactivated, while transrepressing pro-inflammatory transcription factors, such as NF-&#954;B and AP-1. Consequently, inflammation and immune response due to inflammation, the causative factors of psoriasis, are reduced [<xref rid="B165-pharmaceuticals-18-00297" ref-type="bibr">165</xref>]. The prodrug (35) is a doubly esterified form of the parent drug (36); its increased lipophilicity facilitates stratum corneum penetration and once it reaches the dermis it is hydrolyzed, releasing the parent drug [<xref rid="B166-pharmaceuticals-18-00297" ref-type="bibr">166</xref>]. In a phase II clinical trial of a betamethasone dipropionate (35) containing cream with a concentration of 0.644 mg/g, about 27 subjects received a weekly average dose of 79 g of the cream. After four weeks, 24 subjects had undetectable betamethasone dipropionate plasma levels and three of them had levels ranging from 13 to 31 pg/mL, indicating low systemic absorption [<xref rid="B167-pharmaceuticals-18-00297" ref-type="bibr">167</xref>,<xref rid="B168-pharmaceuticals-18-00297" ref-type="bibr">168</xref>].</p><p>To improve BBB permeability, a more elaborate prodrug approach is needed, as is the case of Chemical Delivery Systems (CDSs), a prodrug approach with multiple bioactivating steps. Such an approach was employed for an estradiol CDS prodrug consisting of a dihydrotrigonelline moiety esterified to an estradiol molecule (<xref rid="pharmaceuticals-18-00297-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B169-pharmaceuticals-18-00297" ref-type="bibr">169</xref>]. The CDS would benefit from increased lipophilicity (logP 4.5) from the esterification and cross the BBB, followed by oxidation of the dihydrotrigonelline moiety to trigonelline, which is positively charged. Once the CDS acquires a charge, its lipophilicity dramatically decreases (logP &#8722;0.17), making it unable to cross the BBB again and getting trapped inside the CNS, where it lingers long enough to be slowly hydrolyzed, releasing estradiol locally [<xref rid="B169-pharmaceuticals-18-00297" ref-type="bibr">169</xref>,<xref rid="B170-pharmaceuticals-18-00297" ref-type="bibr">170</xref>]. Unfortunately, this CDS, known as Estredox or IDR-90104, had its phase II clinical trials discontinued [<xref rid="B171-pharmaceuticals-18-00297" ref-type="bibr">171</xref>].</p><p>Levodopa (37) (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>) is one of the few approved CNS targeting prodrugs designed to increase BBB permeability to treat Parkinson&#8217;s disease (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>). It is taken orally and absorbed in the intestine; however, enzyme <italic toggle="yes">L</italic>-amino acid decarboxylase (AADC) quickly metabolizes it and only 30% of the initial dose reaches systemic circulation. To avoid presystemic metabolism, levodopa is taken in combination with an AADC inhibitor, which is either benserazide or carbidopa; in this manner, oral bioavailability is nearly tripled [<xref rid="B172-pharmaceuticals-18-00297" ref-type="bibr">172</xref>]. Fasting absorption is rapid, reaching peak plasma concentrations after 15 to 60 min [<xref rid="B173-pharmaceuticals-18-00297" ref-type="bibr">173</xref>]. Once it reaches the BBB, levodopa is taken in through LAT1 [<xref rid="B174-pharmaceuticals-18-00297" ref-type="bibr">174</xref>] and once it reaches the CNS, it is bioactivated by AADC, releasing dopamine (38) [<xref rid="B175-pharmaceuticals-18-00297" ref-type="bibr">175</xref>]. The synthesized dopamine aims to replenish the deficit caused by substantia nigra degeneration [<xref rid="B176-pharmaceuticals-18-00297" ref-type="bibr">176</xref>].</p><p>The prodrug strategy applied to codeine (39) (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>), like most approved prodrugs targeting the CNS, does not improve its BBB permeability but rather its permeability in the gastrointestinal tract, due to increased lipophilicity resulting from hydroxyl masking [<xref rid="B177-pharmaceuticals-18-00297" ref-type="bibr">177</xref>]. After oral administration, codeine (39) is quickly absorbed, followed by peak plasma concentrations after 1 h, with a half-life of 3 to 3.5 h. It may also be administered intramuscularly, resulting in a faster plasma peak after 0.5 h [<xref rid="B178-pharmaceuticals-18-00297" ref-type="bibr">178</xref>]. Codeine (39) is metabolized into its parent drug, morphine (40), by cytochrome p450 enzyme, CYP2D6 [<xref rid="B178-pharmaceuticals-18-00297" ref-type="bibr">178</xref>]. In turn, morphine (40) crosses the BBB and binds as an agonist to the &#956;-opioid receptor, providing an analgesic effect (<xref rid="pharmaceuticals-18-00297-t002" ref-type="table">Table 2</xref>) [<xref rid="B179-pharmaceuticals-18-00297" ref-type="bibr">179</xref>].</p></sec><sec id="sec3dot2-pharmaceuticals-18-00297"><title>3.2. The Use of Drug Transporters in the Pharmaceutical Market</title><p>The transport of pharmaceuticals and endogenous molecules across cellular membranes is mediated by drug transporters, which are integral membrane proteins crucial for the pharmacokinetic processes of drugs. These transporters facilitate the movement of drugs and other substances via active transport, utilizing the energy derived from ATP hydrolysis or through ion or concentration gradients [<xref rid="B180-pharmaceuticals-18-00297" ref-type="bibr">180</xref>]. Drug transporters are typically classified into three major superfamilies: ATP-Binding Cassette (ABC), Solute-Linked Carrier (SLC), and Solute Carrier Organic Anion (SLCO). The role of these transporters in facilitating the movement of molecules is particularly significant in drug development, where their interaction with therapeutic agents can have profound implications for drug efficacy and safety [<xref rid="B22-pharmaceuticals-18-00297" ref-type="bibr">22</xref>,<xref rid="B181-pharmaceuticals-18-00297" ref-type="bibr">181</xref>]. In prodrug design, structural scaffolds can be strategically tailored to target transporters expressed in specific tissues, enhancing pharmacokinetic properties and minimizing off-target effects. After crossing the membrane, the prodrug undergoes cleavage within the cytoplasm, releasing the active drug. Several transporters have been explored to improve drug permeability including: transporters of amino acids, oligopeptides, carbohydrates, bile acid, vitamins, and carnitine [<xref rid="B182-pharmaceuticals-18-00297" ref-type="bibr">182</xref>].</p><p>The ABC superfamily predominantly consists of primary active uniporters, which employ ATP hydrolysis to translocate molecules unidirectionally across cellular membranes [<xref rid="B183-pharmaceuticals-18-00297" ref-type="bibr">183</xref>]. The SLC superfamily comprises secondary active transporters that utilize electrochemical or concentration gradients to mediate the transport of drugs and ions and may also harness the energy derived from ion gradients generated by ATP-dependent pumps [<xref rid="B184-pharmaceuticals-18-00297" ref-type="bibr">184</xref>]. The SLCO superfamily, previously categorized under the SLC21 subfamily and now recognized as Organic Anion Transporting Polypeptide (OATP), is responsible for the transport of larger molecules, such as xenobiotics and bile acids, and plays a critical role in the absorption and elimination of both endogenous and exogenous compounds. These superfamilies exemplify the diversity of transport mechanisms, each with distinct roles in optimizing the absorption and disposition of drugs, which is crucial for the development of effective drug delivery systems [<xref rid="B22-pharmaceuticals-18-00297" ref-type="bibr">22</xref>]. This transporter-mediated transport is essential for the ADME of drugs, significantly influencing their therapeutic efficacy and safety profiles within the body [<xref rid="B180-pharmaceuticals-18-00297" ref-type="bibr">180</xref>,<xref rid="B181-pharmaceuticals-18-00297" ref-type="bibr">181</xref>,<xref rid="B182-pharmaceuticals-18-00297" ref-type="bibr">182</xref>,<xref rid="B183-pharmaceuticals-18-00297" ref-type="bibr">183</xref>,<xref rid="B184-pharmaceuticals-18-00297" ref-type="bibr">184</xref>,<xref rid="B185-pharmaceuticals-18-00297" ref-type="bibr">185</xref>,<xref rid="B186-pharmaceuticals-18-00297" ref-type="bibr">186</xref>,<xref rid="B187-pharmaceuticals-18-00297" ref-type="bibr">187</xref>].</p><p>Among the widely used transport systems, the amino acid transporter LAT1/SLC7A5 stands out. LAT1 is a non-glycosylated protein that forms a complex with the membrane protein 4F2hc/SLC3A2, and is expressed in several cells of the central nervous system and also in brain tumors such as gliomas [<xref rid="B188-pharmaceuticals-18-00297" ref-type="bibr">188</xref>]. Several drugs are known to use this transport system to cross the BBB, including gabapentin, levodopa, baclofen, methyldopa, pregabalin, and melphalan. The design of prodrugs exploiting this transport system usually involves conjugation of the drug with the amino acids phenylalanine or tyrosine [<xref rid="B184-pharmaceuticals-18-00297" ref-type="bibr">184</xref>].</p><p>Similarly, valacyclovir (42) (<xref rid="pharmaceuticals-18-00297-t004" ref-type="table">Table 4</xref>), an ester prodrug of acyclovir (41), utilizes transporter systems such as human peptide transporter-1 (hPEPT-1) to enhance the bioavailability of acyclovir, which is limited by its low intestinal absorption (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>). Upon oral administration, valacyclovir (42) is absorbed in the gastrointestinal tract via specific peptide transporter proteins, including hPEPT-1, which is responsible for the active transport of dipeptides and structurally similar compounds, such as valacyclovir (42), which is esterified with the amino acid <italic toggle="yes">L</italic>-valine. This interaction with transporters underscores the central role of transporter-mediated absorption in overcoming bioavailability limitations of certain drugs [<xref rid="B189-pharmaceuticals-18-00297" ref-type="bibr">189</xref>].</p><p>The esterification of acyclovir (41) (<xref rid="pharmaceuticals-18-00297-t004" ref-type="table">Table 4</xref>) with <italic toggle="yes">L</italic>-valine increases valacyclovir&#8217;s (23) affinity for hPEPT-1 and potentially other peptide transporters, such as human intestinal peptide transporter-1 (HPT-1). This interaction with high-capacity transporters facilitates its translocation across the intestinal epithelium, resulting in significantly higher bioavailability compared to acyclovir administered orally. After absorption, valacyclovir (42) undergoes hydrolytic cleavage by esterase enzymes in intestinal and hepatic tissues, rapidly releasing acyclovir (41), the pharmacologically active molecule. The improved bioavailability of valacyclovir (42) mirrors the benefits observed with XP13512, as both prodrugs enhance the systemic availability of their active components through transporter-mediated mechanisms [<xref rid="B189-pharmaceuticals-18-00297" ref-type="bibr">189</xref>].</p><p>The improved bioavailability of valacyclovir (42) enables the dosing frequency and dosage to be reduced compared to acyclovir (41), which optimizes patient compliance. Furthermore, the efficient conversion and enhanced transport of valacyclovir (42) contribute to elevated plasma concentrations of acyclovir (52), thereby improving its therapeutic efficacy in the treatment of herpes zoster, genital herpes, and as a prophylactic treatment for cytomegalovirus in immunocompromised patients [<xref rid="B190-pharmaceuticals-18-00297" ref-type="bibr">190</xref>].</p><p>In the context of neurological treatments, the role of drug transporters is also evident in the action of valbenazine (54) (<xref rid="pharmaceuticals-18-00297-t004" ref-type="table">Table 4</xref>), which is a selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Valbenazine (54) is a valine ester of the active metabolite [+]-&#945;-dihydrotetrabenazine ([+]-&#945;-HTBZ) (55), which, after metabolic conversion, exerts most of the pharmacological activity of the compound (<xref rid="pharmaceuticals-18-00297-t003" ref-type="table">Table 3</xref>) [<xref rid="B191-pharmaceuticals-18-00297" ref-type="bibr">191</xref>]. This metabolite has high affinity for VMAT2, with significant selectivity for VMAT2 over off-target receptors, minimizing the risk of unwanted interactions. Pharmacokinetically, valbenazine (54) has a half-life of 15 to 20 h and is administered once daily, with stable pharmacokinetics unaffected by food intake [<xref rid="B191-pharmaceuticals-18-00297" ref-type="bibr">191</xref>,<xref rid="B192-pharmaceuticals-18-00297" ref-type="bibr">192</xref>,<xref rid="B193-pharmaceuticals-18-00297" ref-type="bibr">193</xref>].</p><p>Several studies in the literature highlight the design of prodrugs exploring conjugation with transporter substrates to increase drug permeability. This strategy is a powerful tool to explore in drug design aiming to enhance permeability across the membranes [<xref rid="B19-pharmaceuticals-18-00297" ref-type="bibr">19</xref>,<xref rid="B85-pharmaceuticals-18-00297" ref-type="bibr">85</xref>,<xref rid="B191-pharmaceuticals-18-00297" ref-type="bibr">191</xref>,<xref rid="B192-pharmaceuticals-18-00297" ref-type="bibr">192</xref>,<xref rid="B193-pharmaceuticals-18-00297" ref-type="bibr">193</xref>,<xref rid="B194-pharmaceuticals-18-00297" ref-type="bibr">194</xref>,<xref rid="B195-pharmaceuticals-18-00297" ref-type="bibr">195</xref>,<xref rid="B196-pharmaceuticals-18-00297" ref-type="bibr">196</xref>].</p></sec></sec><sec id="sec4-pharmaceuticals-18-00297"><title>4. New Technologies in Prodrugs to Enrich Permeability Properties</title><sec id="sec4dot1-pharmaceuticals-18-00297"><title>4.1. Prodrugs of PROteolysis TArgeting Chimeras (PROTACs)</title><p>With the advances in understanding the human genome, it has become possible to estimate that protein-coding genes may give rise to more than 20,000 proteins that could serve as potential therapeutic targets [<xref rid="B197-pharmaceuticals-18-00297" ref-type="bibr">197</xref>]. However, despite this knowledge, many of these potential targets remain challenging to address, such as transcription factors. In this regard, new intervention strategies must be developed, such as PROTACs. The term PROTAC was first introduced over 20 years ago by Crews and colleagues. This innovative approach leverages heterobifunctional molecules designed to degrade specific target proteins. These molecules bind to a protein of interest (POI), facilitating its ubiquitination and subsequent degradation via the proteasome [<xref rid="B198-pharmaceuticals-18-00297" ref-type="bibr">198</xref>].</p><p>Since the first PROTAC was reported by the Crews group, it has been noted that, despite its effectiveness in protein degradation and low cytotoxicity, challenges such as low chemical stability, solubility, permeability, and failure to comply with Lipinski&#8217;s rule of five (Ro5) may impact its oral bioavailability [<xref rid="B199-pharmaceuticals-18-00297" ref-type="bibr">199</xref>,<xref rid="B200-pharmaceuticals-18-00297" ref-type="bibr">200</xref>].</p><p>Typically, strategies for optimizing the properties of PROTACs to improve permeability and solubility involve modifications in the linker chains. Small linkers containing polar and/or ionizable groups can help achieve an appropriate balance of physicochemical properties, thereby enhancing these physicochemical properties [<xref rid="B201-pharmaceuticals-18-00297" ref-type="bibr">201</xref>]. For solubility, for example, it has been proposed that the use of values superior to 60 &#956;g/mL seems to be reasonable as a starting point [<xref rid="B202-pharmaceuticals-18-00297" ref-type="bibr">202</xref>]. The prediction of solubility for PROTACs is a difficult task due to molecular conformation and chameleonicity issues related to the PROTACs, but some authors have proposed that BRlogD and TPSA values with threshold values of 2.58 and 289 &#197;<sup>2</sup> could be desirable for soluble PROTACs [<xref rid="B201-pharmaceuticals-18-00297" ref-type="bibr">201</xref>]. Nevertheless, due to the requirement for recognition by the POI, it is also necessary to establish conformational restrictions to ensure the correct geometry of the ternary complex. This can, however, lead to an increase in the lipophilicity of PROTACs, making it more challenging to maintain a proper balance of physicochemical properties [<xref rid="B200-pharmaceuticals-18-00297" ref-type="bibr">200</xref>]. In such situations, incorporating rigid linkers with cationic subunits can help improve permeability. Moreover, exploring strategies to enhance intracellular uptake, such as the use of carriers like cell-penetrating peptides that are recognized by membrane receptors, holds significant promise for addressing the challenges of low permeability. Additionally, the prodrug approach presents an interesting and effective strategy to overcome the limitations of PROTACs, particularly with respect to solubility and permeability.</p><p>Recently, the concept of prodrug PROTACs (pro-PROTACs) has emerged as an alternative that may optimize these compounds, enabling selective delivery to target tissues while minimizing off-target effects [<xref rid="B203-pharmaceuticals-18-00297" ref-type="bibr">203</xref>]. Controllable PROTACs have been thoughtfully designed through various innovative approaches, such as light activation, photocaging, and photoswitchable systems, as well as conjugation with peptides, aptamers, and folate (<xref rid="pharmaceuticals-18-00297-f005" ref-type="fig">Figure 5</xref>). Moreover, strategies like hypoxia activation, radiotherapy-triggering, and reactive oxygen species-responsiveness have also been explored and described in the literature [<xref rid="B204-pharmaceuticals-18-00297" ref-type="bibr">204</xref>].</p><p>Wang and colleagues (2024) explored a novel strategy to enhance the permeability of PROTACs by designing an amphiphilic PROTAC incorporating a long-chain polyethylene glycol (PEG) linked to a disulfide bond, which acts as a glutathione-responsive subunit, allowing for selective cleavage inside tumor cells. The authors focused on degrading the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), a protein implicated in several cancers, including non-small cell lung cancer (NSCLC). By using this protein as the target, they employed ceritinib as the ligand and pomalidomide for cereblon (CRBN) recognition by the E3 ligase. PEG was chosen as the linker due to its hydrophilic properties, and the amphiphilic nature of the PROTAC led the authors to hypothesize that the pro-PROTAC could self-assemble into micelles in aqueous environments, significantly improving its solubility. Given the high glutathione levels in tumor cells, the disulfide bond would be reduced and cleaved, facilitating PROTAC release within tumor cells. The authors demonstrated the antiproliferative effects of the PROTAC through ALK degradation. In vivo, the pro-PROTAC B1-PEG exhibited an impressive absolute bioavailability of 84.8%, compared to 63.5% for the conventional PROTAC. Moreover, studies using the H3122 xenograft mouse model demonstrated the superior efficacy of the pro-PROTAC over both the conventional PROTAC and ceritinib, highlighting the enhanced physicochemical properties and cell permeability of the pro-PROTAC (<xref rid="pharmaceuticals-18-00297-f006" ref-type="fig">Figure 6</xref>) [<xref rid="B206-pharmaceuticals-18-00297" ref-type="bibr">206</xref>].</p><p>The incorporation of folate as a carrier can improve drug uptake, thereby enhancing the permeability of anticancer agents. The use of folate as a carrier group to improve permeability and facilitate uptake by tumor cells has been extensively applied in the design of novel antitumor agents. In tumors, three folate uptake systems have been identified: folate receptors (FRs), the reduced folate carrier (RFC), and the proton-coupled folate transporter (PCFT) [<xref rid="B207-pharmaceuticals-18-00297" ref-type="bibr">207</xref>]. The incorporation of folate as a carrier can improve drug uptake, thereby enhancing the permeability of anticancer agents. In a compelling study conducted by Liu and colleagues, the use of folate as a carrier for PROTACs was thoughtfully investigated. The authors conjugated the von Hippel&#8211;Lindau (VHL) E3 ubiquitin ligase to four distinct PROTACs, aiming to degrade BRDs (compound ARV771-N), MEKs (MS-432N), and ALK (compound MS99N) (<xref rid="pharmaceuticals-18-00297-f007" ref-type="fig">Figure 7</xref>). Given the high expression of folate receptors in various cancers (such as breast, lung, and ovarian cancers), utilizing folate as a carrier significantly enhances uptake by tumor cells, facilitating the degradation of these overexpressed proteins. The study elegantly demonstrated that targeting folate receptor-1 (FOLR1) can greatly improve the permeability of PROTACs in tumor cells, while also reducing their potential toxicity [<xref rid="B208-pharmaceuticals-18-00297" ref-type="bibr">208</xref>].</p><p>In another study led by Chen and colleagues (2021), the use of folate was investigated to enhance the permeability and uptake of pro-PROTACs (<xref rid="pharmaceuticals-18-00297-f007" ref-type="fig">Figure 7</xref>). The authors employed pomalidomide as a ligand for the CRBN E3 ligase and utilized a reduction-cleavable disulfide linker, which could be cleaved by glutathione inside the cell, enabling the release of the PROTAC named FA-S2-MS4048. Since GSH levels are relatively low in the bloodstream but significantly higher in the cytoplasm, this mechanism may offer a more selective release, potentially reducing toxicity to non-tumor cells. In this study, anaplastic lymphoma kinase (ALK) was chosen as the POI for the PROTAC, and MS4048 was employed as the ligand for ALK. The folate&#8211;disulfide linker&#8211;glutarimide conjugate was designed to minimize interaction with CRBN in other cells, enabling selective activation following disulfide reduction to release the PROTAC. Furthermore, through FOLR1 knockdown experiments using shRNA, the authors demonstrated that the degradation of the NPM-ALK fusion by FA-S2-MS4048 was absent, reinforcing that the pro-PROTAC targets FOLR1-positive cancer cells, emphasizing the critical role of folate as a carrier for the pro-PROTAC FA-S2-MS4048 [<xref rid="B205-pharmaceuticals-18-00297" ref-type="bibr">205</xref>].</p><p>The modulation of physicochemical properties in PROTACs presents several challenges, which have driven the exploration of innovative conjugation methodologies to enhance both permeability and selectivity of action. Notably, strategies such as utilizing aptamers, antibodies, peptides, or nano-based carriers have been highlighted in the literature as promising solutions for addressing issues related to permeability [<xref rid="B209-pharmaceuticals-18-00297" ref-type="bibr">209</xref>].</p><p>The conjugation of PROTACs with aptamers offers an innovative strategy to enhance tumor permeability while reducing off-target effects. Aptamers are single-stranded oligonucleotide sequences that can selectively bind to specific targets or proteins [<xref rid="B209-pharmaceuticals-18-00297" ref-type="bibr">209</xref>]. Since the FDA&#8217;s approval of pegaptanib (Macugen<sup>&#174;</sup>) for macular degeneration in 2004, numerous clinical trials have investigated the therapeutic potential of these "chemical antibodies". Aptamers present several advantages over conventional antibodies, including lower immunogenicity and higher permeability through tissues [<xref rid="B210-pharmaceuticals-18-00297" ref-type="bibr">210</xref>]. Their precise target recognition, particularly in tumor cells, makes aptamers an intriguing carrier group to explore in the development of pro-PROTACs.</p><p>He and his colleagues (2020) have described the conjugation of the aptamer AS1411, which selectively binds to nucleolin, a protein highly expressed on tumor cell membranes (<xref rid="pharmaceuticals-18-00297-f008" ref-type="fig">Figure 8</xref>) [<xref rid="B211-pharmaceuticals-18-00297" ref-type="bibr">211</xref>]. In this approach, the PROTAC utilized JQ-1 as the ligand for bromodomain (BRD4) and VHL as the E3 ligase ligand, connected by an ethoxylated spacer. A disulfide spacer was incorporated as a cleavage bond into the VHL ligand, and it was designed to be cleaved by endogenous glutathione. This linker was also coupled with the aptamers to enhance the uptake and permeability of the pro-PROTAC. Studies conducted in fetal bovine serum demonstrated high chemical stability, alongside significant cellular uptake, highlighting the improved permeability of the conjugate in comparison to conventional PROTACs. The antitumor effect in vivo was evaluated using an MCF-7 xenograft mouse model with intravenous administration at a 10 &#956;M concentration. The conjugate showed superior in vivo antitumoral effects compared to both the PROTAC and aptamers alone [<xref rid="B212-pharmaceuticals-18-00297" ref-type="bibr">212</xref>].</p><p>With the aim of degrading nucleolin, Zhang and co-workers (2022) developed a combination of the PROTAC ZL226 with the aptamer AS1411. This combination enhances the permeability of cancer cells, improving selectivity towards these cells. The compound demonstrated its chemical stability, with a half-life of approximately 70.5 h [<xref rid="B215-pharmaceuticals-18-00297" ref-type="bibr">215</xref>]. The relatively small size of aptamers (30 kDa for a 100 bp ssDNA) compared to antibodies has been recognized as a significant advantage, allowing for more efficient penetration into cells and tissues, including the central nervous system [<xref rid="B216-pharmaceuticals-18-00297" ref-type="bibr">216</xref>]. In an insightful study by Shi and colleagues (2019), the permeability of two aptamers, GMT8 and Gint4.T, which target U87MG cells and PDGFR&#946; for glioblastoma treatment, was carefully examined. The researchers developed an in vitro model using U87MG and bEnd.3 cells seeded in transwell inserts. Their findings demonstrated the aptamers&#8217; capacity to permeate through blood&#8211;brain barrier mimetic assays. Furthermore, they explored the complexation of the aptamers with paclitaxel, an anticancer drug known for promoting microtubule stabilization, which does not naturally cross the blood&#8211;brain barrier in an intact form. The aptamer&#8211;paclitaxel complex successfully facilitated paclitaxel&#8217;s cellular entry, suggesting that this aptamer transport system may offer valuable potential in enhancing drug permeability within the central nervous system [<xref rid="B217-pharmaceuticals-18-00297" ref-type="bibr">217</xref>].</p><p>Shih and colleagues (2023) investigated the conjugation of PROTACs with aptamers to target the degradation of the signal transducer and activator of transcription 3 (STAT3) (<xref rid="pharmaceuticals-18-00297-f008" ref-type="fig">Figure 8</xref>). STAT3, a transcription factor identified in the 1990s, plays a crucial role in cancer progression but presents a significant challenge for small molecule interventions, as is often the case with transcription factors. The pro-PROTAC was thoughtfully designed by incorporating an oligonucleotide that binds to STAT3 (the POI) and pomalidomide as the cereblon ligand, linked by a spacer. The rationale behind this design is that cereblon, acting as an E3 ubiquitin ligase, would facilitate the ubiquitination and degradation of STAT3. The prodrug exhibited enhanced efficacy compared to pomalidomide or the STAT3-targeting decoy oligonucleotide alone, with a Degradation Concentration 50% (DC<sub>50</sub>) of 261 nM and a Growth Inhibition 50% (GI<sub>50</sub>) of 792 nM [<xref rid="B213-pharmaceuticals-18-00297" ref-type="bibr">213</xref>].</p><p>The use of antibody&#8211;drug conjugates to enhance the selectivity of cytotoxic agents has become a well-established approach in cancer chemotherapy. This strategy involves the binding of a monoclonal antibody to specific antigens on the surface of tumor cells, facilitating their internalization and the subsequent intracellular release of the cytotoxic agent. The choice of a spacer agent plays a crucial role in modulating the physicochemical and pharmacokinetic properties, thereby improving the conjugate&#8217;s half-life and permeability [<xref rid="B218-pharmaceuticals-18-00297" ref-type="bibr">218</xref>].</p><p>While conjugates provide notable benefits in selectively delivering cytotoxic agents, certain challenges remain in their design. These challenges, including limited penetration into the microenvironment of specific solid tumors, suboptimal payload potency, potential immunogenicity, emergence of resistance, and reduced chemical stability of the conjugate, highlight the need for exploring novel approaches [<xref rid="B219-pharmaceuticals-18-00297" ref-type="bibr">219</xref>]. Antibody&#8211;PROTAC conjugation presents a promising alternative for enhancing permeability while minimizing the use of agents that are highly cytotoxic to healthy cells.</p><p>While PROTACs represent a promising strategy for targeting the degradation of specific proteins, they often face challenges such as limited selectivity, variable permeability, and suboptimal pharmacokinetic properties for oral administration. These limitations can be addressed and improved through antibody conjugation [<xref rid="B200-pharmaceuticals-18-00297" ref-type="bibr">200</xref>]. Several studies have highlighted the promising potential of antibody&#8211;PROTAC conjugates, showcasing their ability to reduce toxicity, enhance selectivity and potency, and improve permeability [<xref rid="B220-pharmaceuticals-18-00297" ref-type="bibr">220</xref>,<xref rid="B221-pharmaceuticals-18-00297" ref-type="bibr">221</xref>,<xref rid="B222-pharmaceuticals-18-00297" ref-type="bibr">222</xref>]. This review does not aim to cover all examples of antibody&#8211;PROTAC conjugates used to enhance selectivity and permeability, as these can be explored in other articles [<xref rid="B222-pharmaceuticals-18-00297" ref-type="bibr">222</xref>,<xref rid="B223-pharmaceuticals-18-00297" ref-type="bibr">223</xref>,<xref rid="B224-pharmaceuticals-18-00297" ref-type="bibr">224</xref>,<xref rid="B225-pharmaceuticals-18-00297" ref-type="bibr">225</xref>]. Instead, we will provide an example of the application of this strategy developed by Chan and colleagues (2023). These authors developed novel PROTACs targeting the degradation of serine- and threonine-protein kinase 2 (RIPK2) in HER2+ cell lines. RIPK2 is a kinase implicated in various diseases, including cancer, inflammation, and multiple sclerosis. To achieve selectivity, the authors employed trastuzumab (Abn) as a monoclonal antibody, conjugating it to the PROTAC via a linker containing dibromopyridazinedione for the formation of a disulfide bridge with the antibody, and a cleavable valine&#8211;citrulline&#8211;para-aminobenzyl alcohol moiety (<xref rid="pharmaceuticals-18-00297-f008" ref-type="fig">Figure 8</xref>). The conjugation yielded a drug-to-antibody ratio (DAR) of 4.0 for trastuzumab. A control conjugate anti-IL-4 with DAR 3.7 was also prepared to assess selectivity. In studies using the SKOV3 HER2+ ovarian cancer cell line, both the PROTAC and antibody&#8211;PROTAC demonstrated similar activity at 10 nM concentrations. However, the antibody&#8211;PROTAC offered the added advantage of acting specifically on HER2+ cells. Beyond selectivity, the antibody&#8211;PROTAC exhibited improved permeability due to selective internalization via endocytosis [<xref rid="B214-pharmaceuticals-18-00297" ref-type="bibr">214</xref>].</p><p>The use of peptides to enhance permeability and facilitate membrane crossing is a significant strategy in medicinal chemistry. The discovery that certain peptides, such as the HIV transactivator (TAT) factor and specific oligoarginines, possess the ability to traverse cell membranes and enter cells led to the development of the concept of CPPs (<xref rid="pharmaceuticals-18-00297-f009" ref-type="fig">Figure 9</xref>) [<xref rid="B226-pharmaceuticals-18-00297" ref-type="bibr">226</xref>]. Typically, CPPs are small peptides composed of fewer than 40 amino acids that promote cellular entry through various mechanisms, including direct penetration through membranes and endocytosis. These peptides can be utilized as transport systems to improve compound permeability when conjugated as prodrugs, and commonly CPPs exhibit positive charge in physiological pHs due to the presence of lysine and arginine residues [<xref rid="B227-pharmaceuticals-18-00297" ref-type="bibr">227</xref>,<xref rid="B228-pharmaceuticals-18-00297" ref-type="bibr">228</xref>,<xref rid="B229-pharmaceuticals-18-00297" ref-type="bibr">229</xref>]. Predicting the cell-penetrating ability of peptides is a valuable tool in designing CPP sequences. Artificial intelligence models, such as artificial neural networks (ANNs), have been shown to offer high predictive accuracy (80&#8211;100%), making them a powerful resource in this planning process [<xref rid="B230-pharmaceuticals-18-00297" ref-type="bibr">230</xref>].</p><p>The use of peptides to enhance cell permeability holds significant potential for the development of new conjugates with PROTACs. Given the challenges associated with the low solubility, permeability, and bioavailability of PROTACs, peptide conjugation emerges as a promising strategy for improving their physicochemical properties and biological activity. He and colleagues initially employed a conventional approach utilizing VHL-based PROTACs to target BRD4 degradation. However, they encountered challenges with inadequate tumor penetration, which threatened to compromise the efficacy of the PROTACs in vivo. To overcome this obstacle, they innovated pro-PROTAC by integrating peptides containing the RGD integrin recognition motif (<xref rid="pharmaceuticals-18-00297-f009" ref-type="fig">Figure 9</xref>). This design specifically targets &#945;v&#946;3 integrin, a protein abundantly expressed in tumor cells. Upon administration, the RGD peptide (iRGD, CRGDKGPDC) undergoes cleavage, resulting in the formation of NRP1 recognition peptides (CRGDK). NRP1, a transmembrane protein present on the tumor surface, facilitates the entry of PROTACs into tumor cells, thereby enhancing permeability. This peptide conjugation notably improved the water solubility of the PROTACs, achieving values exceeding 10 mM, in contrast to the conventional PROTACs, which exhibited a solubility of 29.5 &#956;M. Furthermore, the pro-PROTACs demonstrated commendable chemical stability in PBS containing 5% serum. In vivo experiments using a mouse model with MDA-MB-231 xenografts revealed that this peptide conjugation significantly enhanced antitumor effects without any adverse effects during treatment. Specifically, daily administration of 5 &#956;M of conventional PROTACs for 21 days suppressed tumor growth by up to 36%, whereas the pro-PROTACs achieved a reduction of up to 62.3% at the same concentration. These findings underscore the potential of the prodrug approach in improving PROTAC permeability and efficacy [<xref rid="B231-pharmaceuticals-18-00297" ref-type="bibr">231</xref>].</p><p>Recently, Zhang and collaborators (2024) synthesized 26 novel peptides to improve permeability, utilizing lymphoma and leukemia cell models. Among these peptides, two&#8212;C9C-f(3Bta) and Cyclo-C9C&#8211;R&#8212;exhibited enhanced permeability and stability within the cellular environment. The researchers subsequently conjugated one of these peptides with a PROTAC designed to degrade the Bcr-Abl protein in K562 cells. Their findings revealed that peptide conjugation resulted in a substantial increase in the PROTAC&#8217;s permeability across the cell membrane, demonstrating the effectiveness of this approach for improving the cellular uptake of PROTACs [<xref rid="B232-pharmaceuticals-18-00297" ref-type="bibr">232</xref>].</p><p>Dai and collaborators (2022) employed a strategy of conjugating CPPs with PROTACs to enhance cell permeability and promote the degradation of programmed cell death protein 1 (PD-1). PD-1 plays a critical role in suppressing T-cell-mediated immune responses by binding to its primary ligand, PD-L1, which reduces immune activation. Elevated expression of PD-L1 has been linked to tumor cells evading immune responses, and its inhibition is considered a promising approach to improving cancer immunotherapy. To address this, the authors designed PROTACs targeting the degradation of PD-1 or PD-L1, conjugating them with peptides to enhance permeability in cervical cancer cell lines (C33A and HeLa). In their design, VHL was utilized as the E3-ligase ligand, and the peptide sequence &#8220;RRRRRRRR&#8221; was identified as particularly effective in improving PROTAC&#8217;s permeability [<xref rid="B233-pharmaceuticals-18-00297" ref-type="bibr">233</xref>]. Yokoo and colleagues (2021) conducted an intriguing study in which they developed a chimeric helix-stabilized peptide (stPERML) incorporating the CPP hepta-arginine to enhance the permeability of a PROTAC targeting estrogen receptor &#945;, demonstrating the effectiveness of this approach in addressing the permeability challenges commonly associated with PROTACs [<xref rid="B234-pharmaceuticals-18-00297" ref-type="bibr">234</xref>].</p></sec><sec id="sec4dot2-pharmaceuticals-18-00297"><title>4.2. PROTACs and Polymers</title><p>An alternative and promising strategy to address the various limitations of PROTACs, such as off-target effects due to inadequate distribution in the body, low solubility, and limited permeability, involves the use of Nanosized Drug Delivery Systems (NDDSs) and polymer conjugation. In the first approach, encapsulating PROTACs within nanoparticulate systems enhances their stability and pharmacokinetic properties, including an extended half-life. Furthermore, NDDSs can facilitate tumor cell uptake by improving permeability through various mechanisms, such as receptor-mediated pathways and endocytosis. Nanoparticulate systems&#8212;including polymeric, lipid-based, metallic, dendrimeric, metal&#8211;organic frameworks (MOFs), and mesoporous silica&#8212;offer a valuable opportunity to advance the study of PROTACs [<xref rid="B235-pharmaceuticals-18-00297" ref-type="bibr">235</xref>]. Nanoparticulate systems often leverage molecular interactions between polymeric matrices and PROTACs during physical encapsulation. However, chemical conjugation with carriers and biomaterials presents a promising alternative, as it helps maintain the stability of the pro-PROTAC during transport while enabling selective activation in specific compartments. In polymer conjugation, the linkers employed can be triggered by external stimuli (e.g., magnetism, ultrasound, and radiation) or internal stimuli (e.g., hypoxia, acidic environment, and oxidative stress) [<xref rid="B236-pharmaceuticals-18-00297" ref-type="bibr">236</xref>]. A noteworthy example was presented by Gao and colleagues (2022), who designed a system in which bromodomain-containing protein 4 (BRD4)-degrading PROTACs were conjugated with an amphiphilic copolymer containing a disulfide bond. These polymer conjugates, referred to as POLY-PROTACs, demonstrated the ability to self-assemble into nanoparticulate micelles that respond to metalloproteinase-2 activity and the reductive tumor microenvironment, leading to the accumulation of POLY-PROTAC in tumor tissue (<xref rid="pharmaceuticals-18-00297-f010" ref-type="fig">Figure 10</xref>). Once inside tumor cells, the disulfide bond is cleaved by glutathione (GSH), releasing the PROTAC to facilitate BRD4 degradation. Additionally, the authors further modified the nanoparticulate system to introduce an azide functional group, enabling click chemistry reactions with dibenzocyclooctyne (DBCO). This modified polymeric conjugate exhibited a 3.9-fold higher accumulation in tumor tissue compared to the original POLY-PROTAC, highlighting its potential for the selective delivery of pro-PROTACs to tumor sites [<xref rid="B237-pharmaceuticals-18-00297" ref-type="bibr">237</xref>].</p><p>Another example of PROTAC conjugation with polymers was reported by Zhang and colleagues (2021). In this study, the PROTAC was designed to include the von Hippel-Lindau protein (VHL) as the E3 ligase ligand and indoleamine 2,3-dioxygenase (IDO) as the protein of interest (POI), an enzyme involved in tryptophan catabolism that is overexpressed in tumor tissues and contributes to the suppression of dendritic cell activity. As the POI substrate, the previously described inhibitor NLG919 was employed. In this PROTAC, VHL and NLG919 was coupled through a succinic acid linker (<xref rid="pharmaceuticals-18-00297-f011" ref-type="fig">Figure 11</xref>A). The VHL subunit was conjugated to a cathepsin B substrate, which is commonly overexpressed in solid tumors such as breast, colorectal, and prostate cancers. The cathepsin B substrate was further linked to an amphiphilic semiconducting polymer containing a PEG group. This system represents an intriguing approach that integrates the pro-PROTAC strategy with polymer conjugation, aiming to develop more efficient PROTAC delivery systems. In vivo experiments conducted on 4T1 tumor-bearing mice demonstrated that, 24 h after the administration of PROTAC-conjugated nanoparticles, a significant inhibition of tumor growth was observed [<xref rid="B238-pharmaceuticals-18-00297" ref-type="bibr">238</xref>].</p><p>In a subsequent study, the group synthesized and evaluated another smart nano-PROTAC, in which the indomethacin subunit was selected as a ligand for COX-1/2, the protein of interest for degradation. The rationale behind COX-1/2 degradation in tumor cells was to reduce prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) levels, as this molecule is known to promote immunosuppressive cells, potentially enhancing tumor immunogenicity. The PROTAC was designed with a COX-1/2 ligand (indomethacin) conjugated to a VHL-targeting segment (<xref rid="pharmaceuticals-18-00297-f011" ref-type="fig">Figure 11</xref>B). Additionally, the authors incorporated a substrate for cathepsin B recognition and cleavage. As a carrier system, an amphiphilic self-assembling polymer&#8212;poly(cyclopentadithiophene-alt-benzothiadiazole) (PCB) conjugated to poly(ethylene glycol) (PEG, Mw = 2000)&#8212;was utilized to deliver the pro-PROTAC via click chemistry. The authors demonstrated COX-1/2 degradation through in vitro (90%) and in vivo (80%) experiments, resulting in up to 90% depletion of PGE2 [<xref rid="B239-pharmaceuticals-18-00297" ref-type="bibr">239</xref>]. This polymer conjugation strategy represents an innovative approach to reprogramming the immune response and reactivating it against tumors. Furthermore, it highlights how drug delivery conjugation strategies can help mitigate the challenges commonly associated with PROTACs.</p><p>This article does not intend to provide an exhaustive review of studies exploring the conjugation of PROTACs with polymers for nanosystem development; however, several noteworthy articles have already addressed this topic [<xref rid="B239-pharmaceuticals-18-00297" ref-type="bibr">239</xref>,<xref rid="B241-pharmaceuticals-18-00297" ref-type="bibr">241</xref>,<xref rid="B242-pharmaceuticals-18-00297" ref-type="bibr">242</xref>,<xref rid="B243-pharmaceuticals-18-00297" ref-type="bibr">243</xref>,<xref rid="B244-pharmaceuticals-18-00297" ref-type="bibr">244</xref>]. The examples presented in this work illustrate how the conjugation of PROTACs with excipients commonly used in formulation development can lead to pro-PROTACs with enhanced solubility and permeability. This serves as an important optimization tool, considering that, due to the intrinsic properties of PROTACs, they are often classified within the BCS system as Class II or IV, where permeability is generally moderate or low [<xref rid="B245-pharmaceuticals-18-00297" ref-type="bibr">245</xref>].</p><p>Another strategy to enhance permeability involves the use of dendrimers as carriers [<xref rid="B246-pharmaceuticals-18-00297" ref-type="bibr">246</xref>,<xref rid="B247-pharmaceuticals-18-00297" ref-type="bibr">247</xref>,<xref rid="B248-pharmaceuticals-18-00297" ref-type="bibr">248</xref>]. Dendrimers are highly structured polymeric macromolecules at the nanoscale, consisting of multiple branched monomers extending from a central core [<xref rid="B248-pharmaceuticals-18-00297" ref-type="bibr">248</xref>]. When used as carriers, drugs or bioactive compounds can be conjugated to dendrimers through various approaches, including interaction with a spacer, direct attachment to the dendrimer surface, or incorporation into the growing branches of the dendrimer [<xref rid="B247-pharmaceuticals-18-00297" ref-type="bibr">247</xref>].</p><p>The use of dendrimers can enhance the permeability of PROTACs while promoting event-driven degradation control. In an insightful study by Jin and colleagues (2023), a PAMAM dendrimer functionalized with trans-cyclooctene (TCO) was utilized to scavenge intracellular PROTACs containing a tetrazine-modified linker through a Diels&#8211;Alder reaction (<xref rid="pharmaceuticals-18-00297-f011" ref-type="fig">Figure 11</xref>C). The authors referred to this strategy as &#8220;ligation to scavenging&#8221;, designed to disrupt event-driven degradation by using dendrimers [<xref rid="B240-pharmaceuticals-18-00297" ref-type="bibr">240</xref>].</p></sec><sec id="sec4dot3-pharmaceuticals-18-00297"><title>4.3. Co-Crystal and Prodrugs</title><p>Co-crystals are defined as crystalline substances composed of two or more distinct molecular entities, typically active pharmaceutical ingredients (APIs) or APIs in combination with co-crystal formers. These entities are stabilized within the crystal lattice through various molecular non-covalent interactions, including Van der Waals forces, ionic interactions, hydrogen bonding, and hydrophobic interactions [<xref rid="B249-pharmaceuticals-18-00297" ref-type="bibr">249</xref>].</p><p>The formation of co-crystals is often explored to enhance solubility, while their use to improve permeability is less extensively described [<xref rid="B250-pharmaceuticals-18-00297" ref-type="bibr">250</xref>]. Despite that, both physic-chemical properties allow the combination of fixed-dose regimens to integrate components that act synergistically in several treatments. The development of co-crystals not only simplifies treatment by combining two active pharmaceutical ingredients (APIs) but also enhances patient adherence and therapeutic outcomes. Furthermore, the co-crystallization of two APIs can significantly improve bioavailability and stabilize certain drugs that may otherwise exhibit instability [<xref rid="B251-pharmaceuticals-18-00297" ref-type="bibr">251</xref>,<xref rid="B252-pharmaceuticals-18-00297" ref-type="bibr">252</xref>,<xref rid="B253-pharmaceuticals-18-00297" ref-type="bibr">253</xref>,<xref rid="B254-pharmaceuticals-18-00297" ref-type="bibr">254</xref>,<xref rid="B255-pharmaceuticals-18-00297" ref-type="bibr">255</xref>].</p><p>Entresto<sup>&#174;</sup>, for example, is a medication developed by Novartis in 2015 for the treatment of heart failure (<xref rid="pharmaceuticals-18-00297-f012" ref-type="fig">Figure 12</xref>). It is formulated as a co-crystal composed of valsartan and sacubitril in a 1:1 ratio. Sacubitril is a prodrug that functions as an inhibitor of neprilysin, an enzyme involved in the degradation of vasoactive substances such as brain natriuretic peptide (BNP) and other peptides. By inhibiting neprilysin, sacubitril contributes to lowering blood pressure, increasing natriuresis, and reducing afterload. Valsartan, in turn, acts as an angiotensin II type-1 (AT-1) receptor blocker, and its combination with sacubitril enhances antihypertensive effects [<xref rid="B255-pharmaceuticals-18-00297" ref-type="bibr">255</xref>]. Beyond their pharmacodynamic synergy, co-crystal formulation also offers advantages in improving the bioavailability of valsartan [<xref rid="B256-pharmaceuticals-18-00297" ref-type="bibr">256</xref>].</p><p>Another example of how co-crystal improved permeability was reported by Cheney and colleagues (2011), where meloxicam was co-crystallized with acetylsalicylic acid, leading to a fourfold increase in bioavailability and up to a 44-fold improvement in solubility (<xref rid="pharmaceuticals-18-00297-f012" ref-type="fig">Figure 12</xref>) [<xref rid="B257-pharmaceuticals-18-00297" ref-type="bibr">257</xref>].</p><p>Yu et al. (2020) developed a co-crystal of the anticancer agent tegafur. This prodrug, which is converted in vivo into 5-fluorouracil, has low permeability and solubility, resulting in limited bioavailability and necessitating the administration of high doses. Syringic acid, a natural compound found in various plant species, was selected as the co-crystal former. The authors evaluated the intrinsic dissolution rate (IDR) of both tegafur and the co-crystal at pH levels 1.2, 4.0, and 6.8. At pH 6.8, for instance, the IDR values for tegafur and the co-crystal were 1.76 and 3.17 mg&#183;min<sup>&#8722;1</sup>&#183;cm<sup>&#8722;2</sup>, respectively. Furthermore, the co-crystal demonstrated a 4.14-fold increase in permeability compared to tegafur. Pharmacokinetic studies in rats indicate that the co-crystal exhibits higher bioavailability, and a longer half-life compared to the prodrug tegafur alone. The authors suggest that several factors may contribute to this enhancement, including improved solubility and dissolution rate, which increase the concentration gradient across the membrane and facilitate diffusion. Additionally, the logP of syringic acid is 1.04, whereas tegafur has a logP value of &#8722;0.27 (<xref rid="pharmaceuticals-18-00297-f012" ref-type="fig">Figure 12</xref>). Consequently, the incorporation of these compounds into the co-crystal lattice enhances the hydrophobic character of the crystal, improving its membrane permeability [<xref rid="B258-pharmaceuticals-18-00297" ref-type="bibr">258</xref>]. Additional mechanisms have been suggested to explain the enhanced permeability induced by co-crystals, including their ability to reduce transepithelial electrical resistance (TEER) by influencing tight junctions between membranes, thereby facilitating drug diffusion [<xref rid="B259-pharmaceuticals-18-00297" ref-type="bibr">259</xref>].</p><p>Understanding how co-crystals, particularly those containing prodrugs, can enhance permeability and influence pharmacokinetic parameters presents a valuable opportunity for innovation.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-18-00297"><title>5. Conclusions</title><p>This review article aims to summarize the seamless integration of computational and experimental methodologies in prodrug development. Methods to characterize drug permeability using advanced in silico tools, including ML-based predictive models and molecular dynamics simulations, are complemented by robust experimental platforms such as PAMPA assays, cellular models (e.g., Caco-2 and MDCK), and ex vivo techniques (e.g., everted gut sacs and diffusion chambers). These approaches enable comprehensive characterization of molecular properties, elucidating transport mechanisms and the role of specific carriers such as PepT1 and LAT1 in selective and efficient drug delivery.</p><p>Case studies of clinically significant prodrugs, including paclitaxel, oseltamivir, and dabigatran etexilate, underscore the transformative potential of rational molecular design. These examples demonstrate how structural modifications&#8212;such as masking carboxylic groups or incorporating hydrophilic moieties&#8212;enhance permeability, chemical stability, and bioavailability. The success of dual prodrug strategies, exemplified by dabigatran etexilate, further illustrates the capacity of strategic design to optimize pharmacokinetics, enabling precise activation of the parent drug at therapeutic targets.</p><p>The emergence of PROTACs represents a complementary advancement in targeted drug development. Unlike prodrugs, which rely on bioreversible chemical modifications to optimize pharmacokinetics and pharmacodynamics, PROTACs employ a bifunctional design to selectively degrade disease-related proteins via the ubiquitin&#8211;proteasome pathway. By addressing limitations in druggability and specificity, PROTACs expand the toolkit of medicinal chemistry, particularly for targets previously considered inaccessible. While distinct in mechanism, the integration of PROTACs into drug discovery paradigms aligns with the overarching goal of improving therapeutic efficacy and overcoming barriers related to solubility, permeability, and selective targeting.</p><p>The prodrug approach represents a pivotal strategy in modern medicinal chemistry, addressing critical limitations in biopharmaceutical and pharmacokinetic properties, such as permeability, solubility, and bioavailability. By leveraging chemically modified, bioreversible derivatives, this strategy provides a systematic solution to overcome barriers associated with drug absorption, distribution, and therapeutic efficacy, ultimately optimizing pharmacological profiles and safety margins.</p><p>In conclusion, the prodrug paradigm transcends conventional drug design by offering a robust, scientifically grounded framework for addressing pharmacokinetic and pharmacodynamic challenges. The integration of computational advancements, experimental rigor, and rational design principles provides an unparalleled pathway for innovation in drug development. As medicinal chemistry continues to evolve, the prodrug strategy will remain indispensable, particularly in overcoming complex challenges of bioavailability and therapeutic targeting, ensuring the development of safer, more effective treatments.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the National Council for Scientific and Technological Development (CNPq) (process number 302433/2023-6) and the Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de S&#227;o Paulo (FAPESP), process numbers 2023/05739-6 and 2023/14078-3. Finally, the authors gratefully acknowledge the support of Coordena&#231;&#227;o de Aperfei&#231;oamento de Pessoal de N&#237;vel Superior (CAPES), Brazil, finance code 001 and Pro-reitoria de P&#243;s-Gradua&#231;&#227;o UNESP (PROPG edital 01/2025).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.M.d.S., A.L.R.G., J.A.M., C.B.S., C.M.C. and J.L.d.S.; methodology, M.M.d.S., A.L.R.G., J.A.M., C.B.S., C.M.C. and J.L.d.S.; formal analysis, M.M.d.S., A.L.R.G. and J.L.d.S.; investigation, M.M.d.S., A.L.R.G., J.A.M. and J.L.d.S.; resources, M.M.d.S. and J.L.d.S.; data curation, M.M.d.S., A.L.R.G., J.A.M., C.B.S., C.M.C. and J.L.d.S.; writing&#8212;original draft preparation, M.M.d.S., A.L.R.G., J.A.M. and J.L.d.S.; writing&#8212;review and editing, M.M.d.S., A.L.R.G., J.A.M., C.B.S., C.M.C. and J.L.d.S.; visualization, M.M.d.S., A.L.R.G., J.A.M., C.B.S., C.M.C. and J.L.d.S.; supervision, C.B.S., C.M.C. and J.L.d.S.; project administration, M.M.d.S., A.L.R.G., J.A.M. and J.L.d.S.; funding acquisition, C.B.S., C.M.C. and J.L.d.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data sharing is not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">5&#8242;-DFUR</td><td align="left" valign="middle" rowspan="1" colspan="1">5&#8242;-deoxy-5-fluorouridine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5-FU</td><td align="left" valign="middle" rowspan="1" colspan="1">5-fluorouracil</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AADC</td><td align="left" valign="middle" rowspan="1" colspan="1">L-amino acid decarboxylase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AAMD</td><td align="left" valign="middle" rowspan="1" colspan="1">All-atom MD</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ABC</td><td align="left" valign="middle" rowspan="1" colspan="1">ATP-Binding Cassette</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACh</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetylcholine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AChE</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetylcholinesterase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACV</td><td align="left" valign="middle" rowspan="1" colspan="1">Acyclovir</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADEPT</td><td align="left" valign="middle" rowspan="1" colspan="1">Antibody-directed enzyme prodrug therapy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADME</td><td align="left" valign="middle" rowspan="1" colspan="1">Absorption, distribution, metabolism, and excretion</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALK</td><td align="left" valign="middle" rowspan="1" colspan="1">Anaplastic lymphoma kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ANNs</td><td align="left" valign="middle" rowspan="1" colspan="1">Artificial neural networks</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">API</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine triphosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AT1</td><td align="left" valign="middle" rowspan="1" colspan="1">Active pharmaceutical ingredients</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATP</td><td align="left" valign="middle" rowspan="1" colspan="1">Angiotensin II type-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUC</td><td align="left" valign="middle" rowspan="1" colspan="1">Area under the curve</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BBB</td><td align="left" valign="middle" rowspan="1" colspan="1">Blood&#8211;brain barrier</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCS</td><td align="left" valign="middle" rowspan="1" colspan="1">Biopharmaceutical Classification System</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BNP</td><td align="left" valign="middle" rowspan="1" colspan="1">Brain natriuretic peptide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BRD4</td><td align="left" valign="middle" rowspan="1" colspan="1">Bromodomain-containing protein 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDSs</td><td align="left" valign="middle" rowspan="1" colspan="1">Chemical delivery systems</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CES1</td><td align="left" valign="middle" rowspan="1" colspan="1">Carboxylesterase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CGMD</td><td align="left" valign="middle" rowspan="1" colspan="1">Coarse-grained MD</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CME</td><td align="left" valign="middle" rowspan="1" colspan="1">Cystoid macular edema</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CNS</td><td align="left" valign="middle" rowspan="1" colspan="1">Central nervous system</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COX-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclooxygenase-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COX-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclooxygenase-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CPPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Cell-penetrating peptides</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRBN</td><td align="left" valign="middle" rowspan="1" colspan="1">Cereblon</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DAR</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug-to-antibody ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DBCO</td><td align="left" valign="middle" rowspan="1" colspan="1">Dibenzocyclooctyne</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DC<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">Degradation Concentration 50%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">deuHTBZ</td><td align="left" valign="middle" rowspan="1" colspan="1">Deuterated dihydrotetrabenazine isomers</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DL</td><td align="left" valign="middle" rowspan="1" colspan="1">Deep learning</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMF</td><td align="left" valign="middle" rowspan="1" colspan="1">Dimethyl fumarate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">dThdPase</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytidine deaminase and thymidine phosphorylase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EC<sub>50</sub>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Effective concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK</td><td align="left" valign="middle" rowspan="1" colspan="1">Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESBLs</td><td align="left" valign="middle" rowspan="1" colspan="1">Extended-spectrum &#946;-lactamases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FOLR1</td><td align="left" valign="middle" rowspan="1" colspan="1">Folate receptor-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FRs</td><td align="left" valign="middle" rowspan="1" colspan="1">Folate receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GI<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">Growth Inhibition 50%</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gly</td><td align="left" valign="middle" rowspan="1" colspan="1">Glycine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GSH</td><td align="left" valign="middle" rowspan="1" colspan="1">Glutathione</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCAR2</td><td align="left" valign="middle" rowspan="1" colspan="1">Hydroxycarboxylic acid receptor 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCV</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic hepatitis C virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">His</td><td align="left" valign="middle" rowspan="1" colspan="1">Histidine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV</td><td align="left" valign="middle" rowspan="1" colspan="1">Human immunodeficiency virus </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hPEPT-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Human peptide transporter 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IC<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibitory concentration </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IMPDH</td><td align="left" valign="middle" rowspan="1" colspan="1">Inosine monophosphate dehydrogenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LASSO</td><td align="left" valign="middle" rowspan="1" colspan="1">Least Absolute Shrinkage and Selection Operator</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LAT1</td><td align="left" valign="middle" rowspan="1" colspan="1">l-type amino acid transporter</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="left" valign="middle" rowspan="1" colspan="1">Liquid Chromatography&#8211;Mass Spectrometry </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDV</td><td align="left" valign="middle" rowspan="1" colspan="1">Ledipasvir</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leu</td><td align="left" valign="middle" rowspan="1" colspan="1">Leucine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LogD</td><td align="left" valign="middle" rowspan="1" colspan="1">Logarithm of the distribution coefficient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LogP</td><td align="left" valign="middle" rowspan="1" colspan="1">Logarithm of the octanol/water partition coefficient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MBLs</td><td align="left" valign="middle" rowspan="1" colspan="1">Metallo-&#946;-lactamases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MD</td><td align="left" valign="middle" rowspan="1" colspan="1">Molecular dynamics</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDCK</td><td align="left" valign="middle" rowspan="1" colspan="1">Madin&#8211;Darby Canine Kidney</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ML</td><td align="left" valign="middle" rowspan="1" colspan="1">Machine learning</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MOFs</td><td align="left" valign="middle" rowspan="1" colspan="1">Metal&#8211;organic frameworks</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NDDSs</td><td align="left" valign="middle" rowspan="1" colspan="1">Nanosized Drug Delivery Systems</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF-&#954;B</td><td align="left" valign="middle" rowspan="1" colspan="1">Factor nuclear kappa B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nrf2</td><td align="left" valign="middle" rowspan="1" colspan="1">Erythroid-derived factor 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSAID</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-steroidal anti-inflammatory drugs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-small cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OATP</td><td align="left" valign="middle" rowspan="1" colspan="1">Organic Anion Transporting Polypeptide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PAMPA</td><td align="left" valign="middle" rowspan="1" colspan="1">Parallel Artificial Membrane Permeability Assay</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Papp</td><td align="left" valign="middle" rowspan="1" colspan="1">Apparent permeability coefficient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PBPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Penicillin-binding proteins</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCFT</td><td align="left" valign="middle" rowspan="1" colspan="1">Proton-coupled folate transporter</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Cell death protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pe</td><td align="left" valign="middle" rowspan="1" colspan="1">Permeability coefficient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">P<sub>eff</sub>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Effective permeation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PEG</td><td align="left" valign="middle" rowspan="1" colspan="1">Polyethylene glycol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PGE<sub>2</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">Prostaglandin E<sub>2</sub></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">POI</td><td align="left" valign="middle" rowspan="1" colspan="1">Protein of interest</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">POM</td><td align="left" valign="middle" rowspan="1" colspan="1">Pivaloyloxymethyl</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PROTACs</td><td align="left" valign="middle" rowspan="1" colspan="1">PROteolysis TArgeting Chimeras</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PS-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Presenilin-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RAFT</td><td align="left" valign="middle" rowspan="1" colspan="1">Reversible Addition Fragmentation chain Transfer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RFC</td><td align="left" valign="middle" rowspan="1" colspan="1">Reduced folate carrier </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RIPK2</td><td align="left" valign="middle" rowspan="1" colspan="1">Serine- and threonine-protein kinase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ro5</td><td align="left" valign="middle" rowspan="1" colspan="1">Rule of five</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Solute-Linked Carrier</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLCO</td><td align="left" valign="middle" rowspan="1" colspan="1">Solute Carrier Organic Anion</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SOF</td><td align="left" valign="middle" rowspan="1" colspan="1">Sofosbuvir</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">STAT3</td><td align="left" valign="middle" rowspan="1" colspan="1">Signal transducer and activator of transcription 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAF</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir alafenamide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEER</td><td align="left" valign="middle" rowspan="1" colspan="1">Transepithelial electrical resistance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TFV</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TFV-DP</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir diphosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tyr</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyrosine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Val</td><td align="left" valign="middle" rowspan="1" colspan="1">Valine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VHL</td><td align="left" valign="middle" rowspan="1" colspan="1">von Hippel&#8211;Lindau protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VMAT2</td><td align="left" valign="middle" rowspan="1" colspan="1">Vesicular monoamine transporter 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WHO</td><td align="left" valign="middle" rowspan="1" colspan="1">World Health Organization</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00297"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sertkaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beleche</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jessup</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sommers</surname><given-names>B.D.</given-names></name></person-group><article-title>Costs of Drug Development and Research and Development Intensity in the US, 2000&#8211;2018</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><fpage>e2415445</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.15445</pub-id><pub-id pub-id-type="pmid">38941099</pub-id><pub-id pub-id-type="pmcid">PMC11214120</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-18-00297"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowden</surname><given-names>H.</given-names></name><name name-style="western"><surname>Munro</surname><given-names>J.</given-names></name></person-group><article-title>Trends in Clinical Success Rates and Therapeutic Focus</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>18</volume><fpage>495</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/d41573-019-00074-z</pub-id><pub-id pub-id-type="pmid">31267067</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-18-00297"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alavijeh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>A.M.</given-names></name></person-group><article-title>The Pivotal Role of Drug Metabolism and Pharmacokinetics in the Discovery and Development of New Medicines</article-title><source>IDrugs</source><year>2004</year><volume>7</volume><fpage>755</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">15334309</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-18-00297"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Mano</surname><given-names>T.</given-names></name></person-group><article-title>Bridging Solubility between Drug Discovery and Development</article-title><source>Drug Discov. Today</source><year>2012</year><volume>17</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2011.11.007</pub-id><pub-id pub-id-type="pmid">22138563</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-18-00297"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Trevaskis</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Charman</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Shanker</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Charman</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Pouton</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>C.J.H.</given-names></name></person-group><article-title>Strategies to Address Low Drug Solubility in Discovery and Development</article-title><source>Pharmacol. Rev.</source><year>2013</year><volume>65</volume><fpage>315</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1124/pr.112.005660</pub-id><pub-id pub-id-type="pmid">23383426</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-18-00297"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title>Pharmaceutical Particle Technologies: An Approach to Improve Drug Solubility, Dissolution and Bioavailability</article-title><source>Asian J. Pharm. Sci.</source><year>2014</year><volume>9</volume><fpage>304</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2014.05.005</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-18-00297"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Cyclodextrin-Based Oral Drug Delivery Formulations for Disease Therapy</article-title><source>Carbohydr. Polym.</source><year>2024</year><volume>329</volume><fpage>121763</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2023.121763</pub-id><pub-id pub-id-type="pmid">38286540</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-18-00297"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesharwani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.K.</given-names></name></person-group><article-title>Lipid-Based Drug Delivery System (LBDDS): An Emerging Paradigm to Enhance Oral Bioavailability of Poorly Soluble Drugs</article-title><source>Biomed. Mater. Devices</source><year>2023</year><volume>1</volume><fpage>648</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s44174-022-00041-0</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-18-00297"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schittny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huwyler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Puchkov</surname><given-names>M.</given-names></name></person-group><article-title>Mechanisms of Increased Bioavailability through Amorphous Solid Dispersions: A Review</article-title><source>Drug Deliv.</source><year>2020</year><volume>27</volume><fpage>110</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1080/10717544.2019.1704940</pub-id><pub-id pub-id-type="pmid">31885288</pub-id><pub-id pub-id-type="pmcid">PMC6968646</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-18-00297"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhari</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Dugar</surname><given-names>R.P.</given-names></name></person-group><article-title>Application of Surfactants in Solid Dispersion Technology for Improving Solubility of Poorly Water Soluble Drugs</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2017</year><volume>41</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2017.06.010</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-18-00297"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haghbakhsh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raeissi</surname><given-names>S.</given-names></name></person-group><article-title>Overview and Thermodynamic Modelling of Deep Eutectic Solvents as Co-Solvents to Enhance Drug Solubilities in Water</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2023</year><volume>193</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2023.10.007</pub-id><pub-id pub-id-type="pmid">37838144</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-18-00297"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serajuddin</surname><given-names>A.T.M.</given-names></name></person-group><article-title>Salt Formation to Improve Drug Solubility</article-title><source>Adv. Drug Deliv. Rev.</source><year>2007</year><volume>59</volume><fpage>603</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.05.010</pub-id><pub-id pub-id-type="pmid">17619064</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-18-00297"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Censi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Martino</surname><given-names>P.</given-names></name></person-group><article-title>Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>18759</fpage><lpage>18776</lpage><pub-id pub-id-type="doi">10.3390/molecules201018759</pub-id><pub-id pub-id-type="pmid">26501244</pub-id><pub-id pub-id-type="pmcid">PMC6331817</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-18-00297"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elder</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diego</surname><given-names>H.L.</given-names></name></person-group><article-title>de Use of Pharmaceutical Salts and Cocrystals to Address the Issue of Poor Solubility</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>453</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.11.028</pub-id><pub-id pub-id-type="pmid">23182973</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-18-00297"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanches</surname><given-names>B.M.A.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>E.I.</given-names></name></person-group><article-title>Is Prodrug Design an Approach to Increase Water Solubility?</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>568</volume><fpage>118498</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118498</pub-id><pub-id pub-id-type="pmid">31301465</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-18-00297"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jornada</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>dos Santos Fernandes</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>de Melo</surname><given-names>T.R.F.</given-names></name><name name-style="western"><surname>dos Santos</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M.C.</given-names></name></person-group><article-title>The Prodrug Approach: A Successful Tool for Improving Drug Solubility</article-title><source>Molecules</source><year>2015</year><volume>21</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21010042</pub-id><pub-id pub-id-type="pmid">26729077</pub-id><pub-id pub-id-type="pmcid">PMC6273601</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-18-00297"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rautio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meanwell</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Di</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hageman</surname><given-names>M.J.</given-names></name></person-group><article-title>The Expanding Role of Prodrugs in Contemporary Drug Design and Development</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>559</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.46</pub-id><pub-id pub-id-type="pmid">29700501</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-18-00297"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbaiah</surname><given-names>M.A.M.</given-names></name><name name-style="western"><surname>Rautio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meanwell</surname><given-names>N.A.</given-names></name></person-group><article-title>Prodrugs as Empowering Tools in Drug Discovery and Development: Recent Strategic Applications of Drug Delivery Solutions to Mitigate Challenges Associated with Lead Compounds and Drug Candidates</article-title><source>Chem. Soc. Rev.</source><year>2024</year><volume>53</volume><fpage>2099</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1039/D2CS00957A</pub-id><pub-id pub-id-type="pmid">38226865</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-18-00297"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fralish</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reker</surname><given-names>D.</given-names></name></person-group><article-title>The Landscape of Small-Molecule Prodrugs</article-title><source>Nat. Rev. Drug Discov.</source><year>2024</year><volume>23</volume><fpage>365</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/s41573-024-00914-7</pub-id><pub-id pub-id-type="pmid">38565913</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-18-00297"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kansy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Avdeef</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bendels</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ecker</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Faller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gerebtzoff</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Coexistence of Passive and Carrier-Mediated Processes in Drug Transport</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>597</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1038/nrd3187</pub-id><pub-id pub-id-type="pmid">20671764</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-18-00297"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobson</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Kell</surname><given-names>D.B.</given-names></name></person-group><article-title>Carrier-Mediated Cellular Uptake of Pharmaceutical Drugs: An Exception or the Rule?</article-title><source>Nat. Rev. Drug Discov.</source><year>2008</year><volume>7</volume><fpage>205</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nrd2438</pub-id><pub-id pub-id-type="pmid">18309312</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-18-00297"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giacomini</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Tweedie</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>K.L.R.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dahlin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hillgren</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Membrane Transporters in Drug Development</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrd3028</pub-id><pub-id pub-id-type="pmid">20190787</pub-id><pub-id pub-id-type="pmcid">PMC3326076</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-18-00297"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agrahari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Khurana</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>Transporter Effects on Cell Permeability in Drug Delivery</article-title><source>Expert Opin. Drug Deliv.</source><year>2017</year><volume>14</volume><fpage>385</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1080/17425247.2016.1214565</pub-id><pub-id pub-id-type="pmid">27449574</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-18-00297"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennion</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Be</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>McNerney</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Malfatti</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Enright</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lightstone</surname><given-names>F.C.</given-names></name><etal/></person-group><article-title>Predicting a Drug&#8217;s Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data</article-title><source>J. Phys. Chem. B</source><year>2017</year><volume>121</volume><fpage>5228</fpage><lpage>5237</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.7b02914</pub-id><pub-id pub-id-type="pmid">28453293</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-18-00297"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samineni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chimakurthy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Konidala</surname><given-names>S.</given-names></name></person-group><article-title>Emerging Role of Biopharmaceutical Classification and Biopharmaceutical Drug Disposition System in Dosage Form Development: A Systematic Review</article-title><source>Turk. J. Pharm. Sci.</source><year>2022</year><volume>19</volume><fpage>706</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.4274/tjps.galenos.2021.73554</pub-id><pub-id pub-id-type="pmid">36544401</pub-id><pub-id pub-id-type="pmcid">PMC9780568</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-18-00297"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Lennern&#228;s</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Crison</surname><given-names>J.R.</given-names></name></person-group><article-title>A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability</article-title><source>Pharm. Res.</source><year>1995</year><volume>12</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1023/A:1016212804288</pub-id><pub-id pub-id-type="pmid">7617530</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-18-00297"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name></person-group><article-title>G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. <italic toggle="yes">A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability</italic>, Pharm Res 12, 413&#8211;420, 1995&#8212;Backstory of BCS</article-title><source>AAPS J.</source><year>2014</year><volume>16</volume><fpage>894</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1208/s12248-014-9620-9</pub-id><pub-id pub-id-type="pmid">24961917</pub-id><pub-id pub-id-type="pmcid">PMC4147045</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-18-00297"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butnarasu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garbero</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Petrini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Visai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Visentin</surname><given-names>S.</given-names></name></person-group><article-title>Permeability Assessment of a High-Throughput Mucosal Platform</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>380</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020380</pub-id><pub-id pub-id-type="pmid">36839702</pub-id><pub-id pub-id-type="pmcid">PMC9966667</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-18-00297"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubatsch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ragnarsson</surname><given-names>E.G.E.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name></person-group><article-title>Determination of Drug Permeability and Prediction of Drug Absorption in Caco-2 Monolayers</article-title><source>Nat. Protoc.</source><year>2007</year><volume>2</volume><fpage>2111</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.303</pub-id><pub-id pub-id-type="pmid">17853866</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-18-00297"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lennern&#228;s</surname><given-names>H.</given-names></name></person-group><article-title>Regional Intestinal Drug Permeation: Biopharmaceutics and Drug Development</article-title><source>Eur. J. Pharm. Sci.</source><year>2014</year><volume>57</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2013.08.025</pub-id><pub-id pub-id-type="pmid">23988845</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-18-00297"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahlgren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sj&#246;gren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lennern&#228;s</surname><given-names>H.</given-names></name></person-group><article-title>Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><fpage>2702</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1002/jps.24258</pub-id><pub-id pub-id-type="pmid">25410736</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-18-00297"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Szab&#243;-R&#233;v&#233;sz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horv&#225;th</surname><given-names>T.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ambrus</surname><given-names>R.</given-names></name></person-group><article-title>Comparison of Modern In Vitro Permeability Methods with the Aim of Investigation Nasal Dosage Forms</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>846</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13060846</pub-id><pub-id pub-id-type="pmid">34201053</pub-id><pub-id pub-id-type="pmcid">PMC8227734</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-18-00297"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teksin</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Polli</surname><given-names>J.E.</given-names></name></person-group><article-title>Comparison of Drug Permeabilities and BCS Classification: Three Lipid-Component PAMPA System Method versus Caco-2 Monolayers</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>238</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9176-2</pub-id><pub-id pub-id-type="pmid">20224985</pub-id><pub-id pub-id-type="pmcid">PMC2844511</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-18-00297"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ben-Shabat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dahan</surname><given-names>A.</given-names></name></person-group><article-title>Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>1031</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12111031</pub-id><pub-id pub-id-type="pmid">33137942</pub-id><pub-id pub-id-type="pmcid">PMC7692606</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-18-00297"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lomize</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Hage</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schnitzer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Golobokov</surname><given-names>K.</given-names></name><name name-style="western"><surname>LaFaive</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Forsyth</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Pogozheva</surname><given-names>I.D.</given-names></name></person-group><article-title>PerMM: A Web Tool and Database for Analysis of Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules</article-title><source>J. Chem. Inf. Model.</source><year>2019</year><volume>59</volume><fpage>3094</fpage><lpage>3099</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b00225</pub-id><pub-id pub-id-type="pmid">31259547</pub-id><pub-id pub-id-type="pmcid">PMC6781619</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-18-00297"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>admetSAR 2.0: Web-Service for Prediction and Optimization of Chemical ADMET Properties</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><fpage>1067</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty707</pub-id><pub-id pub-id-type="pmid">30165565</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-18-00297"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>admetSAR3.0: A Comprehensive Platform for Exploration, Prediction and Optimization of Chemical ADMET Properties</article-title><source>Nucleic Acids Res.</source><year>2024</year><volume>52</volume><fpage>W432</fpage><lpage>W438</lpage><pub-id pub-id-type="doi">10.1093/nar/gkae298</pub-id><pub-id pub-id-type="pmid">38647076</pub-id><pub-id pub-id-type="pmcid">PMC11223829</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-18-00297"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>ADMETopt: A Web Server for ADMET Optimization in Drug Design via Scaffold Hopping</article-title><source>J. Chem. Inf. Model.</source><year>2018</year><volume>58</volume><fpage>2051</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.8b00532</pub-id><pub-id pub-id-type="pmid">30251842</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-18-00297"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><etal/></person-group><article-title>OptADMET: A Web-Based Tool for Substructure Modifications to Improve ADMET Properties of Lead Compounds</article-title><source>Nat. Protoc.</source><year>2024</year><volume>19</volume><fpage>1105</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1038/s41596-023-00942-4</pub-id><pub-id pub-id-type="pmid">38263521</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-18-00297"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>Interpretable-ADMET: A Web Service for ADMET Prediction and Optimization Based on Deep Neural Representation</article-title><source>Bioinformatics</source><year>2022</year><volume>38</volume><fpage>2863</fpage><lpage>2871</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btac192</pub-id><pub-id pub-id-type="pmid">35561160</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-18-00297"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name></person-group><article-title>SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>42717</elocation-id><pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28256516</pub-id><pub-id pub-id-type="pmcid">PMC5335600</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-18-00297"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>D.E.V.</given-names></name><name name-style="western"><surname>Blundell</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ascher</surname><given-names>D.B.</given-names></name></person-group><article-title>pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>4066</fpage><lpage>4072</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id><pub-id pub-id-type="pmid">25860834</pub-id><pub-id pub-id-type="pmcid">PMC4434528</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-18-00297"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dominy</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><article-title>Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>46</volume><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00129-0</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-18-00297"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Comer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Herndon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pavlova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Swift</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Tung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Amaro</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Chipot</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Simulation-Based Approaches for Determining Membrane Permeability of Small Compounds</article-title><source>J. Chem. Inf. Model.</source><year>2016</year><volume>56</volume><fpage>721</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.6b00022</pub-id><pub-id pub-id-type="pmid">27043429</pub-id><pub-id pub-id-type="pmcid">PMC5280572</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-18-00297"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>W.F.D.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirshner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bennion</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>T.S.</given-names></name></person-group><article-title>Advances in Computational Approaches for Estimating Passive Permeability in Drug Discovery</article-title><source>Membranes</source><year>2023</year><volume>13</volume><elocation-id>851</elocation-id><pub-id pub-id-type="doi">10.3390/membranes13110851</pub-id><pub-id pub-id-type="pmid">37999336</pub-id><pub-id pub-id-type="pmcid">PMC10673305</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-18-00297"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.-F.</given-names></name></person-group><article-title>In Silico Log P Prediction for a Large Data Set with Support Vector Machines, Radial Basis Neural Networks and Multiple Linear Regression</article-title><source>Chem. Biol. Drug Des.</source><year>2009</year><volume>74</volume><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2009.00840.x</pub-id><pub-id pub-id-type="pmid">19549084</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-18-00297"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghose</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Viswanadhan</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Wendoloski</surname><given-names>J.J.</given-names></name></person-group><article-title>Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods:&#8201; An Analysis of ALOGP and CLOGP Methods</article-title><source>J. Phys. Chem. A</source><year>1998</year><volume>102</volume><fpage>3762</fpage><lpage>3772</lpage><pub-id pub-id-type="doi">10.1021/jp980230o</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-18-00297"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mannhold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rekker</surname><given-names>R.F.</given-names></name></person-group><article-title>The Hydrophobic Fragmental Constant Approach Forcalculating Log P in Octanol/Water and Aliphatic Hydrocarbon/Water Systems</article-title><source>Perspect. Drug Discov. Des.</source><year>2000</year><volume>18</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1023/A:1008782809845</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-18-00297"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolk</surname><given-names>O.</given-names></name><name name-style="western"><surname>Agbaria</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dahan</surname><given-names>A.</given-names></name></person-group><article-title>Provisional In-Silico Biopharmaceutics Classification (BCS) to Guide Oral Drug Product Development</article-title><source>Drug Des. Dev. Ther.</source><year>2014</year><volume>8</volume><fpage>1563</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S68909</pub-id><pub-id pub-id-type="pmcid">PMC4181551</pub-id><pub-id pub-id-type="pmid">25284986</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-18-00297"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venable</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Kr&#228;mer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pastor</surname><given-names>R.W.</given-names></name></person-group><article-title>Molecular Dynamics Simulations of Membrane Permeability</article-title><source>Chem. Rev.</source><year>2019</year><volume>119</volume><fpage>5954</fpage><lpage>5997</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00486</pub-id><pub-id pub-id-type="pmid">30747524</pub-id><pub-id pub-id-type="pmcid">PMC6506413</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-18-00297"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.-J.</given-names></name><name name-style="western"><surname>Deserno</surname><given-names>M.</given-names></name></person-group><article-title>A Systematically Coarse-Grained Solvent-Free Model for Quantitative Phospholipid Bilayer Simulations</article-title><source>J. Phys. Chem. B</source><year>2010</year><volume>114</volume><fpage>11207</fpage><lpage>11220</lpage><pub-id pub-id-type="doi">10.1021/jp102543j</pub-id><pub-id pub-id-type="pmid">20695631</pub-id><pub-id pub-id-type="pmcid">PMC2928645</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-18-00297"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monticelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kandasamy</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Periole</surname><given-names>X.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Tieleman</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Marrink</surname><given-names>S.-J.</given-names></name></person-group><article-title>The MARTINI Coarse-Grained Force Field: Extension to Proteins</article-title><source>J. Chem. Theory Comput.</source><year>2008</year><volume>4</volume><fpage>819</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1021/ct700324x</pub-id><pub-id pub-id-type="pmid">26621095</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-18-00297"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>A Machine-Learning-Assisted Study of the Permeability of Small Drug-like Molecules across Lipid Membranes</article-title><source>Phys. Chem. Chem. Phys.</source><year>2020</year><volume>22</volume><fpage>19687</fpage><lpage>19696</lpage><pub-id pub-id-type="doi">10.1039/D0CP03243C</pub-id><pub-id pub-id-type="pmid">32830206</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-18-00297"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Rensi</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Torng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>R.B.</given-names></name></person-group><article-title>Machine Learning in Chemoinformatics and Drug Discovery</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>1538</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.05.010</pub-id><pub-id pub-id-type="pmid">29750902</pub-id><pub-id pub-id-type="pmcid">PMC6078794</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-18-00297"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazumder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Aktar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohiuddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Abid</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Fukase</surname><given-names>K.</given-names></name></person-group><article-title>In Silico Analysis and Experimental Evaluation of Ester Prodrugs of Ketoprofen for Oral Delivery: With a View to Reduce Toxicity</article-title><source>Processes</source><year>2021</year><volume>9</volume><elocation-id>2221</elocation-id><pub-id pub-id-type="doi">10.3390/pr9122221</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-18-00297"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Onnainty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Usseglio</surname><given-names>N.</given-names></name><name name-style="western"><surname>Granero</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Ravetti</surname><given-names>S.</given-names></name></person-group><article-title>Preformulation Studies of Novel Menthol Prodrugs with Antiparasitic Activity: Chemical Stability, In Silico, and In Vitro Permeability Assays</article-title><source>Drugs Drug Candidates</source><year>2023</year><volume>2</volume><fpage>770</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.3390/ddc2030038</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-18-00297"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheetham</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Angacian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name></person-group><article-title>Peptide&#8211;Drug Conjugates as Effective Prodrug Strategies for Targeted Delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2017</year><volume>110&#8211;111</volume><fpage>112</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.06.015</pub-id><pub-id pub-id-type="pmid">27370248</pub-id><pub-id pub-id-type="pmcid">PMC5199637</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-18-00297"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fishelson</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><elocation-id>1971</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines11071971</pub-id><pub-id pub-id-type="pmid">37509610</pub-id><pub-id pub-id-type="pmcid">PMC10377493</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-18-00297"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name></person-group><article-title>Predicting Peptide Permeability Across Diverse Barriers: A Systematic Investigation</article-title><source>Mol. Pharm.</source><year>2024</year><volume>21</volume><fpage>4116</fpage><lpage>4127</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.4c00478</pub-id><pub-id pub-id-type="pmid">39031123</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-18-00297"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name></person-group><article-title>BBPpredict: A Web Service for Identifying Blood-Brain Barrier Penetrating Peptides</article-title><source>Front. Genet.</source><year>2022</year><volume>13</volume><elocation-id>845747</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.845747</pub-id><pub-id pub-id-type="pmid">35656322</pub-id><pub-id pub-id-type="pmcid">PMC9152268</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-18-00297"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bhisetti</surname><given-names>G.</given-names></name></person-group><article-title>Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>1264</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29061264</pub-id><pub-id pub-id-type="pmid">38542901</pub-id><pub-id pub-id-type="pmcid">PMC10975190</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-18-00297"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name></person-group><article-title>Predict Drug Permeability to Blood-Brain-Barrier from Clinical Phenotypes: Drug Side Effects and Drug Indications</article-title><source>Bioinformatics</source><year>2017</year><volume>33</volume><fpage>901</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw713</pub-id><pub-id pub-id-type="pmid">27993785</pub-id><pub-id pub-id-type="pmcid">PMC5860495</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-18-00297"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alexiou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bilgrami</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>G.M.</given-names></name></person-group><article-title>DeePred-BBB: A Blood Brain Barrier Permeability Prediction Model With Improved Accuracy</article-title><source>Front. Neurosci.</source><year>2022</year><volume>16</volume><elocation-id>858126</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2022.858126</pub-id><pub-id pub-id-type="pmid">35592264</pub-id><pub-id pub-id-type="pmcid">PMC9112838</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-18-00297"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>BBBper: A Machine Learning-Based Online Tool for Blood-Brain Barrier (BBB) Permeability Prediction</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2024</year><pub-id pub-id-type="doi">10.2174/0118715273328174241007060331</pub-id><pub-id pub-id-type="pmid">39415574</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-18-00297"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name></person-group><article-title>Blood Brain Barrier Permeability Prediction Using Machine Learning Techniques: An Update</article-title><source>Curr. Pharm. Biotechnol.</source><year>2019</year><volume>20</volume><fpage>1163</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.2174/1389201020666190821145346</pub-id><pub-id pub-id-type="pmid">31433750</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-18-00297"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>A Merged Molecular Representation Deep Learning Method for Blood-Brain Barrier Permeability Prediction</article-title><source>Brief. Bioinform.</source><year>2022</year><volume>23</volume><elocation-id>bbac357</elocation-id><pub-id pub-id-type="doi">10.1093/bib/bbac357</pub-id><pub-id pub-id-type="pmid">36002937</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-18-00297"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>E.T.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>K.Y.K.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>W.C.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>M.</given-names></name><name name-style="western"><surname>Compas</surname><given-names>C.</given-names></name><name name-style="western"><surname>See</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>F.-J.</given-names></name></person-group><article-title>Predicting Blood&#8211;Brain Barrier Permeability of Molecules with a Large Language Model and Machine Learning</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>15844</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-66897-y</pub-id><pub-id pub-id-type="pmid">38982309</pub-id><pub-id pub-id-type="pmcid">PMC11233737</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-18-00297"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kansy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Senner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gubernator</surname><given-names>K.</given-names></name></person-group><article-title>Physicochemical High Throughput Screening:&#8201; Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes</article-title><source>J. Med. Chem.</source><year>1998</year><volume>41</volume><fpage>1007</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1021/jm970530e</pub-id><pub-id pub-id-type="pmid">9544199</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-18-00297"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burton</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>J.T.</given-names></name></person-group><article-title>Solubility and Permeability Measurement and Applications in Drug Discovery</article-title><source>Comb. Chem. High Throughput Screen.</source><year>2010</year><volume>13</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.2174/138620710790596763</pub-id><pub-id pub-id-type="pmid">20053165</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-18-00297"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name></person-group><article-title>A New PAMPA Model Proposed on the Basis of a Synthetic Phospholipid Membrane</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0116502</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0116502</pub-id><pub-id pub-id-type="pmid">25647086</pub-id><pub-id pub-id-type="pmcid">PMC4315410</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-18-00297"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermejo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Avdeef</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nalda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Tsinman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>C.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garrigues</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>PAMPA&#8212;A Drug Absorption in Vitro Model 7. Comparing Rat in Situ, Caco-2, and PAMPA Permeability of Fluoroquinolones</article-title><source>Eur. J. Pharm. Sci.</source><year>2004</year><volume>21</volume><fpage>429</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2003.10.009</pub-id><pub-id pub-id-type="pmid">14998573</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-18-00297"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mtewa</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Ngwira</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lampiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weisheit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tolo</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Ogwang</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Sesaazi</surname><given-names>D.C.</given-names></name></person-group><article-title>Fundamental Methods in Drug Permeability, pKa, LogP and LogDx Determination</article-title><source>J. Drug Res. Dev.</source><year>2019</year><volume>5</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.16966/2470-1009.146</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-18-00297"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhiti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barba-Bon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hennig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nau</surname><given-names>W.M.</given-names></name></person-group><article-title>Real-Time Parallel Artificial Membrane Permeability Assay Based on Supramolecular Fluorescent Artificial Receptors</article-title><source>Front. Chem.</source><year>2020</year><volume>8</volume><elocation-id>597927</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2020.597927</pub-id><pub-id pub-id-type="pmid">33330387</pub-id><pub-id pub-id-type="pmcid">PMC7673371</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-18-00297"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleiter</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>J&#228;gle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gresser</surname><given-names>U.</given-names></name><name name-style="western"><surname>M&#246;rike</surname><given-names>K.</given-names></name></person-group><article-title>Candesartan</article-title><source>Cardiovasc. Drug Rev.</source><year>2004</year><volume>22</volume><fpage>263</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1111/j.1527-3466.2004.tb00146.x</pub-id><pub-id pub-id-type="pmid">15592574</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-18-00297"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>G.</given-names></name><name name-style="western"><surname>Massarella</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>P.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of the Prodrug Oseltamivir and Its Active Metabolite Ro 64-0802</article-title><source>Clin. Pharmacokinet.</source><year>1999</year><volume>37</volume><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.2165/00003088-199937060-00003</pub-id><pub-id pub-id-type="pmid">10628898</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-18-00297"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M.</given-names></name></person-group><article-title>Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models</article-title><source>J. Pharm. Sci.</source><year>2021</year><volume>110</volume><fpage>925</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2020.10.018</pub-id><pub-id pub-id-type="pmid">33065127</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-18-00297"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balimane</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>S.</given-names></name></person-group><article-title>Utility of 96 Well Caco-2 Cell System for Increased Throughput of P-Gp Screening in Drug Discovery</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2004</year><volume>58</volume><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2004.02.014</pub-id><pub-id pub-id-type="pmid">15207543</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-18-00297"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpe</surname><given-names>D.A.</given-names></name></person-group><article-title>Drug-Permeability and Transporter Assays in Caco-2 and MDCK Cell Lines</article-title><source>Future Med. Chem.</source><year>2011</year><volume>3</volume><fpage>2063</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.4155/fmc.11.149</pub-id><pub-id pub-id-type="pmid">22098353</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-18-00297"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tolan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Selick</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Grove</surname><given-names>J.R.</given-names></name></person-group><article-title>MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening</article-title><source>J. Pharm. Sci.</source><year>1999</year><volume>88</volume><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1021/js9803205</pub-id><pub-id pub-id-type="pmid">9874698</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-18-00297"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oberle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Juzwin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Gryszkiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Streeter</surname><given-names>A.J.</given-names></name></person-group><article-title>Optimizing Caco-2 Cell Monolayers to Increase Throughput in Drug Intestinal Absorption Analysis</article-title><source>J. Pharmacol. Toxicol. Methods</source><year>2001</year><volume>46</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S1056-8719(01)00161-7</pub-id><pub-id pub-id-type="pmid">12164260</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-18-00297"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Breemen</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Caco-2 Cell Permeability Assays to Measure Drug Absorption</article-title><source>Expert. Opin. Drug Metab. Toxicol.</source><year>2005</year><volume>1</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1517/17425255.1.2.175</pub-id><pub-id pub-id-type="pmid">16922635</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-18-00297"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>Prodrug Approach to Improve Absorption of Prednisolone</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>487</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.04.029</pub-id><pub-id pub-id-type="pmid">25888804</pub-id><pub-id pub-id-type="pmcid">PMC4535455</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-18-00297"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Katragadda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gunda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>In Vivo Ocular Pharmacokinetics of Acyclovir Dipeptide Ester Prodrugs by Microdialysis in Rabbits</article-title><source>Mol. Pharm.</source><year>2006</year><volume>3</volume><fpage>431</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1021/mp0498998</pub-id><pub-id pub-id-type="pmid">16889437</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-18-00297"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>Circumvention of P-Gp and MRP2 Mediated Efflux of Lopinavir by a Histidine Based Dipeptide Prodrug</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>512</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.08.027</pub-id><pub-id pub-id-type="pmid">27543355</pub-id><pub-id pub-id-type="pmcid">PMC5030192</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-18-00297"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A Carrier-Mediated Prodrug Approach To Improve the Oral Absorption of Antileukemic Drug Decitabine</article-title><source>Mol. Pharm.</source><year>2013</year><volume>10</volume><fpage>3195</fpage><lpage>3202</lpage><pub-id pub-id-type="doi">10.1021/mp400233x</pub-id><pub-id pub-id-type="pmid">23822717</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-18-00297"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpe</surname><given-names>D.A.</given-names></name></person-group><article-title>Application of Method Suitability for Drug Permeability Classification</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>670</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9227-8</pub-id><pub-id pub-id-type="pmid">20811966</pub-id><pub-id pub-id-type="pmcid">PMC2976984</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-18-00297"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schanker</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Tocco</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Brodie</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Hogben</surname><given-names>C.A.</given-names></name></person-group><article-title>Absorption of Drugs from the Rat Small Intestine</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1958</year><volume>123</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(25)12018-1</pub-id><pub-id pub-id-type="pmid">13539795</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-18-00297"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stappaerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P.</given-names></name></person-group><article-title>In Situ Perfusion in Rodents to Explore Intestinal Drug Absorption: Challenges and Opportunities</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>478</volume><fpage>665</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.11.035</pub-id><pub-id pub-id-type="pmid">25448559</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-18-00297"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holenarsipur</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Gaud</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sivaprasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhutani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Arla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paruchury</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Absorption and Cleavage of Enalapril, a Carboxyl Ester Prodrug, in the Rat Intestine: In Vitro, in Situ Intestinal Perfusion and Portal Vein Cannulation Models</article-title><source>Biopharm. Drug Dispos.</source><year>2015</year><volume>36</volume><fpage>385</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1002/bdd.1950</pub-id><pub-id pub-id-type="pmid">25832562</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-18-00297"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name></person-group><article-title>Preparation and in Vitro Evaluation of Amphiphilic Paclitaxel Small Molecule Prodrugs and Enhancement of Oral Absorption</article-title><source>Eur. J. Med. Chem.</source><year>2021</year><volume>215</volume><fpage>113276</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113276</pub-id><pub-id pub-id-type="pmid">33611186</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-18-00297"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gynther</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laine</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ropponen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lepp&#228;nen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mannila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nevalainen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Savolainen</surname><given-names>J.</given-names></name><name name-style="western"><surname>J&#228;rvinen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rautio</surname><given-names>J.</given-names></name></person-group><article-title>Large Neutral Amino Acid Transporter Enables Brain Drug Delivery via Prodrugs</article-title><source>J. Med. Chem.</source><year>2008</year><volume>51</volume><fpage>932</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1021/jm701175d</pub-id><pub-id pub-id-type="pmid">18217702</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-18-00297"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gynther</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pickering</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Denny</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Huttunen</surname><given-names>K.M.</given-names></name></person-group><article-title>Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs</article-title><source>Mol. Pharm.</source><year>2016</year><volume>13</volume><fpage>2484</fpage><lpage>2491</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00217</pub-id><pub-id pub-id-type="pmid">27266990</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-18-00297"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#228;rvinen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montaser</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Adla</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Lepp&#228;nen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lehtonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vellonen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Laitinen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jalkanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elmquist</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Timonen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Altering Distribution Profile of Palbociclib by Its Prodrugs</article-title><source>Eur. J. Pharm. Sci.</source><year>2024</year><volume>192</volume><fpage>106637</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2023.106637</pub-id><pub-id pub-id-type="pmid">37967656</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-18-00297"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Al-Jenoobi</surname><given-names>F.I.</given-names></name><name name-style="western"><surname>Al-Mohizea</surname><given-names>A.M.</given-names></name></person-group><article-title>Everted Gut Sac Model as a Tool in Pharmaceutical Research: Limitations and Applications</article-title><source>J. Pharm. Pharmacol.</source><year>2012</year><volume>64</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2011.01391.x</pub-id><pub-id pub-id-type="pmid">22309264</pub-id></element-citation></ref><ref id="B95-pharmaceuticals-18-00297"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Woodley</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kenworthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Houin</surname><given-names>G.</given-names></name></person-group><article-title>An Improved Everted Gut Sac as a Simple and Accurate Technique to Measure Paracellular Transport across the Small Intestine</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>1998</year><volume>23</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1007/BF03189357</pub-id><pub-id pub-id-type="pmid">9725499</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-18-00297"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gualdesi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bri&#241;&#243;n</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Quevedo</surname><given-names>M.A.</given-names></name></person-group><article-title>Intestinal Permeability of Lamivudine (3TC) and Two Novel 3TC Prodrugs. Experimental and Theoretical Analyses</article-title><source>Eur. J. Pharm. Sci.</source><year>2012</year><volume>47</volume><fpage>965</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2012.10.002</pub-id><pub-id pub-id-type="pmid">23072916</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-18-00297"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sodano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cristiano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rolando</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lazzarato</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cuozzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Albrizio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rimoli</surname><given-names>M.G.</given-names></name></person-group><article-title>Galactosylated Prodrugs: A Strategy to Improve the Profile of Nonsteroidal Anti-Inflammatory Drugs</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>552</elocation-id><pub-id pub-id-type="doi">10.3390/ph15050552</pub-id><pub-id pub-id-type="pmid">35631377</pub-id><pub-id pub-id-type="pmcid">PMC9142922</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-18-00297"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>L.-P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.-Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D.-N.</given-names></name><name name-style="western"><surname>Cordell</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>S.X.</given-names></name></person-group><article-title>Prediction of Human Absorption of Natural Compounds by the Non-Everted Rat Intestinal Sac Model</article-title><source>Eur. J. Med. Chem.</source><year>2006</year><volume>41</volume><fpage>605</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2006.01.013</pub-id><pub-id pub-id-type="pmid">16546303</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-18-00297"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antunes Viegas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>M.</given-names></name><name name-style="western"><surname>Francisco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Falc&#227;o</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>G.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A.O.</given-names></name></person-group><article-title>Development and Application of an Ex Vivo Fosphenytoin Nasal Bioconversion/Permeability Evaluation Method</article-title><source>Eur. J. Pharm. Sci.</source><year>2016</year><volume>89</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.04.018</pub-id><pub-id pub-id-type="pmid">27106504</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-18-00297"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitovs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohylyuk</surname><given-names>V.</given-names></name></person-group><article-title>Ex Vivo Permeability Study of Poorly Soluble Drugs across Gastrointestinal Membranes: Acceptor Compartment Media Composition</article-title><source>Drug Discov. Today</source><year>2024</year><volume>29</volume><fpage>104214</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2024.104214</pub-id><pub-id pub-id-type="pmid">39428083</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-18-00297"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dezani</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Caffaro</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Serra</surname><given-names>C.H.D.R.</given-names></name></person-group><article-title>Determination of Lamivudine and Zidovudine Permeability Using a Different Ex Vivo Method in Franz Cells</article-title><source>J. Pharmacol. Toxicol. Methods</source><year>2013</year><volume>67</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.vascn.2013.01.005</pub-id><pub-id pub-id-type="pmid">23337245</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-18-00297"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tukker</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Clercq</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Den Mooter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kinget</surname><given-names>R.</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P.</given-names></name></person-group><article-title>In Vitro, Ex Vivo, and in Situ Intestinal Absorption Characteristics of the Antiviral Ester Prodrug Adefovir Dipivoxil</article-title><source>J. Pharm. Sci.</source><year>2000</year><volume>89</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1520-6017(200008)89:8&amp;#x0003c;1054::AID-JPS10&amp;#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">10906729</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-18-00297"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Hinner</surname><given-names>M.J.</given-names></name></person-group><article-title>Getting across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1266</volume><fpage>29</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2272-7_3</pub-id><pub-id pub-id-type="pmid">25560066</pub-id><pub-id pub-id-type="pmcid">PMC4891184</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-18-00297"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schweckendiek</surname><given-names>W.</given-names></name></person-group><article-title>Treatment of psoriasis vulgaris</article-title><source>Med. Monatsschr.</source><year>1959</year><volume>13</volume><fpage>103</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">13643669</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-18-00297"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matteo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Federico</surname><given-names>D.</given-names></name><name name-style="western"><surname>Emanuela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giulia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tommaso</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alfredo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Anna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Annamaria</surname><given-names>O.</given-names></name></person-group><article-title>New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2732</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14122732</pub-id><pub-id pub-id-type="pmid">36559226</pub-id><pub-id pub-id-type="pmcid">PMC9788528</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-18-00297"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landeck</surname><given-names>L.</given-names></name><name name-style="western"><surname>Asadullah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amasuno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pau-Charles</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mrowietz</surname><given-names>U.</given-names></name></person-group><article-title>Dimethyl Fumarate (DMF) vs. Monoethyl Fumarate (MEF) Salts for the Treatment of Plaque Psoriasis: A Review of Clinical Data</article-title><source>Arch. Dermatol. Res.</source><year>2018</year><volume>310</volume><fpage>475</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1007/s00403-018-1825-9</pub-id><pub-id pub-id-type="pmid">29574575</pub-id><pub-id pub-id-type="pmcid">PMC6060759</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-18-00297"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mrowietz</surname><given-names>U.</given-names></name><name name-style="western"><surname>Christophers</surname><given-names>E.</given-names></name><name name-style="western"><surname>Altmeyer</surname><given-names>P.</given-names></name><collab>The German Fumaric Acid Ester Consensus Conference</collab></person-group><article-title>Treatment of Severe Psoriasis with Fumaric Acid Esters: Scientific Background and Guidelines for Therapeutic Use</article-title><source>Br. J. Dermatol.</source><year>1999</year><volume>141</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.1999.03034.x</pub-id><pub-id pub-id-type="pmid">10584060</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-18-00297"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza</collab><name name-style="western"><surname>Bautista</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chotpitayasunondh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uyeki</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>362</volume><fpage>1708</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1000449</pub-id><pub-id pub-id-type="pmid">20445182</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-18-00297"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>B.E.</given-names></name></person-group><article-title>Pharmacokinetics of Oseltamivir: An Oral Antiviral for the Treatment and Prophylaxis of Influenza in Diverse Populations</article-title><source>J. Antimicrob. Chemother.</source><year>2010</year><volume>65</volume><issue>(Suppl. S2)</issue><fpage>ii5</fpage><lpage>ii10</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq015</pub-id><pub-id pub-id-type="pmid">20215135</pub-id><pub-id pub-id-type="pmcid">PMC2835511</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-18-00297"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Escarpe</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Eisenberg</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Cundy</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jakeman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Merson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lew</surname><given-names>W.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071</article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>647</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.3.647</pub-id><pub-id pub-id-type="pmid">9517946</pub-id><pub-id pub-id-type="pmcid">PMC105512</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-18-00297"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lew</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.U.</given-names></name></person-group><article-title>Discovery and Development of GS 4104 (Oseltamivir): An Orally Active Influenza Neuraminidase Inhibitor</article-title><source>Curr. Med. Chem.</source><year>2000</year><volume>7</volume><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.2174/0929867003374886</pub-id><pub-id pub-id-type="pmid">10702632</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-18-00297"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>LeCluyse</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Black</surname><given-names>C.</given-names></name><name name-style="western"><surname>You</surname><given-names>L.</given-names></name><name name-style="western"><surname>Akhlaghi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name></person-group><article-title>Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2006</year><volume>319</volume><fpage>1477</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.111807</pub-id><pub-id pub-id-type="pmid">16966469</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-18-00297"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H.</given-names></name></person-group><article-title>Oseltamivir Carboxylate, the Active Metabolite of Oseltamivir Phosphate (Tamiflu), Detected in Sewage Discharge and River Water in Japan</article-title><source>Environ. Health Perspect.</source><year>2010</year><volume>118</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1289/ehp.0900930</pub-id><pub-id pub-id-type="pmid">20056566</pub-id><pub-id pub-id-type="pmcid">PMC2831951</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-18-00297"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allison</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Eugui</surname><given-names>E.M.</given-names></name></person-group><article-title>Mycophenolate Mofetil and Its Mechanisms of Action</article-title><source>Immunopharmacology</source><year>2000</year><volume>47</volume><fpage>85</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S0162-3109(00)00188-0</pub-id><pub-id pub-id-type="pmid">10878285</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-18-00297"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staatz</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Tett</surname><given-names>S.E.</given-names></name></person-group><article-title>Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients</article-title><source>Clin. Pharmacokinet.</source><year>2007</year><volume>46</volume><fpage>13</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.2165/00003088-200746010-00002</pub-id><pub-id pub-id-type="pmid">17201457</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-18-00297"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullingham</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>B.R.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Mycophenolate Mofetil</article-title><source>Clin. Pharmacokinet.</source><year>1998</year><volume>34</volume><fpage>429</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.2165/00003088-199834060-00002</pub-id><pub-id pub-id-type="pmid">9646007</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-18-00297"><label>117.</label><element-citation publication-type="gov"><article-title>PubChem Mycophenolate Mofetil</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/5281078" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/5281078</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-26">(accessed on 26 December 2024)</date-in-citation></element-citation></ref><ref id="B118-pharmaceuticals-18-00297"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sone</surname><given-names>T.</given-names></name><name name-style="western"><surname>Isobe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>S.</given-names></name></person-group><article-title>Involvement of Carboxylesterase 1 and 2 in the Hydrolysis of Mycophenolate Mofetil</article-title><source>Drug Metab. Dispos.</source><year>2010</year><volume>38</volume><fpage>2210</fpage><lpage>2217</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.034249</pub-id><pub-id pub-id-type="pmid">20823294</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-18-00297"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taskar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tatke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>S.</given-names></name></person-group><article-title>Advances in the Use of Prodrugs for Drug Delivery to the Eye</article-title><source>Expert Opin. Drug Deliv.</source><year>2017</year><volume>14</volume><fpage>49</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1080/17425247.2016.1208649</pub-id><pub-id pub-id-type="pmid">27441817</pub-id><pub-id pub-id-type="pmcid">PMC7337245</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-18-00297"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonijevic</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Zivkovic</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Matic</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Kocica</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mrdovic</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Kanjuh</surname><given-names>V.I.</given-names></name><name name-style="western"><surname>Culafic</surname><given-names>M.D.</given-names></name></person-group><article-title>Dabigatran&#8212;Metabolism, Pharmacologic Properties and Drug Interactions</article-title><source>Curr. Drug Metab.</source><year>2017</year><volume>18</volume><fpage>622</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.2174/1389200218666170427113504</pub-id><pub-id pub-id-type="pmid">28460624</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-18-00297"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fawzy</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lip</surname><given-names>G.Y.H.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants Used in Atrial Fibrillation</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2019</year><volume>15</volume><fpage>381</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1080/17425255.2019.1604686</pub-id><pub-id pub-id-type="pmid">30951640</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-18-00297"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paik</surname><given-names>J.</given-names></name></person-group><article-title>Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism</article-title><source>Pediatr. Drugs</source><year>2022</year><volume>24</volume><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1007/s40272-022-00516-z</pub-id><pub-id pub-id-type="pmid">35699915</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-18-00297"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandstetter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Turk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoeffken</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Grosse</surname><given-names>D.</given-names></name><name name-style="western"><surname>St&#252;rzebecher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>B.F.P.</given-names></name><name name-style="western"><surname>Bode</surname><given-names>W.</given-names></name></person-group><article-title>Refined 2&#183;3&#197;X-Ray Crystal Structure of Bovine Thrombin Complexes Formed with the Benzamidine and Arginine-Based Thrombin Inhibitors NAPAP, 4-TAPAP and MQPA</article-title><source>J. Mol. Biol.</source><year>1992</year><volume>226</volume><fpage>1085</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(92)91054-S</pub-id><pub-id pub-id-type="pmid">1518046</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-18-00297"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Ryn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hauel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wienen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Priepke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>A.</given-names></name></person-group><article-title>The Discovery of Dabigatran Etexilate</article-title><source>Front. Pharmacol.</source><year>2013</year><volume>4</volume><elocation-id>40985</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2013.00012</pub-id><pub-id pub-id-type="pmid">23408233</pub-id><pub-id pub-id-type="pmcid">PMC3569592</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-18-00297"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellens</surname><given-names>J.H.M.</given-names></name></person-group><article-title>Capecitabine</article-title><source>Oncologist</source><year>2007</year><volume>12</volume><fpage>152</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.12-2-152</pub-id><pub-id pub-id-type="pmid">17296810</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-18-00297"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R.-J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.-H.</given-names></name><etal/></person-group><article-title>Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1001/jama.2020.23370</pub-id><pub-id pub-id-type="pmid">33300950</pub-id><pub-id pub-id-type="pmcid">PMC7729589</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-18-00297"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Godara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Saif</surname><given-names>M.W.</given-names></name></person-group><article-title>Capecitabine for the Treatment of Pancreatic Cancer</article-title><source>Expert Opin. Pharmacother.</source><year>2019</year><volume>20</volume><fpage>399</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1080/14656566.2018.1560422</pub-id><pub-id pub-id-type="pmid">30649964</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-18-00297"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alzahrani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al Doghaither</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-ghafari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pushparaj</surname><given-names>P.</given-names></name></person-group><article-title>5-Fluorouracil and Capecitabine Therapies for the Treatment of Colorectal Cancer (Review)</article-title><source>Oncol. Rep.</source><year>2023</year><volume>50</volume><fpage>175</fpage><pub-id pub-id-type="doi">10.3892/or.2023.8612</pub-id><pub-id pub-id-type="pmid">37594133</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-18-00297"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Primrose</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corrie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Falk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Finch-Jones</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study</article-title><source>Lancet Oncol.</source><year>2019</year><volume>20</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30915-X</pub-id><pub-id pub-id-type="pmid">30922733</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-18-00297"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reigner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blesch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weidekamm</surname><given-names>E.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Capecitabine</article-title><source>Clin. Pharmacokinet.</source><year>2001</year><volume>40</volume><fpage>85</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.2165/00003088-200140020-00002</pub-id><pub-id pub-id-type="pmid">11286326</pub-id></element-citation></ref><ref id="B131-pharmaceuticals-18-00297"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabiszak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frymark</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Skroba&#324;ska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jastrzab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>M.T.</given-names></name></person-group><article-title>Complexes of &#946;-Lactam Antibiotics and Their Schiff-Base Derivatives as a Weapon in the Fight against Bacterial Resistance</article-title><source>Coord. Chem. Rev.</source><year>2023</year><volume>493</volume><fpage>215326</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2023.215326</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-18-00297"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jubeh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Breijyeh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R.</given-names></name></person-group><article-title>Antibacterial Prodrugs to Overcome Bacterial Resistance</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>1543</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25071543</pub-id><pub-id pub-id-type="pmid">32231026</pub-id><pub-id pub-id-type="pmcid">PMC7180472</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-18-00297"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>C.J.L.</given-names></name><name name-style="western"><surname>Ikuta</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sharara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Swetschinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Robles Aguilar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bisignano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wool</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-18-00297"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smyth</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>St Ledger</surname><given-names>J.O.</given-names></name></person-group><article-title>&#946;-Lactamase-Dependent Prodrugs&#8212;Recent Developments</article-title><source>Tetrahedron</source><year>2000</year><volume>56</volume><fpage>5699</fpage><lpage>5707</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(00)00419-1</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-18-00297"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakimelahi</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Shia</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hakimelahi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moosavi-Movahedi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Saboury</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Khalafi-Nezhad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soltani-Rad</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Osyetrov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.-P.</given-names></name><etal/></person-group><article-title>Design, Synthesis, and Biological Evaluation of a Series of &#946;-Lactam-Based Prodrugs</article-title><source>Bioorganic Med. Chem.</source><year>2002</year><volume>10</volume><fpage>3489</fpage><lpage>3498</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(02)00256-0</pub-id><pub-id pub-id-type="pmid">12213463</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-18-00297"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Wuest</surname><given-names>W.M.</given-names></name></person-group><article-title>Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics</article-title><source>ACS Infect. Dis.</source><year>2019</year><volume>5</volume><fpage>816</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00019</pub-id><pub-id pub-id-type="pmid">30969100</pub-id><pub-id pub-id-type="pmcid">PMC6570538</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-18-00297"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su&#225;rez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gudiol</surname><given-names>F.</given-names></name></person-group><article-title>Antibi&#243;ticos Betalact&#225;micos</article-title><source>Enfermedades Infecc. Y Microbiol. Cl&#237;n.</source><year>2009</year><volume>27</volume><fpage>116</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.eimc.2008.12.001</pub-id><pub-id pub-id-type="pmid">19254642</pub-id></element-citation></ref><ref id="B138-pharmaceuticals-18-00297"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambo</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Mukhtar</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Labaran</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Labaran</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Mustapha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M.</given-names></name></person-group><article-title>Chemistry, Mode of Action, Bacterial Resistance, Classification and Adverse Effects of Beta-Lactam Antibiotics: A Review</article-title><source>Int. J. Dermatol. Res.</source><year>2023</year><volume>5</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.33545/26646471.2023.v5.i1a.37</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-18-00297"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varela</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lekshmi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sanford</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Parvathi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.H.</given-names></name></person-group><article-title>Bacterial Resistance to Antimicrobial Agents</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>593</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10050593</pub-id><pub-id pub-id-type="pmid">34067579</pub-id><pub-id pub-id-type="pmcid">PMC8157006</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-18-00297"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruddle</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>T.P.</given-names></name></person-group><article-title>Exploring the Chemistry of Penicillin as a &#946;-Lactamase-Dependent Prodrug</article-title><source>Org. Biomol. Chem.</source><year>2007</year><volume>5</volume><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1039/B614758E</pub-id><pub-id pub-id-type="pmid">17164921</pub-id></element-citation></ref><ref id="B141-pharmaceuticals-18-00297"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Livermore</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.W.</given-names></name></person-group><article-title>Metallo-&#946;-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e00397-20</fpage><pub-id pub-id-type="doi">10.1128/AAC.00397-20</pub-id><pub-id pub-id-type="pmid">32690645</pub-id><pub-id pub-id-type="pmcid">PMC7508574</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-18-00297"><label>142.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bryskier</surname><given-names>A.</given-names></name></person-group><article-title>&#946;-Lactam Prodrugs</article-title><source>Antimicrobial Agents</source><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2005</year><fpage>348</fpage><lpage>376</lpage><isbn>978-1-68367-191-6</isbn></element-citation></ref><ref id="B143-pharmaceuticals-18-00297"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.J.</given-names></name></person-group><article-title>Microbial Esterases and Ester Prodrugs: An Unlikely Marriage for Combating Antibiotic Resistance</article-title><source>Drug Dev. Res.</source><year>2019</year><volume>80</volume><fpage>33</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1002/ddr.21468</pub-id><pub-id pub-id-type="pmid">30302779</pub-id><pub-id pub-id-type="pmcid">PMC6377847</pub-id></element-citation></ref><ref id="B144-pharmaceuticals-18-00297"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuenca-Lopez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rivero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivero-Ju&#225;rez</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics and Pharmacodynamics of Sofosbuvir and Ledipasvir for the Treatment of Hepatitis C</article-title><source>Expert. Opin. Drug Metab. Toxicol.</source><year>2017</year><volume>13</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1080/17425255.2017.1255725</pub-id><pub-id pub-id-type="pmid">27797596</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-18-00297"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Fordyce</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Hitchcock</surname><given-names>M.J.M.</given-names></name></person-group><article-title>Tenofovir Alafenamide: A Novel Prodrug of Tenofovir for the Treatment of Human Immunodeficiency Virus</article-title><source>Antivir. Res.</source><year>2016</year><volume>125</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.11.009</pub-id><pub-id pub-id-type="pmid">26640223</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-18-00297"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>M.</given-names></name></person-group><article-title>Investigation of the Structure and Dynamics of Antiviral Drug Adefovir Dipivoxil by Site-Specific Spin&#8211;Lattice Relaxation Time Measurements and Chemical Shift Anisotropy Tensor Measurements</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>29373</fpage><lpage>29381</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c04205</pub-id><pub-id pub-id-type="pmid">33225168</pub-id><pub-id pub-id-type="pmcid">PMC7676337</pub-id></element-citation></ref><ref id="B147-pharmaceuticals-18-00297"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>R.-Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.-J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.-B.</given-names></name></person-group><article-title>Mechanism Study on Stability Enhancement of Adefovir Dipivoxil by Cocrystallization: Degradation Kinetics and Structure-Stability Correlation</article-title><source>Eur. J. Pharm. Sci.</source><year>2016</year><volume>85</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2015.10.006</pub-id><pub-id pub-id-type="pmid">26462447</pub-id></element-citation></ref><ref id="B148-pharmaceuticals-18-00297"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takagi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimazaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kageyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsugi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gabelt</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>H.</given-names></name></person-group><article-title>Pharmacological Characteristics of AFP-168 (Tafluprost), a New Prostanoid FP Receptor Agonist, as an Ocular Hypotensive Drug</article-title><source>Exp. Eye Res.</source><year>2004</year><volume>78</volume><fpage>767</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2003.12.007</pub-id><pub-id pub-id-type="pmid">15037111</pub-id></element-citation></ref><ref id="B149-pharmaceuticals-18-00297"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaarniranta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ik&#228;heimo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mannermaa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ropo</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics, Efficacy, and Safety of the Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-Free Monotherapies</article-title><source>Clin. Pharmacokinet.</source><year>2016</year><volume>55</volume><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0331-x</pub-id><pub-id pub-id-type="pmid">26391697</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-18-00297"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantcheva</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Seibold</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Awadallah</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Kahook</surname><given-names>M.Y.</given-names></name></person-group><article-title>Tafluprost: A Novel Prostaglandin Analog for Treatment of Glaucoma</article-title><source>Adv. Ther.</source><year>2011</year><volume>28</volume><fpage>707</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1007/s12325-011-0055-8</pub-id><pub-id pub-id-type="pmid">21858491</pub-id></element-citation></ref><ref id="B151-pharmaceuticals-18-00297"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandell</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Stentz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kitabchi</surname><given-names>A.E.</given-names></name></person-group><article-title>Dipivalyl Epinephrine: A New pro-Drug in the Treatment of Glaucoma</article-title><source>Ophthalmology</source><year>1978</year><volume>85</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(78)35668-2</pub-id><pub-id pub-id-type="pmid">662280</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-18-00297"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Epinephrine Reduces Intraocular Pressure by Regulating the Trabecular Meshwork Cytoskeleton and Extracellular Matrix Via &#946;2-AR</article-title><source>Heliyon</source><fpage>2023</fpage></element-citation></ref><ref id="B153-pharmaceuticals-18-00297"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinecke</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Kuwabara</surname><given-names>T.</given-names></name></person-group><article-title>Corneal Deposits Secondary to Topical Epinephrine</article-title><source>Arch. Ophthalmol.</source><year>1963</year><volume>70</volume><fpage>170</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1001/archopht.1963.00960050172005</pub-id><pub-id pub-id-type="pmid">14060094</pub-id></element-citation></ref><ref id="B154-pharmaceuticals-18-00297"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>J.A.</given-names></name></person-group><article-title>Systemic Absorption of Topical Ocularly Applied Epinephrine and Dipivefrin</article-title><source>Arch. Ophthalmol.</source><year>1980</year><volume>98</volume><fpage>350</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1001/archopht.1980.01020030346024</pub-id><pub-id pub-id-type="pmid">7352887</pub-id></element-citation></ref><ref id="B155-pharmaceuticals-18-00297"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Ament</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ferrufino-Ponce</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Grabowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>S.L.</given-names></name></person-group><article-title>Clinical Pseudophakic Cystoid Macular Edema. Risk Factors for Development and Duration after Treatment</article-title><source>J. Cataract. Refract. Surg.</source><year>2007</year><volume>33</volume><fpage>1550</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2007.05.013</pub-id><pub-id pub-id-type="pmid">17720069</pub-id></element-citation></ref><ref id="B156-pharmaceuticals-18-00297"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>The Comparative Efficacy and Safety of Topical Non-Steroidal Anti-Inflammatory Drugs for the Treatment of Anterior Chamber Inflammation after Cataract Surgery: A Systematic Review and Network Meta-Analysis</article-title><source>Graefes Arch. Clin. Exp. Ophthalmol.</source><year>2017</year><volume>255</volume><fpage>639</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1007/s00417-017-3599-8</pub-id><pub-id pub-id-type="pmid">28130595</pub-id></element-citation></ref><ref id="B157-pharmaceuticals-18-00297"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bereczki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zagato</surname><given-names>E.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sullins</surname><given-names>G.</given-names></name><name name-style="western"><surname>Notivol</surname><given-names>R.</given-names></name></person-group><article-title>Analgesic and Anti-Inflammatory Effectiveness of Nepafenac 0.1% for Cataract Surgery</article-title><source>Clin. Ophthalmol.</source><year>2007</year><volume>1</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">19668532</pub-id><pub-id pub-id-type="pmcid">PMC2704522</pub-id></element-citation></ref><ref id="B158-pharmaceuticals-18-00297"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Neville</surname><given-names>M.W.</given-names></name></person-group><article-title>Nepafenac: An Ophthalmic Nonsteroidal Antiinflammatory Drug for Pain after Cataract Surgery</article-title><source>Ann. Pharmacother.</source><year>2013</year><volume>47</volume><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1345/aph.1R757</pub-id><pub-id pub-id-type="pmid">23715071</pub-id></element-citation></ref><ref id="B159-pharmaceuticals-18-00297"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talpur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>K.</given-names></name><name name-style="western"><surname>Duvic</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and Safety of Topical Tazarotene: A Review</article-title><source>Expert. Opin. Drug Metab. Toxicol.</source><year>2009</year><volume>5</volume><fpage>195</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1517/17425250902721250</pub-id><pub-id pub-id-type="pmid">20213916</pub-id></element-citation></ref><ref id="B160-pharmaceuticals-18-00297"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Orlandi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campione</surname><given-names>E.</given-names></name><name name-style="western"><surname>Angeloni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Costanzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spagnoli</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Chimenti</surname><given-names>S.</given-names></name></person-group><article-title>Topical Treatment of Basal Cell Carcinoma with Tazarotene: A Clinicopathological Study on a Large Series of Cases</article-title><source>Br. J. Dermatol.</source><year>2004</year><volume>151</volume><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2004.06044.x</pub-id><pub-id pub-id-type="pmid">15270884</pub-id></element-citation></ref><ref id="B161-pharmaceuticals-18-00297"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bardazzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Parente</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guareschi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Landi</surname><given-names>C.</given-names></name></person-group><article-title>A Pilot Study on the Use of Topical Tazarotene to Treat Squamous Cell Carcinoma in Situ</article-title><source>J. Am. Acad. Dermatol.</source><year>2005</year><volume>52</volume><fpage>1102</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2003.07.003</pub-id><pub-id pub-id-type="pmid">15928641</pub-id></element-citation></ref><ref id="B162-pharmaceuticals-18-00297"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Eichenfield</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Ali&#243;</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Buka</surname><given-names>R.L.</given-names></name></person-group><article-title>Treatment of Ichthyosiform Diseases with Topically Applied Tazarotene: Risk of Systemic Absorption</article-title><source>J. Am. Acad. Dermatol.</source><year>2007</year><volume>57</volume><fpage>S123</fpage><lpage>S125</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2006.05.028</pub-id><pub-id pub-id-type="pmid">17938025</pub-id></element-citation></ref><ref id="B163-pharmaceuticals-18-00297"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandraratna</surname><given-names>R.A.S.</given-names></name></person-group><article-title>Tazarotene&#8212;First of a New Generation of Receptor-selective Retinoids</article-title><source>Br. J. Dermatol.</source><year>1996</year><volume>135</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1996.tb15662.x</pub-id><pub-id pub-id-type="pmid">9035701</pub-id></element-citation></ref><ref id="B164-pharmaceuticals-18-00297"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebwohl</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Breneman</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Goffe</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Milbauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pincus</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Sibbald</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Swinyer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Tazarotene 0.1% Gel plus Corticosteroid Cream in the Treatment of Plaque Psoriasis</article-title><source>J. Am. Acad. Dermatol.</source><year>1998</year><volume>39</volume><fpage>590</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(98)70008-8</pub-id><pub-id pub-id-type="pmid">9777766</pub-id></element-citation></ref><ref id="B165-pharmaceuticals-18-00297"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandevyver</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dejager</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tuckermann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Libert</surname><given-names>C.</given-names></name></person-group><article-title>New Insights into the Anti-Inflammatory Mechanisms of Glucocorticoids: An Emerging Role for Glucocorticoid-Receptor-Mediated Transactivation</article-title><source>Endocrinology</source><year>2013</year><volume>154</volume><fpage>993</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1210/en.2012-2045</pub-id><pub-id pub-id-type="pmid">23384835</pub-id></element-citation></ref><ref id="B166-pharmaceuticals-18-00297"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Camino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>E.</given-names></name><name name-style="western"><surname>Inatti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>X.</given-names></name></person-group><article-title>Betamethasone Dipropionate Loaded in Nanoliposomes vs Conventional Betamethasone Dipropionate: Comparative Study of Permeability and Penetrability In Vitro and Ex Vivo</article-title><source>J. Biosci. Med.</source><year>2024</year><volume>12</volume><fpage>140</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.4236/jbm.2024.1210013</pub-id></element-citation></ref><ref id="B167-pharmaceuticals-18-00297"><label>167.</label><element-citation publication-type="webpage"><article-title>MC2 Therapeutics A Randomised, Open-Label, Maximal Use Trial, Evaluating the Pharmacokinetic Profile of Active Ingredients and Their Metabolites After Application of MC2-01 Cream Compared With Active Comparator in Subjects With Extensive Psoriasis Vulgaris; Clinicaltrials.Gov, 2019</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kompetenznetz-leukaemie.de/uct_trial/pdf/uct_de/kurzprotokoll_.pdf?oid=:1:&amp;id=1593" ext-link-type="uri">https://www.kompetenznetz-leukaemie.de/uct_trial/pdf/uct_de/kurzprotokoll_.pdf?oid=:1:&amp;id=1593</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-16">(accessed on 16 February 2025)</date-in-citation></element-citation></ref><ref id="B168-pharmaceuticals-18-00297"><label>168.</label><element-citation publication-type="webpage"><article-title>DrugBank Online Betamethasone Dipropionate</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://go.drugbank.com/salts/DBSALT000851" ext-link-type="uri">https://go.drugbank.com/salts/DBSALT000851</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-27">(accessed on 27 December 2024)</date-in-citation></element-citation></ref><ref id="B169-pharmaceuticals-18-00297"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rautio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Laine</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gynther</surname><given-names>M.</given-names></name><name name-style="western"><surname>Savolainen</surname><given-names>J.</given-names></name></person-group><article-title>Prodrug Approaches for CNS Delivery</article-title><source>AAPS J.</source><year>2008</year><volume>10</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1208/s12248-008-9009-8</pub-id><pub-id pub-id-type="pmid">18446509</pub-id><pub-id pub-id-type="pmcid">PMC2751454</pub-id></element-citation></ref><ref id="B170-pharmaceuticals-18-00297"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullersman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Derendorf</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Estes</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Bodor</surname><given-names>N.</given-names></name></person-group><article-title>High-Performance Liquid Chromatographic Assay of a Central Nervous System (CNS)-Directed Estradiol Chemical Delivery System and Its Application after Intravenous Administration to Rats</article-title><source>Pharm. Res.</source><year>1988</year><volume>5</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1023/A:1015964907110</pub-id><pub-id pub-id-type="pmid">3244629</pub-id></element-citation></ref><ref id="B171-pharmaceuticals-18-00297"><label>171.</label><element-citation publication-type="webpage"><article-title>Synapse Delving into the Latest Updates on IDR-90104 with Synapse</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://synapse.patsnap.com/drug/53a45f918d3948b08a3264f813803fc9#overview" ext-link-type="uri">https://synapse.patsnap.com/drug/53a45f918d3948b08a3264f813803fc9#overview</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-27">(accessed on 27 December 2024)</date-in-citation></element-citation></ref><ref id="B172-pharmaceuticals-18-00297"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.-R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F.-F.</given-names></name></person-group><article-title>Role of Cholinergic Signaling in Alzheimer&#8217;s Disease</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1816</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27061816</pub-id><pub-id pub-id-type="pmid">35335180</pub-id><pub-id pub-id-type="pmcid">PMC8949236</pub-id></element-citation></ref><ref id="B173-pharmaceuticals-18-00297"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>P.</given-names></name></person-group><article-title>Pharmacokinetics of Levodopa</article-title><source>J. Neurol.</source><year>2010</year><volume>257</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s00415-010-5728-8</pub-id><pub-id pub-id-type="pmid">21080186</pub-id></element-citation></ref><ref id="B174-pharmaceuticals-18-00297"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruzzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Contin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Procaccianti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Albani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tonello</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>P.</given-names></name></person-group><article-title>Influence of Meal Ingestion Time on Pharmacokinetics of Orally Administered Levodopa in Parkinsonian Patients</article-title><source>Clin. Neuropharmacol.</source><year>1987</year><volume>10</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1097/00002826-198712000-00004</pub-id><pub-id pub-id-type="pmid">3427559</pub-id></element-citation></ref><ref id="B175-pharmaceuticals-18-00297"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawkins</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mokashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>I.A.</given-names></name></person-group><article-title>An Active Transport System in the Blood&#8211;Brain Barrier May Reduce Levodopa Availability</article-title><source>Exp. Neurol.</source><year>2005</year><volume>195</volume><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2005.04.008</pub-id><pub-id pub-id-type="pmid">15925365</pub-id></element-citation></ref><ref id="B176-pharmaceuticals-18-00297"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.-S.</given-names></name></person-group><article-title>Aromatic L-Amino Acid Decarboxylases: Mechanistic Features and Microbial Applications</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2022</year><volume>106</volume><fpage>4445</fpage><lpage>4458</lpage><pub-id pub-id-type="doi">10.1007/s00253-022-12028-4</pub-id><pub-id pub-id-type="pmid">35763068</pub-id></element-citation></ref><ref id="B177-pharmaceuticals-18-00297"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kish</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Shannak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hornykiewicz</surname><given-names>O.</given-names></name></person-group><article-title>Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson&#8217;s Disease</article-title><source>N. Engl. J. Med.</source><year>1988</year><volume>318</volume><fpage>876</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1056/NEJM198804073181402</pub-id><pub-id pub-id-type="pmid">3352672</pub-id></element-citation></ref><ref id="B178-pharmaceuticals-18-00297"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Hatch</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>R.F.</given-names></name></person-group><article-title>Codeine Phosphate in Paediatric Medicine</article-title><source>Br. J. Anaesth.</source><year>2001</year><volume>86</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1093/bja/86.3.413</pub-id><pub-id pub-id-type="pmid">11573533</pub-id></element-citation></ref><ref id="B179-pharmaceuticals-18-00297"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moolenaar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grasmeijer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>D.K.F.</given-names></name></person-group><article-title>Rectal versus Oral Absorption of Codeine Phosphate in Man</article-title><source>Biopharm. Drug Dispos.</source><year>1983</year><volume>4</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1002/bdd.2510040212</pub-id><pub-id pub-id-type="pmid">6683976</pub-id></element-citation></ref><ref id="B180-pharmaceuticals-18-00297"><label>180.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Sanfilippo</surname><given-names>G.</given-names></name></person-group><article-title>Bollettino Della Societ&#224; Italiana Di Biologia Sperimentale (in SafetyLit)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.safetylit.org/week/journalpage.php?jid=9782" ext-link-type="uri">https://www.safetylit.org/week/journalpage.php?jid=9782</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-27">(accessed on 27 December 2024)</date-in-citation></element-citation></ref><ref id="B181-pharmaceuticals-18-00297"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>E.</given-names></name></person-group><article-title>Efficacy and Ligand Bias at the &#956;-Opioid Receptor</article-title><source>Br. J. Pharmacol.</source><year>2013</year><volume>169</volume><fpage>1430</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1111/bph.12222</pub-id><pub-id pub-id-type="pmid">23646826</pub-id><pub-id pub-id-type="pmcid">PMC3724102</pub-id></element-citation></ref><ref id="B182-pharmaceuticals-18-00297"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>The Physiological Role of Drug Transporters</article-title><source>Protein Cell</source><year>2015</year><volume>6</volume><fpage>334</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1007/s13238-015-0148-2</pub-id><pub-id pub-id-type="pmid">25797421</pub-id><pub-id pub-id-type="pmcid">PMC4417677</pub-id></element-citation></ref><ref id="B183-pharmaceuticals-18-00297"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nigam</surname><given-names>S.K.</given-names></name></person-group><article-title>What Do Drug Transporters Really Do?</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nrd4461</pub-id><pub-id pub-id-type="pmid">25475361</pub-id><pub-id pub-id-type="pmcid">PMC4750486</pub-id></element-citation></ref><ref id="B184-pharmaceuticals-18-00297"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyimesi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hediger</surname><given-names>M.A.</given-names></name></person-group><article-title>Transporter-Mediated Drug Delivery</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>1151</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28031151</pub-id><pub-id pub-id-type="pmid">36770817</pub-id><pub-id pub-id-type="pmcid">PMC9919865</pub-id></element-citation></ref><ref id="B185-pharmaceuticals-18-00297"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sz&#246;ll&#337;si</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rose-Sperling</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hellmich</surname><given-names>U.A.</given-names></name><name name-style="western"><surname>Stockner</surname><given-names>T.</given-names></name></person-group><article-title>Comparison of Mechanistic Transport Cycle Models of ABC Exporters</article-title><source>Biochim. Et Biophys. Acta (BBA)-Biomembr.</source><year>2018</year><volume>1860</volume><fpage>818</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2017.10.028</pub-id><pub-id pub-id-type="pmid">29097275</pub-id><pub-id pub-id-type="pmcid">PMC7610611</pub-id></element-citation></ref><ref id="B186-pharmaceuticals-18-00297"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lauschke</surname><given-names>V.M.</given-names></name></person-group><article-title>The Genetic Landscape of the Human Solute Carrier (SLC) Transporter Superfamily</article-title><source>Hum. Genet.</source><year>2019</year><volume>138</volume><fpage>1359</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1007/s00439-019-02081-x</pub-id><pub-id pub-id-type="pmid">31679053</pub-id><pub-id pub-id-type="pmcid">PMC6874521</pub-id></element-citation></ref><ref id="B187-pharmaceuticals-18-00297"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cundy</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Branch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chernov-Rogan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>T.</given-names></name><name name-style="western"><surname>Estrada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hold</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panuwat</surname><given-names>M.</given-names></name><etal/></person-group><article-title>XP13512 [(&#177;)-1-([(&#945;-Isobutanoyloxyethoxy)Carbonyl] Aminomethyl)-1-Cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2004</year><volume>311</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.067934</pub-id><pub-id pub-id-type="pmid">15146028</pub-id></element-citation></ref><ref id="B188-pharmaceuticals-18-00297"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kageyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takakura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hashida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsuruo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Minato</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The 4F2hc/LAT1 Complex Transports l-DOPA across the Blood&#8211;Brain Barrier</article-title><source>Brain Res.</source><year>2000</year><volume>879</volume><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(00)02758-X</pub-id><pub-id pub-id-type="pmid">11011012</pub-id></element-citation></ref><ref id="B189-pharmaceuticals-18-00297"><label>189.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mondal</surname><given-names>D.</given-names></name></person-group><article-title>Valacyclovir</article-title><source>xPharm: The Comprehensive Pharmacology Reference</source><person-group person-group-type="editor"><name name-style="western"><surname>Enna</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bylund</surname><given-names>D.B.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2007</year><fpage>1</fpage><lpage>4</lpage><isbn>978-0-08-055232-3</isbn></element-citation></ref><ref id="B190-pharmaceuticals-18-00297"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDougall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guglielmo</surname><given-names>B.J.</given-names></name></person-group><article-title>Pharmacokinetics of Valaciclovir</article-title><source>J. Antimicrob. Chemother.</source><year>2004</year><volume>53</volume><fpage>899</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh244</pub-id><pub-id pub-id-type="pmid">15140857</pub-id></element-citation></ref><ref id="B191-pharmaceuticals-18-00297"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khorassani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Luther</surname><given-names>K.</given-names></name><name name-style="western"><surname>Talreja</surname><given-names>O.</given-names></name></person-group><article-title>Valbenazine and Deutetrabenazine: Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia</article-title><source>Am. J. Health-Syst. Pharm.</source><year>2020</year><volume>77</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1093/ajhp/zxz299</pub-id><pub-id pub-id-type="pmid">31974564</pub-id></element-citation></ref><ref id="B192-pharmaceuticals-18-00297"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vijan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Grigoriadis</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Loewen</surname><given-names>G.</given-names></name></person-group><article-title>Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2023</year><volume>12</volume><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1002/cpdd.1205</pub-id><pub-id pub-id-type="pmid">36530055</pub-id></element-citation></ref><ref id="B193-pharmaceuticals-18-00297"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varma</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Ambler</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rotter</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Litchfield</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fenner</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>El-Kattan</surname><given-names>A.F.</given-names></name></person-group><article-title>Targeting Intestinal Transporters for Optimizing Oral Drug Absorption</article-title><source>Curr. Drug Metab.</source><year>2010</year><volume>11</volume><fpage>730</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.2174/138920010794328850</pub-id><pub-id pub-id-type="pmid">21189135</pub-id></element-citation></ref><ref id="B194-pharmaceuticals-18-00297"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estudante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morais</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Soveral</surname><given-names>G.</given-names></name><name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name></person-group><article-title>Intestinal Drug Transporters: An Overview</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>1340</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.09.042</pub-id><pub-id pub-id-type="pmid">23041352</pub-id></element-citation></ref><ref id="B195-pharmaceuticals-18-00297"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Transporter-Mediated Tissue Targeting of Therapeutic Molecules in Drug Discovery</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2015</year><volume>25</volume><fpage>993</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.01.016</pub-id><pub-id pub-id-type="pmid">25650254</pub-id></element-citation></ref><ref id="B196-pharmaceuticals-18-00297"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gynther</surname><given-names>M.</given-names></name></person-group><article-title>Targeting Transporters for Drug Delivery to the Brain: Can. We Do Better?</article-title><source>Pharm. Res.</source><year>2022</year><volume>39</volume><fpage>1415</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1007/s11095-022-03241-x</pub-id><pub-id pub-id-type="pmid">35359241</pub-id><pub-id pub-id-type="pmcid">PMC9246765</pub-id></element-citation></ref><ref id="B197-pharmaceuticals-18-00297"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bento</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Donadi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Bologa</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Lazikani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name><etal/></person-group><article-title>A Comprehensive Map of Molecular Drug Targets</article-title><source>Nat. Rev. Drug Discov.</source><year>2017</year><volume>16</volume><fpage>19</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.230</pub-id><pub-id pub-id-type="pmid">27910877</pub-id><pub-id pub-id-type="pmcid">PMC6314433</pub-id></element-citation></ref><ref id="B198-pharmaceuticals-18-00297"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;k&#233;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Crews</surname><given-names>C.M.</given-names></name></person-group><article-title>PROTAC Targeted Protein Degraders: The Past Is Prologue</article-title><source>Nat. Rev. Drug Discov.</source><year>2022</year><volume>21</volume><fpage>181</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00371-6</pub-id><pub-id pub-id-type="pmid">35042991</pub-id><pub-id pub-id-type="pmcid">PMC8765495</pub-id></element-citation></ref><ref id="B199-pharmaceuticals-18-00297"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mercurio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crews</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Deshaies</surname><given-names>R.J.</given-names></name></person-group><article-title>Protacs: Chimeric Molecules That Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>8554</fpage><lpage>8559</lpage><pub-id pub-id-type="doi">10.1073/pnas.141230798</pub-id><pub-id pub-id-type="pmid">11438690</pub-id><pub-id pub-id-type="pmcid">PMC37474</pub-id></element-citation></ref><ref id="B200-pharmaceuticals-18-00297"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokoo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demizu</surname><given-names>Y.</given-names></name></person-group><article-title>Investigating the Cell Permeability of Proteolysis-Targeting Chimeras (PROTACs)</article-title><source>Expert Opin. Drug Discov.</source><year>2023</year><volume>18</volume><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1080/17460441.2023.2187047</pub-id><pub-id pub-id-type="pmid">36908022</pub-id></element-citation></ref><ref id="B201-pharmaceuticals-18-00297"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a Jim&#233;nez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rossi Sebastiano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vallaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mileo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pizzirani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ermondi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>G.</given-names></name></person-group><article-title>Designing Soluble PROTACs: Strategies and Preliminary Guidelines</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><fpage>12639</fpage><lpage>12649</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00201</pub-id><pub-id pub-id-type="pmid">35469399</pub-id><pub-id pub-id-type="pmcid">PMC9574862</pub-id></element-citation></ref><ref id="B202-pharmaceuticals-18-00297"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuentz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>C.A.S.</given-names></name></person-group><article-title>Synergistic Computational Modeling Approaches as Team Players in the Game of Solubility Predictions</article-title><source>J. Pharm. Sci.</source><year>2021</year><volume>110</volume><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2020.10.068</pub-id><pub-id pub-id-type="pmid">33217423</pub-id></element-citation></ref><ref id="B203-pharmaceuticals-18-00297"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>8428</fpage><lpage>8440</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00302</pub-id><pub-id pub-id-type="pmid">37317568</pub-id></element-citation></ref><ref id="B204-pharmaceuticals-18-00297"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name></person-group><article-title>Progress in the Controllability Technology of PROTAC</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>265</volume><fpage>116096</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.116096</pub-id><pub-id pub-id-type="pmid">38160619</pub-id></element-citation></ref><ref id="B205-pharmaceuticals-18-00297"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaniskan</surname><given-names>H.&#220;.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name></person-group><article-title>Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>12273</fpage><lpage>12285</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00901</pub-id><pub-id pub-id-type="pmid">34378936</pub-id><pub-id pub-id-type="pmcid">PMC8409242</pub-id></element-citation></ref><ref id="B206-pharmaceuticals-18-00297"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name></person-group><article-title>Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation</article-title><source>J. Med. Chem.</source><year>2024</year><volume>67</volume><fpage>9842</fpage><lpage>9856</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c02340</pub-id><pub-id pub-id-type="pmid">38839424</pub-id></element-citation></ref><ref id="B207-pharmaceuticals-18-00297"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wallace-Povirk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fr&#252;hauf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gangjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matherly</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name></person-group><article-title>Folate Transporter Dynamics and Therapy with Classic and Tumor-Targeted Antifolates</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>6389</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-85818-x</pub-id><pub-id pub-id-type="pmid">33737637</pub-id><pub-id pub-id-type="pmcid">PMC7973545</pub-id></element-citation></ref><ref id="B208-pharmaceuticals-18-00297"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kaniskan</surname><given-names>H.&#220;.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name></person-group><article-title>Cancer Selective Target Degradation by Folate-Caged PROTACs</article-title><source>J. Am. Chem. Soc.</source><year>2021</year><volume>143</volume><fpage>7380</fpage><lpage>7387</lpage><pub-id pub-id-type="doi">10.1021/jacs.1c00451</pub-id><pub-id pub-id-type="pmid">33970635</pub-id><pub-id pub-id-type="pmcid">PMC8219215</pub-id></element-citation></ref><ref id="B209-pharmaceuticals-18-00297"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keefe</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ellington</surname><given-names>A.</given-names></name></person-group><article-title>Aptamers as Therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>537</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nrd3141</pub-id><pub-id pub-id-type="pmid">20592747</pub-id><pub-id pub-id-type="pmcid">PMC7097324</pub-id></element-citation></ref><ref id="B210-pharmaceuticals-18-00297"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>J.</given-names></name></person-group><article-title>Aptamers as Targeted Therapeutics: Current Potential and Challenges</article-title><source>Nat. Rev. Drug Discov.</source><year>2017</year><volume>16</volume><fpage>181</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.199</pub-id><pub-id pub-id-type="pmid">27807347</pub-id><pub-id pub-id-type="pmcid">PMC5700751</pub-id></element-citation></ref><ref id="B211-pharmaceuticals-18-00297"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-Q.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer</article-title><source>J. Am. Chem. Soc.</source><year>2020</year><volume>142</volume><fpage>2699</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1021/jacs.9b10510</pub-id><pub-id pub-id-type="pmid">31910009</pub-id></element-citation></ref><ref id="B212-pharmaceuticals-18-00297"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>C.</given-names></name></person-group><article-title>Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2021</year><volume>60</volume><fpage>23299</fpage><lpage>23305</lpage><pub-id pub-id-type="doi">10.1002/anie.202107347</pub-id><pub-id pub-id-type="pmid">34240523</pub-id></element-citation></ref><ref id="B213-pharmaceuticals-18-00297"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shih</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Naganuma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>G.</given-names></name><name name-style="western"><surname>Demizu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>M.</given-names></name></person-group><article-title>Development of Decoy Oligonucleotide-Warheaded Chimeric Molecules Targeting STAT3</article-title><source>Bioorganic Med. Chem.</source><year>2023</year><volume>95</volume><elocation-id>117507</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2023.117507</pub-id><pub-id pub-id-type="pmid">37922656</pub-id></element-citation></ref><ref id="B214-pharmaceuticals-18-00297"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sathyamurthi</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Queisser</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mullin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shrives</surname><given-names>H.</given-names></name><name name-style="western"><surname>Coe</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Burley</surname><given-names>G.A.</given-names></name></person-group><article-title>Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines</article-title><source>Bioconjug. Chem.</source><year>2023</year><volume>34</volume><fpage>2049</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.3c00366</pub-id><pub-id pub-id-type="pmid">37917829</pub-id><pub-id pub-id-type="pmcid">PMC10655034</pub-id></element-citation></ref><ref id="B215-pharmaceuticals-18-00297"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Development of a Novel PROTAC Using the Nucleic Acid Aptamer as a Targeting Ligand for Tumor Selective Degradation of Nucleolin</article-title><source>Mol. Ther. Nucleic Acids</source><year>2022</year><volume>30</volume><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.09.008</pub-id><pub-id pub-id-type="pmid">36250201</pub-id><pub-id pub-id-type="pmcid">PMC9535278</pub-id></element-citation></ref><ref id="B216-pharmaceuticals-18-00297"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bukari</surname><given-names>B.</given-names></name><name name-style="western"><surname>Samarasinghe</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Noibanchong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shigdar</surname><given-names>S.L.</given-names></name></person-group><article-title>Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery</article-title><source>Biomedicines</source><year>2020</year><volume>8</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8050120</pub-id><pub-id pub-id-type="pmid">32422973</pub-id><pub-id pub-id-type="pmcid">PMC7277349</pub-id></element-citation></ref><ref id="B217-pharmaceuticals-18-00297"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Targeted and Effective Glioblastoma Therapy via Aptamer-Modified Tetrahedral Framework Nucleic Acid-Paclitaxel Nanoconjugates That Can Pass the Blood Brain Barrier</article-title><source>Nanomedicine</source><year>2019</year><volume>21</volume><fpage>102061</fpage><pub-id pub-id-type="doi">10.1016/j.nano.2019.102061</pub-id><pub-id pub-id-type="pmid">31344499</pub-id></element-citation></ref><ref id="B218-pharmaceuticals-18-00297"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Antibody Drug Conjugate: The &#8220;Biological Missile&#8221; for Targeted Cancer Therapy</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00947-7</pub-id><pub-id pub-id-type="pmid">35318309</pub-id><pub-id pub-id-type="pmcid">PMC8941077</pub-id></element-citation></ref><ref id="B219-pharmaceuticals-18-00297"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nejadmoghaddam</surname><given-names>M.-R.</given-names></name><name name-style="western"><surname>Minai-Tehrani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghahremanzadeh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mahmoudi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dinarvand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zarnani</surname><given-names>A.-H.</given-names></name></person-group><article-title>Antibody-Drug Conjugates: Possibilities and Challenges</article-title><source>Avicenna J. Med. Biotechnol.</source><year>2019</year><volume>11</volume><fpage>3</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">30800238</pub-id><pub-id pub-id-type="pmcid">PMC6359697</pub-id></element-citation></ref><ref id="B220-pharmaceuticals-18-00297"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragovich</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Blaquiere</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.-X.</given-names></name><name name-style="western"><surname>den Besten</surname><given-names>W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antibody-Mediated Delivery of Chimeric Protein Degraders Which Target Estrogen Receptor Alpha (ER&#945;)</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2020</year><volume>30</volume><elocation-id>126907</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2019.126907</pub-id><pub-id pub-id-type="pmid">31902710</pub-id></element-citation></ref><ref id="B221-pharmaceuticals-18-00297"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vartak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deore</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanhueza</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name></person-group><article-title>Cetuximab-Based PROteolysis Targeting Chimera for Effectual Downregulation of NSCLC with Varied EGFR Mutations</article-title><source>Int. J. Biol. Macromol.</source><year>2023</year><volume>252</volume><elocation-id>126413</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.126413</pub-id><pub-id pub-id-type="pmid">37598823</pub-id><pub-id pub-id-type="pmcid">PMC12045033</pub-id></element-citation></ref><ref id="B222-pharmaceuticals-18-00297"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>An</surname><given-names>H.</given-names></name></person-group><article-title>Degrader&#8211;Antibody Conjugates: Emerging New Modality</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01791</pub-id><pub-id pub-id-type="pmid">36580273</pub-id></element-citation></ref><ref id="B223-pharmaceuticals-18-00297"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragovich</surname><given-names>P.S.</given-names></name></person-group><article-title>Degrader-Antibody Conjugates</article-title><source>Chem. Soc. Rev.</source><year>2022</year><volume>51</volume><fpage>3886</fpage><lpage>3897</lpage><pub-id pub-id-type="doi">10.1039/D2CS00141A</pub-id><pub-id pub-id-type="pmid">35506708</pub-id></element-citation></ref><ref id="B224-pharmaceuticals-18-00297"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name></person-group><article-title>New-Generation Advanced PROTACs as Potential Therapeutic Agents in Cancer Therapy</article-title><source>Mol. Cancer</source><year>2024</year><volume>23</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s12943-024-02024-9</pub-id><pub-id pub-id-type="pmid">38773495</pub-id><pub-id pub-id-type="pmcid">PMC11107062</pub-id></element-citation></ref><ref id="B225-pharmaceuticals-18-00297"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>What Influences the Activity of Degrader&#8722;Antibody Conjugates (DACs)</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>268</volume><fpage>116216</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2024.116216</pub-id><pub-id pub-id-type="pmid">38387330</pub-id></element-citation></ref><ref id="B226-pharmaceuticals-18-00297"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fathman</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Rothbard</surname><given-names>J.B.</given-names></name></person-group><article-title>Polyarginine Enters Cells More Efficiently than Other Polycationic Homopolymers</article-title><source>J. Pept. Res.</source><year>2000</year><volume>56</volume><fpage>318</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3011.2000.00723.x</pub-id><pub-id pub-id-type="pmid">11095185</pub-id></element-citation></ref><ref id="B227-pharmaceuticals-18-00297"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Copolovici</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Langel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eriste</surname><given-names>E.</given-names></name><name name-style="western"><surname>Langel</surname><given-names>&#220;.</given-names></name></person-group><article-title>Cell-Penetrating Peptides: Design, Synthesis, and Applications</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>1972</fpage><lpage>1994</lpage><pub-id pub-id-type="doi">10.1021/nn4057269</pub-id><pub-id pub-id-type="pmid">24559246</pub-id></element-citation></ref><ref id="B228-pharmaceuticals-18-00297"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Sayers</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Allemann</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Luk</surname><given-names>L.Y.P.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>Y.-H.</given-names></name></person-group><article-title>Cell-Penetrating Peptide Sequence and Modification Dependent Uptake and Subcellular Distribution of Green Florescent Protein in Different Cell Lines</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>6298</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-42456-8</pub-id><pub-id pub-id-type="pmid">31000738</pub-id><pub-id pub-id-type="pmcid">PMC6472342</pub-id></element-citation></ref><ref id="B229-pharmaceuticals-18-00297"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lodigiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Colombarolli</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Bergamaschi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vitali</surname><given-names>A.</given-names></name></person-group><article-title>Cell Penetrating Peptides: Classification, Mechanisms, Methods of Study, and Applications</article-title><source>ChemMedChem</source><year>2023</year><volume>18</volume><fpage>e202300236</fpage><pub-id pub-id-type="doi">10.1002/cmdc.202300236</pub-id><pub-id pub-id-type="pmid">37389978</pub-id></element-citation></ref><ref id="B230-pharmaceuticals-18-00297"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobchev</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tulp</surname><given-names>I.</given-names></name><name name-style="western"><surname>Karelson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tamm</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamm</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Langel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Karelson</surname><given-names>M.</given-names></name></person-group><article-title>Prediction of Cell-Penetrating Peptides Using Artificial Neural Networks</article-title><source>Curr. Comput. Aided Drug Des.</source><year>2010</year><volume>6</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2174/157340910791202478</pub-id><pub-id pub-id-type="pmid">20402661</pub-id></element-citation></ref><ref id="B231-pharmaceuticals-18-00297"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>G.</given-names></name></person-group><article-title>Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>16828</fpage><lpage>16842</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c01539</pub-id><pub-id pub-id-type="pmid">38055861</pub-id></element-citation></ref><ref id="B232-pharmaceuticals-18-00297"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name></person-group><article-title>Discovery of Novel Penetrating Peptides Able to Target Human Leukemia and Lymphoma for Enhanced PROTAC Delivery</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>277</volume><fpage>116734</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2024.116734</pub-id><pub-id pub-id-type="pmid">39094275</pub-id></element-citation></ref><ref id="B233-pharmaceuticals-18-00297"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>M.-Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.-J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.-B.</given-names></name></person-group><article-title>High-Potency PD-1/PD-L1 Degradation Induced by Peptide-PROTAC in Human Cancer Cells</article-title><source>Cell Death Dis.</source><year>2022</year><volume>13</volume><fpage>924</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05375-7</pub-id><pub-id pub-id-type="pmid">36333311</pub-id><pub-id pub-id-type="pmcid">PMC9636179</pub-id></element-citation></ref><ref id="B234-pharmaceuticals-18-00297"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokoo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohoka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kurohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukuhara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demizu</surname><given-names>Y.</given-names></name></person-group><article-title>Peptide Stapling Improves the Sustainability of a Peptide-Based Chimeric Molecule That Induces Targeted Protein Degradation</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8772</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22168772</pub-id><pub-id pub-id-type="pmid">34445478</pub-id><pub-id pub-id-type="pmcid">PMC8396023</pub-id></element-citation></ref><ref id="B235-pharmaceuticals-18-00297"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del Mar Noblejas-L&#243;pez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arenas-Moreira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso-Moreno</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oca&#241;a</surname><given-names>A.</given-names></name></person-group><article-title>Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles</article-title><source>Front. Cell Dev. Biol.</source><year>2022</year><volume>9</volume><elocation-id>805336</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.805336</pub-id><pub-id pub-id-type="pmid">35186955</pub-id><pub-id pub-id-type="pmcid">PMC8851355</pub-id></element-citation></ref><ref id="B236-pharmaceuticals-18-00297"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Heelan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name></person-group><article-title>Proteolysis-Targeting Chimera (PROTAC) Delivery System: Advancing Protein Degraders towards Clinical Translation</article-title><source>Chem. Soc. Rev.</source><year>2022</year><volume>51</volume><fpage>5330</fpage><lpage>5350</lpage><pub-id pub-id-type="doi">10.1039/D1CS00762A</pub-id><pub-id pub-id-type="pmid">35713468</pub-id><pub-id pub-id-type="pmcid">PMC9382890</pub-id></element-citation></ref><ref id="B237-pharmaceuticals-18-00297"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-H.</given-names></name><etal/></person-group><article-title>Engineered Bioorthogonal POLY-PROTAC Nanoparticles for Tumour-Specific Protein Degradation and Precise Cancer Therapy</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4318</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32050-4</pub-id><pub-id pub-id-type="pmid">35882867</pub-id><pub-id pub-id-type="pmcid">PMC9325692</pub-id></element-citation></ref><ref id="B238-pharmaceuticals-18-00297"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K.</given-names></name></person-group><article-title>Semiconducting Polymer Nano-PROTACs for Activatable Photo-Immunometabolic Cancer Therapy</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>2934</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-23194-w</pub-id><pub-id pub-id-type="pmid">34006860</pub-id><pub-id pub-id-type="pmcid">PMC8131624</pub-id></element-citation></ref><ref id="B239-pharmaceuticals-18-00297"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K.</given-names></name></person-group><article-title>Smart Nano-PROTACs Reprogram Tumor Microenvironment for Activatable Photo-metabolic Cancer Immunotherapy</article-title><source>Angew. Chem. Int. Ed.</source><year>2022</year><volume>61</volume><fpage>e202114957</fpage><pub-id pub-id-type="doi">10.1002/anie.202114957</pub-id><pub-id pub-id-type="pmid">34927316</pub-id></element-citation></ref><ref id="B240-pharmaceuticals-18-00297"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>You</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name></person-group><article-title>Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation</article-title><source>J. Am. Chem. Soc.</source><year>2023</year><volume>145</volume><fpage>7218</fpage><lpage>7229</lpage><pub-id pub-id-type="doi">10.1021/jacs.2c12809</pub-id><pub-id pub-id-type="pmid">36971523</pub-id></element-citation></ref><ref id="B241-pharmaceuticals-18-00297"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>X.</given-names></name></person-group><article-title>Nano-PROTACs: State of the Art and Perspectives</article-title><source>Nanoscale</source><year>2024</year><volume>16</volume><fpage>4378</fpage><lpage>4391</lpage><pub-id pub-id-type="doi">10.1039/D3NR06059D</pub-id><pub-id pub-id-type="pmid">38305466</pub-id></element-citation></ref><ref id="B242-pharmaceuticals-18-00297"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs</article-title><source>ChemBioChem</source><year>2023</year><volume>24</volume><elocation-id>e202300413</elocation-id><pub-id pub-id-type="doi">10.1002/cbic.202300413</pub-id><pub-id pub-id-type="pmid">37496112</pub-id></element-citation></ref><ref id="B243-pharmaceuticals-18-00297"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X.</given-names></name></person-group><article-title>Progress of Proteolysis-Targeting Chimeras (PROTACs) Delivery System in Tumor Treatment</article-title><source>Int. J. Biol. Macromol.</source><year>2024</year><volume>275</volume><elocation-id>133680</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.133680</pub-id><pub-id pub-id-type="pmid">38971291</pub-id></element-citation></ref><ref id="B244-pharmaceuticals-18-00297"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q.-Q.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Y.-K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy</article-title><source>Int. J. Nanomed.</source><year>2024</year><volume>19</volume><fpage>5739</fpage><lpage>5761</lpage><pub-id pub-id-type="doi">10.2147/IJN.S448684</pub-id><pub-id pub-id-type="pmcid">PMC11180470</pub-id><pub-id pub-id-type="pmid">38882545</pub-id></element-citation></ref><ref id="B245-pharmaceuticals-18-00297"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Saboo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Askin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bak</surname><given-names>A.</given-names></name></person-group><article-title>Early Evaluation of Opportunities in Oral Delivery of PROTACs to Overcome Their Molecular Challenges</article-title><source>Drug Discov. Today</source><year>2024</year><volume>29</volume><fpage>103865</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103865</pub-id><pub-id pub-id-type="pmid">38154757</pub-id></element-citation></ref><ref id="B246-pharmaceuticals-18-00297"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkby</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabri</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Scurr</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>G.P.</given-names></name></person-group><article-title>Dendrimer-Mediated Permeation Enhancement of Chlorhexidine Digluconate: Determination of in Vitro Skin Permeability and Visualisation of Dermal Distribution</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2021</year><volume>159</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2020.12.014</pub-id><pub-id pub-id-type="pmid">33359754</pub-id></element-citation></ref><ref id="B247-pharmaceuticals-18-00297"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva Santos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Igne Ferreira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giarolla</surname><given-names>J.</given-names></name></person-group><article-title>Dendrimer Prodrugs</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>686</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21060686</pub-id><pub-id pub-id-type="pmid">27258239</pub-id><pub-id pub-id-type="pmcid">PMC6274429</pub-id></element-citation></ref><ref id="B248-pharmaceuticals-18-00297"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>L.-T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name></person-group><article-title>Enhanced Permeability of Charged Dendrimers across Tense Lipid Bilayer Membranes</article-title><source>ACS Nano</source><year>2009</year><volume>3</volume><fpage>2171</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1021/nn9004236</pub-id><pub-id pub-id-type="pmid">19583248</pub-id></element-citation></ref><ref id="B249-pharmaceuticals-18-00297"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>T.</given-names></name></person-group><article-title>Pharmaceutical Cocrystals: A Review of Preparations, Physicochemical Properties and Applications</article-title><source>Acta Pharm. Sin. B</source><year>2021</year><volume>11</volume><fpage>2537</fpage><lpage>2564</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.03.030</pub-id><pub-id pub-id-type="pmid">34522597</pub-id><pub-id pub-id-type="pmcid">PMC8424375</pub-id></element-citation></ref><ref id="B250-pharmaceuticals-18-00297"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Drug-Drug Cocrystals: Opportunities and Challenges</article-title><source>Asian J. Pharm. Sci.</source><year>2021</year><volume>16</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2020.06.004</pub-id><pub-id pub-id-type="pmid">34276820</pub-id><pub-id pub-id-type="pmcid">PMC8261079</pub-id></element-citation></ref><ref id="B251-pharmaceuticals-18-00297"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alavian</surname><given-names>H.</given-names></name></person-group><article-title>A Perspective on the Permeability of Cocrystals/Organic Salts of Oral Drugs</article-title><source>Mol. Pharm.</source><year>2024</year><volume>21</volume><fpage>4860</fpage><lpage>4911</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.4c00786</pub-id><pub-id pub-id-type="pmid">39284012</pub-id></element-citation></ref><ref id="B252-pharmaceuticals-18-00297"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panzade</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Shendarkar</surname><given-names>G.R.</given-names></name></person-group><article-title>Pharmaceutical Cocrystal: A Game Changing Approach for the Administration of Old Drugs in New Crystalline Form</article-title><source>Drug Dev. Ind. Pharm.</source><year>2020</year><volume>46</volume><fpage>1559</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1080/03639045.2020.1810270</pub-id><pub-id pub-id-type="pmid">32799687</pub-id></element-citation></ref><ref id="B253-pharmaceuticals-18-00297"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panzade</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Shendarkar</surname><given-names>G.R.</given-names></name></person-group><article-title>Pharmaceutical Cocrystal: An Antique and Multifaceted Approach</article-title><source>Curr. Drug Deliv.</source><year>2017</year><volume>14</volume><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.2174/1567201813666161018152411</pub-id><pub-id pub-id-type="pmid">27758692</pub-id></element-citation></ref><ref id="B254-pharmaceuticals-18-00297"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>H.</given-names></name></person-group><article-title>Cocrystal and Its Application in the Field of Active Pharmaceutical Ingredients and Food Ingredients</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>2339</fpage><lpage>2348</lpage><pub-id pub-id-type="doi">10.2174/1381612824666180522102732</pub-id><pub-id pub-id-type="pmid">29788878</pub-id></element-citation></ref><ref id="B255-pharmaceuticals-18-00297"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fala</surname><given-names>L.</given-names></name></person-group><article-title>Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure</article-title><source>Am. Health Drug Benefits</source><year>2015</year><volume>8</volume><fpage>330</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">26557227</pub-id><pub-id pub-id-type="pmcid">PMC4636283</pub-id></element-citation></ref><ref id="B256-pharmaceuticals-18-00297"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayalasomayajula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langenickel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boggarapu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sunkara</surname><given-names>G.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor</article-title><source>Clin. Pharmacokinet.</source><year>2017</year><volume>56</volume><fpage>1461</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1007/s40262-017-0543-3</pub-id><pub-id pub-id-type="pmid">28417439</pub-id></element-citation></ref><ref id="B257-pharmaceuticals-18-00297"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheney</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Weyna</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wojtas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zaworotko</surname><given-names>M.J.</given-names></name></person-group><article-title>Coformer Selection in Pharmaceutical Cocrystal Development: A Case Study of a Meloxicam Aspirin Cocrystal That Exhibits Enhanced Solubility and Pharmacokinetics</article-title><source>J. Pharm. Sci.</source><year>2011</year><volume>100</volume><fpage>2172</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1002/jps.22434</pub-id><pub-id pub-id-type="pmid">21491441</pub-id></element-citation></ref><ref id="B258-pharmaceuticals-18-00297"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C.-W.</given-names></name></person-group><article-title>A Supramolecular Adduct of Tegafur and Syringic Acid: The First Tegafur-Nutraceutical Cocrystal with Perfected in Vitro and in Vivo Characteristics as Well as Synergized Anticancer Activities</article-title><source>New J. Chem.</source><year>2020</year><volume>44</volume><fpage>15994</fpage><lpage>16005</lpage><pub-id pub-id-type="doi">10.1039/D0NJ03033C</pub-id></element-citation></ref><ref id="B259-pharmaceuticals-18-00297"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mannava</surname><given-names>M.K.C.</given-names></name><name name-style="western"><surname>Garai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nangia</surname><given-names>A.K.</given-names></name></person-group><article-title>Diffusion and Flux Improvement of Drugs through Complexation</article-title><source>Mol. Pharm.</source><year>2023</year><volume>20</volume><fpage>2293</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00159</pub-id><pub-id pub-id-type="pmid">36974968</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00297-f001" orientation="portrait"><label>Figure 1</label><caption><p>Permeability determination methods. In silico methods: PerMM [<xref rid="B35-pharmaceuticals-18-00297" ref-type="bibr">35</xref>], admetSAR 2.0 [<xref rid="B36-pharmaceuticals-18-00297" ref-type="bibr">36</xref>], admetSAR 3.0 [<xref rid="B37-pharmaceuticals-18-00297" ref-type="bibr">37</xref>], ADMETopt [<xref rid="B38-pharmaceuticals-18-00297" ref-type="bibr">38</xref>], OptADMET [<xref rid="B39-pharmaceuticals-18-00297" ref-type="bibr">39</xref>], Interpretable-ADMET [<xref rid="B40-pharmaceuticals-18-00297" ref-type="bibr">40</xref>], SwissADME [<xref rid="B41-pharmaceuticals-18-00297" ref-type="bibr">41</xref>], pkCSM [<xref rid="B42-pharmaceuticals-18-00297" ref-type="bibr">42</xref>]. (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g001.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f002" orientation="portrait"><label>Figure 2</label><caption><p>Prednisolone peptide prodrug. Adapted from [<xref rid="B82-pharmaceuticals-18-00297" ref-type="bibr">82</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g002.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f003" orientation="portrait"><label>Figure 3</label><caption><p>Adefovir prodrug. Adapted from [<xref rid="B102-pharmaceuticals-18-00297" ref-type="bibr">102</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g003.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f004" orientation="portrait"><label>Figure 4</label><caption><p>Estradiol prodrugs exploring a CDS to enhance BBB permeability. Adapted from [<xref rid="B169-pharmaceuticals-18-00297" ref-type="bibr">169</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g004.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f005" orientation="portrait"><label>Figure 5</label><caption><p>Strategies exploring prodrug approaches to improve PROTAC permeability. Adapted from [<xref rid="B205-pharmaceuticals-18-00297" ref-type="bibr">205</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g005.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f006" orientation="portrait"><label>Figure 6</label><caption><p>PEG-based prodrugs to enhance PROTAC permeability [<xref rid="B206-pharmaceuticals-18-00297" ref-type="bibr">206</xref>]. (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g006.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f007" orientation="portrait"><label>Figure 7</label><caption><p>Folate-based carriers are designed as pro-PROTAC to enhance permeability [<xref rid="B205-pharmaceuticals-18-00297" ref-type="bibr">205</xref>,<xref rid="B208-pharmaceuticals-18-00297" ref-type="bibr">208</xref>]. (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g007.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f008" orientation="portrait"><label>Figure 8</label><caption><p>Aptamer and antibody-based PROTACs. [<xref rid="B212-pharmaceuticals-18-00297" ref-type="bibr">212</xref>,<xref rid="B213-pharmaceuticals-18-00297" ref-type="bibr">213</xref>,<xref rid="B214-pharmaceuticals-18-00297" ref-type="bibr">214</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g008.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f009" orientation="portrait"><label>Figure 9</label><caption><p>Peptide and CPP-based PROTACs [<xref rid="B231-pharmaceuticals-18-00297" ref-type="bibr">231</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g009.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f010" orientation="portrait"><label>Figure 10</label><caption><p>Polymeric PROTAC nanoplatform. Adapted from [<xref rid="B237-pharmaceuticals-18-00297" ref-type="bibr">237</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g010.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f011" orientation="portrait"><label>Figure 11</label><caption><p>Polymeric PROTAC nanoplatform. (<bold>A</bold>) Semiconducting polymer nano-PROTAC [<xref rid="B238-pharmaceuticals-18-00297" ref-type="bibr">238</xref>]. (<bold>B</bold>) Smart nano-proteolysis targeting Chimeras [<xref rid="B239-pharmaceuticals-18-00297" ref-type="bibr">239</xref>]. (<bold>C</bold>) tetrazine-modified PROTACs and TCO-modified dendrimer [<xref rid="B240-pharmaceuticals-18-00297" ref-type="bibr">240</xref>]. (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g011.jpg"/></fig><fig position="float" id="pharmaceuticals-18-00297-f012" orientation="portrait"><label>Figure 12</label><caption><p>Co-crystal and prodrugs. (<bold>A</bold>) Classic co-crystal system, between active pharmaceutical ingredients (APIs) and conformer (<bold>B</bold>) Prodrug co-crystal examples [<xref rid="B256-pharmaceuticals-18-00297" ref-type="bibr">256</xref>,<xref rid="B257-pharmaceuticals-18-00297" ref-type="bibr">257</xref>,<xref rid="B258-pharmaceuticals-18-00297" ref-type="bibr">258</xref>] (Figure created in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com">https://BioRender.com</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-18-00297-g012.jpg"/></fig><table-wrap position="float" id="pharmaceuticals-18-00297-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-18-00297-t001_Table 1</object-id><label>Table 1</label><caption><p>Biopharmaceutical Classification System (BCS).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solubility <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Permeability <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Examples of Drugs</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="left" valign="middle" rowspan="1" colspan="1">Acyclovir, captopril, abacavir</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="left" valign="middle" rowspan="1" colspan="1">Atorvastatin, diclofenac, ciprofloxacin</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td><td align="left" valign="middle" rowspan="1" colspan="1">Cimetidine, atenolol, amoxicillin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Furosemide, chlorthalidone, methotrexate</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> A compound is regarded as highly soluble when its therapeutic dose fully dissolves in 250 mL of an aqueous medium. <sup>2</sup> Likewise, a compound is classified as highly permeable if it demonstrates a bioavailability of &#8805;85%, indicating that at least 85% of the administered dose is recovered in the urine, considering phase 1/2 metabolites. The Biopharmaceutics Classification System (BCS) values are predetermined by the FDA. Adapted from [<xref rid="B25-pharmaceuticals-18-00297" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-18-00297" ref-type="bibr">26</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00297-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-18-00297-t002_Table 2</object-id><label>Table 2</label><caption><p>Marketed prodrugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Code)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LogP <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Current Development Stage</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i001.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Dimethyl fumarate (1)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.51</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i002.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Monomethyl fumarate (2)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.77</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i003.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Oseltamivir (3)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.23</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i004.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Mofetil mycophenolate (4)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.68</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i005.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Mycophenolic acid (5)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.01</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i006.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Dabigatran etexilate (6)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.86</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i007.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Dabigatran (7)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.04</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i008.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Capecitabine (8)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.43</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i009.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">5-fluorouracil (9)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.08</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i010.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Penicillin (10)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.93</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i011.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Ampicillin (11)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.15</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i012.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Amoxicillin (12)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.13</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i013.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Pivmecillinam (13)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.16</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i014.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Talampicillin (14)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.67</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i015.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Bacampicillin (15)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.22</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i016.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Hetacillin (16)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.63</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i017.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Lenampicillin (17)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.97</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i018.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Sofosbuvir (18)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.81</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i019.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir (19)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.30</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i020.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir diphosphate (20)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.84</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i021.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir disoproxil fumarate (21)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.02</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i022.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tenofovir alafenamide (22)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.05</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i023.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Adefovir dipivoxil (23)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.56</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i024.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Adefovir diphosphate (24)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;2.28</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i025.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Fosphenytoin (25)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.81</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i026.jpg"/>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenytoin (26)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.28</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> LogP values calculated by ChemAxon MarvinSketch.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00297-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-18-00297-t003_Table 3</object-id><label>Table 3</label><caption><p>Marketed prodrugs to enhance ocular, skin, and CNS permeability.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Code)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LogP <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Current Development Stage</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i027.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tafluprost (27)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.11</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i028.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostaglandin F2a (28)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.20</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i029.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Epinephrine (29)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.33</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i030.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Dipivefrin (30)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.61</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i031.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Nepafenac (31)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.90</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i032.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Amfenac (32)</td><td align="left" valign="middle" rowspan="1" colspan="1">2.77</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i033.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tazarotene (33)</td><td align="left" valign="middle" rowspan="1" colspan="1">5.30</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i034.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tazarotenic acid (34)</td><td align="left" valign="middle" rowspan="1" colspan="1">4.33</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i035.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Betamethasone <break/>dipropionate (35)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.86</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i036.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Betamethasone (36)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.75</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i037.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Levodopa (37)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.58</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i038.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Dopamine (38)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.85</td><td align="left" valign="middle" rowspan="1" colspan="1">Active metabolite</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i039.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Codeine (39)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.27</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i040.jpg"/>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morphine (40)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.23</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> LogP values calculated by ChemAxon MarvinSketch.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00297-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-18-00297-t004_Table 4</object-id><label>Table 4</label><caption><p>Marketed prodrugs that leverage drug transporter systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Code)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LogP <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Current Development Stage</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i041.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Acyclovir (41)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.85</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i042.jpg"/>
</td><td align="left" valign="middle" rowspan="1" colspan="1">Valacyclovir (42)</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.92</td><td align="left" valign="middle" rowspan="1" colspan="1">Market prodrug</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceuticals-18-00297-i043.jpg"/>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valbenazine (43)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.29</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Market prodrug</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> LogP values calculated by ChemAxon MarvinSketch.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>